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Responsive, polybasic nanoscale hydrogels were synthesized using 
photoemulsion polymerization. The nanoscale hydrogels (nanogels) are approximately 50 
nm in diameter and consist of a pH-responsive poly(2-(diethylaminoethyl methacrylate)) 
core with a poly(ethylene glycol) corona. The nanogels undergo a volume phase 
transition in response to environmental pH, and possess tunable physicochemical 
properties based on the copolymer composition. Aqueous solution properties of the 
nanogels were investigated using dynamic light scattering, pyrene fluorescence 
spectroscopy, and zeta potential measurements. Nanogel-mediated disruption of 
biological membranes was investigated with erythrocytes, giant unilammelar vesicles, 
and live cells to evaluate the potential of these nanogels to act as endosomolytic carriers 
for intracellular delivery of small interfering RNA. Selective membrane disruption was 
achieved by increasing nanogel hydrophobicity via copolymerization with tert-butyl 
methacrylate (TBMA). Nanogels with TBMA possessed an additional advantage of 
increased cytocompatibility owing to their reduced cationic charge density.  
 
 viii 
These nanogels are able to efficiently entrap siRNA in the nanogel core and 
enhance cellular internalization of siRNA in model cell lines. The cell-line dependent 
mechanism of nanogel internalization and uptake and intracellular distribution of 
fluorescent nanogel/siRNA complexes was investigated with imaging flow cytometry. 
Functional activity of delivered siRNA was assessed using gene silencing assays.  
Modifications to the polymer chemistry were also explored to enhance the 
biological activity. A disulfide-containing crosslinker was synthesized, characterized and 
incorporated into nanogels. This crosslinker enabled the rapid nanogel degradation in 
response to reductive environments. A functional phenylalanine-derivative monomer 
(MAPA) was synthesized and characterized to serve as a bio-inspired substitute for 
TBMA. Nanogels copolymerized with MAPA demonstrate comparable siRNA delivery 
efficiency to its TMBA analogue.  
The ability to exert control over physicochemical properties and biological 
interactions of these nanogels by tuning polymer composition is a facile strategy to tailor 
material properties for specific applications. The hydrophobically-modified nanogels 
possess great potential as delivery vehicles to enhance the cellular internalization and 
endosomal escape of siRNA cargoes.  
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Chapter 1:  Introduction 
Recent in vivo successes in knockdown of disease targets indicate that siRNA 
technology is worthy of serious attention from the scientific and medical communities.  
Although much effort has been directed toward synthetic polymer carriers for siRNA, 
there remains a paucity of data on the development of oral delivery systems.  From a drug 
delivery standpoint, the oral route of administration is advantageous because it increases 
patient compliance and comfort over injection, provides a simple, repeatable 
administration, and large surface area for absorption [1].  Oral delivery of fragile 
biological molecules, such as proteins, peptides, and nucleic acids is one of the most 
compelling and difficult problems in drug delivery.  Successful development of an oral 
delivery system for small interfering RNA could revolutionize the treatment of many 
diseases by providing patients a powerful therapeutic in a convenient and accessible 
form.   
The challenges of advancing this promising therapeutic to the clinical stage are 
significant and need to be met with innovative solutions.  This project presents immense 
opportunity to develop the next generation of drug delivery systems by enabling the 
efficient delivery of a potent, highly specific therapeutic via a non-invasive, patient 
friendly route.  Efficient delivery of fragile biotherapeutics, such as peptides, proteins, 
and nucleic acids has long been considered the “Holy Grail” of drug delivery [2].  As 
most biotherapeutics are administered via intravenous, intraperitoneal, or local injection, 




concentrations in the local environment and/or transport of the drug from the intestinal 
lumen to the bloodstream would be of significant scientific and medical importance.  
This proposal emphasizes a unique and innovative approach to develop new 
carrier systems for oral delivery of siRNA.  In this work, we propose to use a facile 
photoemulsion polymerization to synthesize polycationic nanoscale hydrogels for oral 
delivery of small interfering RNA.  This synthesis, unlike many current polycationic 
siRNA delivery agents, does not rely on specialized chemistry or controlled 
polymerization techniques and is conducted on a relatively short time-scale.  
Furthermore, the oral delivery of siRNA for disease treatment is largely unexplored.  
Innovation in this area represents a departure from current thrusts in siRNA delivery, 
which rely on painful intravenous or impractical intraperitoneal injections.  The central 
aim of this proposal is of great medical significance, as advances in this area could 
significantly improve the ease and availability of siRNA therapy to patients.  The final 
result of this proposal will be a platform technology for drug delivery; a safe, efficient 
polymer carrier capable of delivering manifold siRNA cargoes to the epithelial cells in 
the small intestine.  Successful development of this system will pave the way for 
improved treatment of gastrointestinal diseases where current treatment is sub-optimal, 
such as Crohn’s disease, ulcerative colitis, celiac disease, and gastrointestinal carcinomas. 
Current efforts in oral delivery of small interfering RNA [3-5] utilize a two-phase 
delivery system to navigate the extracellular and intracellular barriers posed by oral 
administration.  Similarly, this ultimate goal of this thesis work is to contribute to the 
development of a novel, two-phase platform delivery system for oral siRNA.  The work 




circumvent the intracellular barriers of siRNA delivery.  The full realization of a 
platform delivery system will required continued development and ultimately integration 
of a complementary delivery system carefully engineered to circumvent the extracellular 
barrier to siRNA delivery.   
CHAPTER GUIDE  
The research described in this body of work is divided into several chapters. 
 Chapter 2 offers a detailed background and critical review of synthetic polymers and 
biomaterials used in drug delivery applications.  Particular emphasis is placed on 
responsive nanomaterials with applications in disease detection or treatment. 
 Chapter 3 outlines the objectives of this thesis and the specific aims guiding the work. 
 Chapter 4 describes the use of a photoemulsion polymerization to created nanoscale 
hydrogels, or nanogels, from methacrylate building blocks.  In this chapter, the 
synthesis, purification, and characterization of aqueous solution properties are 
described. 
 Chapter 5 investigates the role of nanogel composition on in vitro physicochemical 
properties.  Nanogel-mediated membrane destabilization is described in three model 
systems and a relationship between acute toxicity and nanogel composition is 
described. 
 Chapter 6 investigates the mechanism of cellular uptake in target cell lines using 
imaging flow cytometry 
 Chapter 7 leverages the insight from Chapters 4 and 5 to select the most promising 
formulation for intracellular delivery of siRNA.  This chapter also describes the 




siRNA delivery efficiency of these degradable nanogels is assessed with imaging and 
conventional flow cytometry. 
 Chapter 8 details the synthesis and purification of a custom, functional phenylalanine-
derived monomer.  This monomer was used in responsive nanogels to modulate 
hydrophobicity.  The resulting nanogels were compared to the most promising 
formulation as determined in Chapter 5. 
 Chapter 9 provides overall conclusions and recommendations for future work. 
APPENDIX GUIDE 
Additional pertinent information is contained in several appendices.   
 Appendix A is a guide to nanogel nomenclature 
 Appendix B describes relevant theoretical considerations in dynamic light scattering 
measurements, including a framework for the Cumulants analysis employed in this 
thesis.  Preliminary experiments to optimize sample preparations for dynamic light 
scattering are also described. 
 Appendix C explains the gating strategy, relevant nomenclature, and analysis 
parameters used in the imaging flow cytometry experiments.    
 Appendix D describes the development and classroom implementation of a drug 
delivery experiment using a facile ionic crosslinking of sodium alginate.  This 
experiment is a core component of an NSF-sponsored high school research program 
in the laboratory of Prof. Nicholas Peppas and also the Principles of Biomedical 
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Chapter 2:  Objectives of Proposed Research 
The central goal of this proposal is to synthesize novel polycationic nanomatrices 
possessing tunable pH-responsive behavior that can encapsulate siRNA, enhance cellular 
uptake in model cells of the gastrointestinal tract, and facilitate its endosomal escape.  
Specifically, the aims for this research are: 
1. Synthesize nanoscale, intelligent, multi-responsive polycationic polymer 
networks, 
2. Optimize molecular architecture for cellular compatibility, endosomal release, 
and siRNA encapsulation 
3. Rigorously investigate in vitro properties and silencing efficiency using cell 
models of intestinal epithelia and resident phagocytes in inflamed intestinal 
tissue. 
A representative example of this experimental work flow used to accomplish 
these aims is seen in Figure 2.1.  The novel aspect of this proposal is that it represents the 
first time that nanoscale hydrogels will be engineered for the oral delivery of siRNA.  
Local delivery of siRNA to the gastrointestinal tract would be ideal for the treatment of 
various gastrointestinal and hepatic conditions, including Crohn’s disease, ulcerative 
colitis, celiac disease, gastrointestinal carcinomas, and hepatitis viruses, where non-
invasive oral administration would represent a significant improvement over current 
treatment.  Ultimately, we foresee an oral delivery system capable of targeting siRNA 
therapeutics to any tissue in the body, eliminating the need for injection and enhancing 











Chapter 3:  Background 
Modern advances in science and medicine have brought about the advent of 
highly specific biological pharmaceutical agents, including proteins (monoclonal 
antibodies, growth factors, hormones, enzymes, synthetic oligopeptides) and nucleic 
acids (plasmid DNA, antisense oligonucleotides, siRNA, miRNA) that can be used to 
treat a variety of diseases[1, 2].  However, a significant obstacle in the emergence of 
highly specific therapies remains the delivery of these macromolecules to their 
subcellular site of action.  Extracellular and intracellular trafficking barriers represent a 
significant limitation in the delivery of fragile therapeutics as systemically administered 
macromolecules are rapidly sequestered by the reticuloendithelial system (RES) and 
internalized molecules are quickly trafficked to lysosomes for acidic and enzymatic 
degradation[3]. 
Many conventional drug delivery modalities indiscriminately distribute drugs 
throughout the body, frequently exerting effects on both diseased and healthy cells and 
tissues.  Patients stand to benefit from both efficient delivery systems of novel, specific 
therapeutics and improved, targeted delivery systems for existing therapeutics.  Couvreur 
and colleagues, among others, have provided some of the earliest commentary on the use 
of nanoparticles for controlled release of therapeutic agents[4, 5].  Recently, the use of 
polymer-mediated delivery systems, such as polymer-drug conjugates, polymer micelles, 
polymer-drug polyplexes, and nanoscale hydrogels (Figure 3.1), have been investigated 
to improve efficacy of these drugs by providing protection from rapid clearance and 
enzymatic digestion, as well as offering the potential for controlled release [6, 7].  Of 




specific targeting or controlled drug release.  Molecular design of intelligent delivery 
systems must consider stability, administration, absorption, metabolism, and 
bioavailability at target site. By controlling the level and location of biotherapeutics 
within the body, lower doses are needed and potentially harmful side effects can be 
minimized[3, 8, 9].   
3.1. RESPONSIVE POLYMER DELIVERY SYSTEMS 
Selective delivery of biotherapeutics hinges on a safe, efficient, and accurate 
delivery vector.  In recent years, there has been much attention on the rational design of 
synthetic polymers for novel treatment modalities because of their facile manufacture, 
large carrying capacity [1], tunable physicochemical characteristics, and modulation of 
biological activity through attachment of targeting ligands and poly(ethylene glycol) 
(PEG)[10].  Interdisciplinary research between polymer chemistry and biomedical 
science has yielded several promising systems for polymer based drug delivery, including 
polymer-drug conjugates, polymeric micelles, multi-component polyplexes, and 
nanoscale hydrogels [11, 12].  In particular, pH-responsive polymers have been 
investigated as delivery agents to overcome intracellular trafficking barriers.  It is well 
known that diseased tissues, tumors, and sites of inflammation exhibit different pH 
profiles than normal tissue [13].  Also, intracellular pH varies substantially depending on 
organelle.  Endosomes and lysosomes typically exhibit pH values of 6.8 - 4.5.  This pH 
variation can be exploited to specifically deliver therapeutics to a specific intracellular or 
extracellular site of action.  By judicious materials selection and careful engineering of 




pH response and drug release[14, 15].  Many pH-responsive polymer delivery systems 
rely on acid catalyzed hydrolysis to control drug release or on weakly charged polymer 
chains to mediate endosomal disruption and enable cytoplasmic release.   
Anionic polymers undergo a conformational change from charged open chains to 
compact, hydrophobically-stabilized structures capable of disrupting the membrane of a 
maturing endosome through pore formation and disruption of membrane integrity.  The 
mechanism of membrane-destabilization by anionic polymers is thought to be related to 
their pH-dependent conformational transition [16] and the extent of polymer association 
with the lipid bilayer and cellular uptake can be enhanced by increased polymer 
hydrophobicity [17].   
Cationic polymers, which are able to electrostatically bind negatively-charged 
nucleic acids such as DNA and RNA, are thought to promote endosomal rupture through 
the “proton sponge” mechanism.  These polymers, which contain ionizable groups, 
absorb incoming protons during endosomal acidification.  This action causes an 
accumulation of protons and counter ions, such as Cl-, within the endosome.  The high 
osmotic strength within the endosomal compartment subsequently leads to osmotic 
swelling and endosomal rupture [18].  The general model for drug delivery through 
endosomal release has been well described[11].  After endocytosis, the decreasing 
endosomal pH induces a conformational change in the polymer.  pH-responsive polymers 
can increase membrane permeability through hydrophobic associations or the proton 
sponge mechanism, releasing the payloads into the cytosol.  Lysosomal trafficking is 




Environmentally-responsive polymers, or smart polymers, are a class of materials 
comprised of a large variety of linear and branched (co)polymers or crosslinked polymer 
networks.  A hallmark of responsive polymers is their ability to undergo a dramatic 
physical or chemical change in response to an external stimulus.  Temperature and pH 
changes are commonly used to trigger behavioral changes but other stimuli, such as 
ultrasound, ionic strength, redox potential, electromagnetic radiation, and chemical or 
biochemical agents can be used.  These stimuli can be subsumed into discrete 
classifications of physical or chemical nature [19].  Physical stimuli (i.e. temperature, 
ultrasound, light, magnetic and electrical field) directly modulate the energy level of the 
polymer/solvent system and induce a polymer response at some critical energy level.  
Chemical stimuli (i.e. pH, redox potential, ionic strength, and chemical agents) induce a 
response by altering molecular interactions between polymer and solvent (adjusting 
hydrophobic/hydrophilic balance) or between polymer chains (influencing crosslink or 
backbone integrity, proclivity for hydrophobic association, or electrostatic repulsion) 
[19].  Types of behavioral change can include transitions in solubility, hydrophilic-
hydrophobic balance, and conformation [20].  These changes are manifested in a number 
of ways, such as the coil-globule transition of polymer chains [21], swelling/deswelling 
of covalently crosslinked hydrogels [22], sol-gel transition of physically crosslinked 
hydrogels [23], and self-assembly of amphiphilic polymers [24] (Figure 3.2).  This aim of 
this section is to review recent developments in temperature and pH-responsive polymers 
and highlight the emerging area of redox-responsive polymers for drug delivery systems.  
Several excellent reviews which provide a comprehensive treatment of the subject are 




3.1.1. Applications and Examples 
The majority of responsive polymers for drug delivery can be broadly categorized 
as hydrogels, micelles, polyplexes, or polymer-drug conjugates.  Hydrogels are 
hydrophilic (co)polymeric networks capable of imbibing large amounts of water or 
biological fluids [30].  Physical or covalent crosslinks render hydrogels insoluble in 
water.  Hydrogels can be engineered to respond to various stimuli [25] and have 
demonstrated utility in the medical and pharmaceutical arenas.  Peppas and coworkers 
have pioneered the use pH-responsive complexation hydrogels of poly(methacrylic acid) 
grafted with PEG, P(MAA-g-EG) for oral protein delivery.  Through interpolymer 
complexation in acidic conditions, this system has been shown to successfully entrap, 
protect, and mediate delivery of insulin [31], calcitonin [32], and recently interferon β 
[33].  Micelle-forming polymers, such as block copolymers of poly(ethylene oxide) and 
poly(propylene oxide), or Pluronics®, have been thoroughly studied in drug delivery 
[26].  These polymers exhibit thermally-responsive micellization [34], as do  block 
copolymers of poly(N-isopropylacrylamide) (PNIPAAm) coupled with  hydrophilic PEG 
[24].  Polyplexes formed by cooperative electrostatic interactions between 
polyethyleneimine (PEI) and DNA are widely studied for gene delivery.  Since the 
seminal paper by Boussif, et al. [35], several facets of PEI-mediated gene delivery have 
been investigated, including the influence of crosslinking, molecular weight, branching, 
and biodegradability [36-38]. 
3.1.1.1. Responsive Systems based on Temperature 
Temperature has been widely investigated as a stimulant for responsive polymer 




[19].  Tanaka observed temperature-dependent swelling of polymer gels [39] following 
its theoretical prediction over 40 years ago [40].  One thermo-responsive polymer, 
PNIPAAm, has been thoroughly investigated for its ability to undergo a reversible, 
inverse (or negative) temperature-dependent phase transition [25].  Below its lower 
critical solution temperature (LCST) near 32°C, PNIPAAm exists as a hydrophilic coil 
while above the LCST, PNIPAAm chains collapse sharply into a hydrophobic globule 
[41].  The nature of this volume phase transition stems from the hydrophilic/hydrophobic 
balance of polymer chains [42], which is  modulated by continual establishment and 
disruption of intra- and intermolecular electrostatic and hydrophobic interactions.  Below 
the LCST, water molecules exist in an ordered state in the local environment of polymer 
chains [43].  As temperature rises above the LCST, polymer-polymer hydrophobic 
interactions dominate [41].  Consequently, polymer chains collapse and water molecules 
are released to the bulk, resulting in a net entropic gain for the polymer/solvent system 
[44].   
For drug delivery applications, it may be desirable to shift the critical temperature 
for volume phase transition to specific temperatures.  This can be accomplished through 
the inclusion of hydrophobic or hydrophilic moieties in the polymer chain.  Polymers 
with a larger hydrophobic hydration area possess stronger hydrophobic interactive forces 
and undergo collapse at a lower temperature[21, 45].  Conversely, increasing the 
hydrophilic content of the polymer chain will increase the LCST.  Polymers that exhibit 
positive temperature-dependent swelling behavior, i.e. globule-to-coil transition with 




These materials, such as poly(acrylic acid) and polyacrylamide interpenetrating networks 
(IPNs), are discussed in more detail elsewhere [46]. 
Physically crosslinked gels, such as methoxy-substituted cellulose derivatives, 
PNIPAAm copolymers,  and various Pluronics can undergo a sol-gel phase transition 
near their LCST [26].  These materials are attractive candidates for in situ implants, in 
which thermoreversible gelation is exploited for the facile implantation of solid drug-
depot preparations [47].  In these systems, a liquid drug/polymer solution is injected to a 
target site at ambient temperature.  As the solution temperature warms to body 
temperature, the polymer gels, entrapping the drug in the physically crosslinked matrix.  
Diffusion of drug from the solid gel allows for sustained-release formulations.  This 
approach was used in a study describing the release of model protein bovine serum 
albumin (BSA) from temperature-responsive chitosan grafted with PEG (PEG-g-
chitosan) [48].  PEG-g-chitosan containing 45 and 55 wt% grafted PEG were loaded with 
BSA and incubated at 37°C to evaluate release kinetics.  Both gels demonstrated initial 
burst release of BSA during the first 5 hours followed by sustained, diffusion-driven 
release until approximately 70 hours.  Crosslinking the gels with genipin resulted in 
prolonged release of BSA for up to 40 days.   
Novel polymerization techniques, such as controlled radical polymerizations and 
click chemistry reactions, offer superior control over molecular architecture and present 
the opportunity to create novel materials highly tailored for specific responsive behavior.  
This approach was employed by Sumerlin and colleagues to produce folate-conjugated 
temperature-responsive block copolymers of N,N-dimethylacrylamide (DMAAm) and 




system, PNIPAAm blocks collapsed into hydrophobic globules while DMAAm blocks 
remained hydrophilic.  Ensuing aggregation resulted in particles of approximately 46 nm, 
postulated to be micelles with PNIPAAm cores and DMAAm shells.  Surface decoration 
of the polymer chains with folate enable the system to be actively targeted to certain 
tissues via receptor-mediated endocytosis.  Self-assembled folate-conjugated polymers 
provided controlled release of a model hydrophobic drug, dipyridamole over the course 
of 12 days.   
3.1.1.2. Responsive Systems based on Redox Potential 
Polymers containing labile linkages present an attractive opportunity to develop 
biodegradable or bioerodible delivery devices.  Much of the early work in this field 
focused on acid labile linkages of polyanhydrides [50, 51], poly(lactic/glycolic acid) [52], 
and more recently poly(β-amino esters) [53, 54].  However, intracellular cues are now 
being investigated as a means to trigger cytoplasmic degradation of polymer carriers 
incorporating advanced therapeutics like siRNA and anticancer drugs.  Disulfide linkages 
are well known to be unstable in a reductive environment as the disulfide bond is readily 
cleaved in favor of corresponding thiol groups.  Polymers with disulfide cross-links have 
been synthesized as polymersomes [55], nanogels [56], and core-cross-linked polyplexes 
[57] and degrade when exposed to cysteine or glutathione, reductive amino-acid based 
molecules present at intracellular concentrations 50 - 1000 fold greater than that of the 
extracellular milieu [57].   
The Hubbell group [55] has used amphiphilic copolymers of PEG and 
poly(propylene sulfide) (PPS) to form vesicular compartments.  Rather than relying on 




accumulation of the polymer carrier, they have incorporated a disulfide linkage between 
the hydrophilic PEG and hydrophobic PPS portions of the polymer, imparting a high 
degree of reductive sensitivity to the polymersomes.   
In another study, glutathione-degradable nanogels were prepared by inverse 
emulsion ATRP [56].  Upon exposure to 10 wt% glutathione, half of the polymer 
degraded in nearly 6 hours.  Exposing polymers to 20 wt% glutathione resulted in 85% 
degradation within 1 hour.  Doxorubicin was efficiently incorporated into the polymer 
matrix at 16 wt% of the polymer with over 50% loading efficiency and the authors 
demonstrated in vitro release of fluorescent dye Rhodamine G6 and doxorubicin.  Dox-
loaded nanogels displayed negligible toxicity toward HeLa cells in the absence of 
glutathione while causing approximately 40% reduction in cell viability following 
introduction of exogenous glutathione to the cellular media.  It remains to be determined 
if this polymer system is capable of degrading and releasing drug upon exposure to 
intracellular glutathione concentrations or if the time-scale for degradation in the 
presence of endogenous glutathione will allow efficient cytoplasmic delivery of 
incorporated therapeutics.    
In a more recent investigation, Kataoka and colleagues [57] synthesized and 
thoroughly characterized a core-cross-linked polyplex comprised of iminothiolane-
modified PEG-block-poly(L-lysine), or [PEG-b-(PLL-IM)], for intracellular siRNA 
delivery.  The use of a block copolymer affords modular functionality; the polycationic 
poly(L-lysine) segment serves to bind siRNA and provide endosomal buffering capacity 
[58] while the hydrophilic PEG segment prolongs circulation time, prevents aggregation, 




with 2-iminothiolane and subsequently oxidized to form disulfide cross-links.  
Introducing crosslinks to the micelle core confers stability to the system, as crosslinked 
polymers maintained micellar structure in physiological salt conditions while their non-
crosslinked counterparts could not.  The resulting polyion complex micelles were 
approximately 60 nm in diameter, a particle size well within the accepted limits (20 - 100 
nm) for avoiding uptake by the RES and renal exclusion [60].  Not surprisingly, micellar 
stability exerted strong influence over the ultimate siRNA transfection efficiency.  The 
authors observed a narrowly defined N/P RATIO at which stable micellization occurred.  
Interestingly, this optimum N/P ratio shifted to higher values with increased crosslinking.  
Highly efficient (over 80%) knockdown of a reporter gene was detected at the optimum 
N/P ratio, however, a considerable decrease in transfection efficiency was observed upon 
slight departure from this critical value.  
3.1.1.3. Responsive Systems based on pH 
Physiological pH varies systematically in the body, particularly along the 
gastrointestinal (GI) tract, where harsh pH and enzymatic conditions in the stomach (pH 
~ 2) degrade macromolecules.  The small intestine is substantially more alkaline, with pH 
~ 6.2 - 7.5. Physiological pH profile will also change amongst cellular compartments.  
Endosomes typically exhibit pH values of 5.0 - 6.8 and lysosomes 4.5 - 5.5 [61, 62].  
Also, it is well known that diseased tissues and sites of inflammation exhibit different pH 
profiles than normal tissue [13].  Tumors have been widely reported to produce acidic 
conditions (pH ~ 6.5) in the extracellular milieu [63].  Thus, it is no surprise that 
scientists and engineers have devoted considerable effort toward the rational design of 




therapeutics to specific intracellular or extracellular sites of action.  By judicious 
materials selection and careful engineering of molecular architecture, pH-responsive 
polymer delivery systems can be developed to give well-controlled pH response and drug 
release. 
Recently, we have synthesized polycationic nanomatrices capable of well-defined 
hydrophilic-hydrophobic transition near physiological pH [64, 65].  Relatively uniform 
particles of poly[2-(diethylamino)ethyl methacrylate-co-t-butyl methacrylate-g-PEG] 
(PDBP) measuring 51 nm were synthesized using a novel photoemulsion polymerization 
technique [64].  Relevant properties of the system, such as swelling ratio, critical swelling 
pH, surface charge, and biocompatibility were tailored by tuning polymer composition, 
crosslinking density, and the incorporation of hydrophobic moieties to the hydrogel core.  
Ongoing work aims to optimize these systems for intracellular siRNA delivery.    
Promising work by Hu et al. [66] describes the development of pH-responsive 
core-shell hydrogels for intracellular delivery of ovalbumin to dendritic cells, a class of 
cells intimately involved with adaptive immunity.  Emulsion polymerization was used to 
create crosslinked PDEAEMA core - PAEMA shell nanoparticles measuring 205 nm in 
diameter.  The authors hypothesized that PDEAEMA would exhibit pH-responsive 
behavior while PAEMA would remain constitutively ionized throughout the 
physiological pH range.  Interestingly, the authors used the cationic PAEMA shell to 
adsorb and protect a model ovalbumin protein, rather than the archetypal practice of 
loading therapeutics to the hydrogel core.  Subsequent studies demonstrated the 
versatility of this approach through intracellular delivery of siRNA and influenza A 




responsive domain represents an intriguing departure from the current paradigm of using 
a neutral, hydrophilic shell, such as PEG, to shield surface charges.  However, several 
drawbacks may limit the feasibility of this design in vivo.  First, charged particles have a 
much higher opsonization rate than neutral particles [59] and the cationic PAEMA shell 
may attract opsonin proteins or promote adsorption of anionic serum proteins, resulting in 
rapid clearance by the RES.  Secondly, the slow dissociation of electrostatically bound 
cargo from polymer shell may provide a kinetic barrier to therapeutic efficacy.   
Bae and colleagues [68-70] have recently reported polymer micelles possessing 
dynamic, multi-functional behavior for drug delivery.  Self-assembling amphoteric 
polyamine-based block copolymers were functionalized with folate [68], biotin [70], and 
HIV peptide TAT ligands [69], demonstrating robust applicability in targeted delivery.  
Folate or biotin ligands enhance cellular uptake via receptor mediated endocytosis [71] 
and TAT is a well-known peptide transduction domain [72].  By conjugating the cell-
penetrating peptide TAT, particles of up to 200 nm gain direct access to the cell [73], 
effectively circumventing the intracellular trafficking pathway.  The polymer system, a 
mixture of two block copolymers 1) poly(L-histidine)-b-PEG (polyHis-b-PEG) and 2) 
poly(L-lactic acid)-b-PEG-b-polyHis-ligand (pLLA-b-PEG-b-polyHis-ligand), self-
assembled into mixed micelles capable of ligand exposure, micelle destabilization, and 
endosomal disruption in response to pH [69, 70].  A short polyHis block preceding the 
ligand serves to anchor the ligand at the core-shell interface, effectively shielding its 
presentation on the micelle surface at neutral pH.  Upon exposure to slightly acidic (6.5 < 
pH < 7.0) environment,  the short polyHis anchor ionizes and PEG-b-polyHis arm 




tumor specificity to the micelle carrier as the ligand will be unavailable to promote 
receptor mediated endocytosis or cellular transduction in normal (pH 7.4) tissue.  Further 
acidification (pH < 6.5) induced micelle dissociation by ionization of the His residues in 
the micelle core.  Breast adenocarcinoma cells exposed to doxorubicin-loaded mixed 
micelles displayed prominent intracellular distribution and nuclear localization of Dox 
after 30 minutes and experienced ~60% reduction in cell viability of after 48 hours. 
3.2. POLYMER-DRUG CONJUGATES 
The use of synthetic polymer-drug conjugates for drug delivery was first proposed 
in 1975 [74].  Generally, these entities are composed of a reactive drug conjugated to a 
water soluble polymer backbone through a biodegradable linkage [75].   Common pH-
responsive linkages include anhydrides, cis-aconityl, hydrazones, and acetals [11].  
Targeting ligands, such as transferrin, can also be conjugated to the polymer backbone.  
The transferrin receptor is typically over-expressed in rapidly proliferating and cancer 
cells [76], providing an attractive opportunity for tumor-targeting. 
Covalent conjugation of anticancer drugs to a polymer backbone via a pH-
sensitive linkage has been explored as an option to liberate compounds such as 
doxorubicin in the local tumor environment.  This type of delivery requires a conjugate 
that is stable in circulation and normal tissue but releases a fully active drug at the target 
site.  Mayumi and colleagues have synthesized a copolymer of vinylpyrrolidone and 
dimethylmaleic anhydride, where the dimethylmaleic anhydride serves as the pH-
responsive linker [77].  The dimethylmaleic anhydride is able to bind amine groups at pH 
> 8.0 and reverts back to anhydride form at pH < 7.0, releasing the bound drug.  The 




Typical concentrations of polymer drug delivery systems are near 200 μg/mL .  The 
polymer-drug conjugate was demonstrated to have increased circulatory half-life and 
enhanced anti-tumor activity compared to doxorubicin alone.  In fact, intravenously 
injected polymer-doxorubicin conjugates were able to completely inhibit tumor growth in 
murine sarcoma models, confirming that the released drug was indeed fully active.   
Doxorubicin has also been conjugated to a N-(hydroxypropyl)methacrylamide 
(HPMA) polymer via degradable hydrazone linkages [78].  Covalent attachment was 
stable at physiological pH, as less than 10% of doxorubicin was released from the 
polymer at pH 7.4.  However, at pH 5.0, nearly 50% was released after 5 hours.  
Intravenous injection in mice significantly slowed tumor growth lasting 60 days and 
prolonged survival for 30 days over control treatments.   
3.3. POLYMER MICELLES 
Many polymer micelles are formed by amphiphilic block copolymers.  These 
supramolecular structures self-assemble to form particles with hydrophobic interior and a 
hydrophilic corona.  Hydrophobic or water-insoluble drugs can be encapsulated in the 
hydrophobic core.  The thermodynamic and kinetic stability of micelle structures allow 
them to retain integrity, even after extreme dilution (e.g. intravenous injection) or 
extended circulation time [79].   Typical micelle size (20 - 100 nm) is large enough to 
avoid renal clearance yet small enough to avoid rapid uptake by the RES [60].  Physical 
encapsulation of hydrophobic drugs within micelles may be a more favorable approach 
than conjugation as covalent attachment of drugs to a polymer carrier may negatively 




Kataoka and colleagues [80] have developed pH-sensitive micelles demonstrating 
release of adriamycin.  Adriamycin was conjugated to poly(aspartate) through an acid-
labile hydrazone linker.  Following acid-catalyzed hydrolysis, the micellar structure was 
disrupted, releasing free drug.  A recent study by Geng, et al. describes the formation of 
cylindrical micelles, or filomicelles, from copolymers of poly(ethylene glycol) and 
poly(caprolactone) (PCL) [81].  These particles, owing to their extended shape, were not 
readily taken up by the RES and achieved circulation times of over one week after 
systemic administration.  Acid catalyzed degradation of PCL promotes micellar 
fragmentation and subsequent extravasation and cellular uptake.  In vivo studies in 
tumor-bearing mice confirmed the benefit of prolonged circulation.  Paclitaxel-loaded 
filomicelles caused significant increase in tumor apoptosis and decrease in tumor volume 
relative to free drug.  Additionally, the magnitude of apoptotic response and tumor size 
reduction increased with filomicelle length (i.e. longer filomicelles delivered paclitaxel 
more efficiently than did short filomicelles).  Long-circulating, pH degradable structures 
such as this could have significant utility in cancer therapy.  Chemotherapeutic agents, 
such as paclitaxel or doxorubicin, could be administered less frequently, decreasing the 
intensity of conventional chemotherapy and improving quality of life for the patient. 
pH-responsive micelles based on acetal polymers have shown promise in 
controlled release of doxorubicin [82].  The acetal block forms a hydrophobic core able 
to efficiently encapsulate doxorubicin (12 wt%).  Upon exposure to mildly acidic 
conditions, the acetal core begins to hydrolyze, exposing polar groups in the micelle core.  
This alters solubility of the core block and disrupts the micelle, releasing free doxorubicin 




hours in pH 4.0 and 40 hours in pH 5.0, while the release rate at pH 7.4 is negligible.  
Thus, the time scale of doxorubicin release suggests this system would be applicable for 
sustained release to the acidic interstitial fluid surrounding tumors.  As intracellular 
trafficking from endosomes to lysosomes occurs on the order of minutes, a carrier 
designed to enhance intracellular delivery through endosomal rupture should possess a 
comparable response time. 
3.4. POLYMER-DRUG POLYPLEX 
Polyplexes are formed by electrostatic or hydrophobic interactions between 
polymers and nucleic acids, proteins, or low molecular weight drugs.  These structures 
are thought to have increased mechanical stability over micelles due to chain 
entanglements and hydrophobic interactions [83].  For example, polycations such as 
polyethyleneimine are routinely used to bind negatively-charged plasmid DNA for gene 
therapy.  These systems contain DNA-binding amines, and may contain targeting ligands 
to direct cell-specific delivery and receptor-mediated endocytosis [18].  In some cases, 
the addition of pH-responsive polyanions or hydrophobic comonomers may aid in the 
endosomal release of multi-component polyplexes [84-86].  In fact, DNA transfer has 
been increased up to three orders of magnitude by introduction of a membrane-lytic 
peptide [18]. 
Work by Shenoy and Amiji [53, 54, 87] has focused on using poly(β-amino 
esters) as pH-responsive polyplexes for delivery of chemotherapeutic agents.  
Copolymers of poly(ethylene oxide) and poly(propylene oxide) were blended with 
poly(β-amino ester) to form spherical nanoparticles of 150 - 200 nm.  These polymers 




in the form of oligonucleotides or plasmid DNA.  Cytotoxicity studies have demonstrated 
that poly(β-amino esters) are significantly less toxic than conventional polymers used for 
nucleic acid delivery, such as poly(ethyleneimine) or poly(L-lysine) [53].  Paclitaxel was 
efficiently loaded into these nanoparticles, achieving 20 wt% drug in polymer 
concentration.  The particles exist in a stable, insoluble form at physiological pH but 
undergo a rapid dissolution at pH < 6.5, releasing drug to the surrounding environment in 
a sudden burst.  When injected intravenously to tumor-bearing mice, paclitaxel-loaded 
nanoparticles significantly inhibited tumor growth relative to paclitaxel injection alone 
[87].  Moreover, body weight and blood count measurements indicated little to no 
adverse toxicity in mice injected with poly(β-amino ester).   
In an effort to explore synergistic advantage of both pH- and temperature-
responsive behavior, Kang, et al. have prepared a series of graft copolymers based on 
temperature-responsive N-isopropylacrylamide and pH-responsive 
sulfamethoxypyridazine [83].  Doxorubicin was loaded into the polyplex at 10 wt % drug 
in polymer and released from the matrix by inducing a hydrophobic to hydrophilic phase 
transition.  As expected, the release rate of doxorubicin was highest when the 
temperature-sensitive and pH-sensitive blocks were simultaneously converted to the 
hydrophilic state.   
3.5. NANOSCALE HYDROGELS 
Nanoscale hydrogels, or nanogels, are materials with diverse biomedical 
applications.  Because of their inherent mechanical integrity and biocompatibility, 
hydrogels have utility in imaging, biosensing, molecular recognition, and therapeutic 




of their tunable nanoscale dimensions (i.e. large enough to avoid renal clearance and 
small enough to evade RES), drug loading capacity, colloidal stability, and large surface 
area for conjugation of active targeting moieties [88].  Furthermore, the nanoscale 
dimensions ensure a rapid response to pH changes, an attractive attribute in drug delivery 
applications.  The pH response of hydrogels can be modulated by the pKa of polymer 
chains and choice of monomer.   
Cationic monomers with pKa > 7, such as poly(dimethylaminoethyl methacrylate) 
(PDMAEMA), will exist in an ionic state at physiological pH.  The positively charged 
amino groups will repel each other and permit the osmotically-driven flux of water into 
the polymer matrix.  However, increasing the pH above the nanogel pKa will deprotonate 
the amino groups and hydrophobic interactions will collapse the gel, excluding water.  
Polymers based on anionic monomers (pKa < 7), such as methacrylic acid, will behave in 
the opposite manner.  At pH below the pKa, pendant carboxyl groups are protonated and 
hydrophobic interactions maintain the gel in the collapsed state.  Increasing the pH above 
the pKa will deprotonate the carboxyl groups, swelling the gel through electrostatic 
repulsions and influx of water.   
Nanogels are being explored as drug delivery agents for a variety of therapeutic 
agents due to their ability to efficiently encapsulate therapeutics through simple 
equilibrium partitioning or electrostatic interactions.  Using a cationic chitosan-based 
nanogel (180 nm diameter), researchers have delivered antitumor therapeutic metotrexate 
disodium to tumor cells [88].  Blanchette and Peppas have explored the use of 
methacrylic acid and ethylene glycol nanogels for oral delivery of chemotherapeutic 




release studies demonstrated favorable release kinetics.  The therapeutic agent was well 
protected in the hydrogel at low pH and nearly 100% of bleomycin was released after 1 
hour at pH 7.4.   
Recently, Peppas and coworkers described the synthesis of polycationic nanogels 
capable of well-defined hydrophilic-hydrophobic transitions near physiological pH[15, 
64, 65] and successfully demonstrated loading of biological therapeutics (e.g. insulin) and 
imaging agents (e.g. gold nanoparticles).  Akiyoshi and colleagues recently completed a 
Phase I clinical trial using a self-assembled, cholesterol-modified pullulan nanogel to 
deliver a HER2 protein fragment for vaccination against cancer [90].  HER2 protein has 
been implicated in increased aggressiveness of tumors, particularly in breast cancer[71].  
Their results indicate that administration of the protein fragment successfully initiated an 
innate immune response against HER2. 
3.6. TARGETED DELIVERY 
3.6.1. Barriers to targeted delivery 
Though localized delivery represents an attractive method for achieving a high 
concentration of biotherapeutics, most tissues are not accessible for localized treatment. 
Thus, systemic and oral administrations are commonly employed to introduce 
therapeutics to the circulatory system.  However, before reaching their site of action, 
biomacromolecular drugs face a series of extracellular obstacles which threaten to reduce 
bioavailability and therapeutic benefit.  The mononuclear phagocytic system (MPS), or 
reticuloendothelial system (RES), presents a major barrier to prolonged circulation of 
polymer nanoparticles [59].  Macrophages and monocytes of the MPS play an important 




the body.  However, they are also highly efficient at removing unprotected polymer 
nanoparticles.  Present in bloodstream and extracellular matrix of tissues, these 
phagocytic bodies are not able to recognize circulating material directly, but must do so 
through the presence of opsonin proteins [59].  The association of opsonin proteins, 
termed opsonization, can occur within seconds after entering the bloodstream as 
complement proteins and immunoglobulins bind to the surface of the polymer particle 
[59].  Bound opsonins stimulate phagocytosis of the associated particle, ultimately 
resulting in its degradation or removal from the bloodstream.  Particle aggregation with 
serum proteins such as serum albumin can also result in phagocytosis and clearance by 
the RES [91].  Typically, this process occurs through non-specific hydrophobic or 
electrostatic interactions between polymer particles and serum proteins [18, 59].  In 
addition to avoiding removal by the RES, polymer therapeutics must also escape 
filtration by the renal system.  Current calculations, based on the sieving coefficient of 
the glomerular capillary wall, estimate that a polymer nanoparticle should be at least 10 
nm in diameter to avoid first-pass renal filtration [60].   Extravasation, or escape from the 
blood vessels, poses a problem because molecules larger than 2 nm in diameter do not 
easily cross the capillary epithelia [60].  Once outside the capillaries, proteins and 
polysaccharides that comprise the extracellular matrix hinder diffusion of nanoparticles, 
increasing opportunity for phagocytosis by macrophages in the interstitial space [92].   
Further obstacles face polymer therapeutics delivered through the oral route 
(Figure 3.3).  The stomach, lumen of the small intestine, mucus layer, and the intestinal 
epithelial cell membrane must be successfully traversed [93].  Ingested formulations 




low pH (pH ~ 2) contribute to the rapid degradation of unprotected therapeutics, 
particularly proteins and nucleic acids.  Though the pH is less extreme in the small 
intestine (pH 5 - 7.4), digestive enzymes in the intestinal lumen threaten to break down 
therapeutics before they cross the epithelium.  The mucus lining, a dense network of 
glycoproteins, coats epithelial cells along the GI tract and provides resistance to 
macromolecular transport [94].  At the luminal surface of the epithelial cell layer, 
macromolecules are largely precluded from paracellular transport due to the presence of 
tight junctions.   These junctions limit the paracellular space to approximately 10 - 50 Å 
[95], defending the body from entry of viruses and toxins through the GI tract.  
Additionally, intestinal motility reduces the residence time for release and absorption by 
the intestine. 
Intracellular trafficking barriers represent a significant obstacle in the delivery of 
biotherapeutics to their subcellular site of action.  Most therapeutics must localize in the 
cytosol to exert functional activity.  After passive or receptor-mediated endocytosis, 
macromolecules are rapidly delivered to early endosomes, where the vesicular pH is 
lowered by the action of ATP-dependent proton pumps [62].  Acidification is an 
important characteristic of endosomal trafficking, serving primarily to dissociate ligands 
from receptors.  Although free receptors are recycled back to the cell surface, the early 
endosome contents are transferred to late endosomes and ultimately lysosomes for 
degradation [61].  The transit from early endosomes to late endosomes is fairly rapid, on 
the order of 2 – 3 minutes [62].  The luminal pH is progressively lowered throughout the 
pathway by ATP-dependent proton pumps.  Typically the pH of early endosomes is 6.8 – 




4.5 [61, 62].  Degradative enzymes populate the lysosome and readily break down 
foreign material.  After successively protecting its cargo through numerous extracellular 
and intracellular barriers, a delivery vehicle must then release the therapeutic in 
functional form [18].  Therefore, enabling efficient translocation of cargo from endosome 
to cytoplasm is an essential feature of any polymer-mediated drug delivery system.   
3.6.1.1. Passive Targeting 
Cellular barriers present formidable obstacles in the delivery of biotherapeutics.   
Researchers in cancer treatment have fortunately been able to exploit certain aspects of 
cancer physiology to achieve passive targeting to tumor sites.  Rapid growth of tumors 
leads to aberrant angiogenic vasculature.  The newly formed blood vessels are often 
disorganized and discontinuous, resulting in increased permeability to macromolecules.  
Moreover, lymphatic drainage systems are often poorly developed or non-existent in 
tumor sites, enabling accumulation of therapeutics [96].  This phenomenon, called the 
enhanced permeation and retention (EPR) effect [96], has increased the tumor 
concentration of anticancer agents up to 70-fold in some cases [11]. 
Since the pioneering work of Couvreur [97], nanoscale systems have been 
aggressively investigated for their utility in drug delivery applications.  Nanoparticle size 
is known to play a critical role in achieving passive targeting.  Nanoparticles above 10 
nm in diameter are generally able to avoid filtration by the kidneys, while less well 
understood, the upper size limit for passively targeted nanoparticles is thought to be 
approximately 150 nm [60, 98].  Extravasation and diffusional barriers limit nanoparticle 




have shown that nanoparticle clearance rate increases with size [99].  One such 
investigation demonstrated that the blood clearance of 80 nm nanoparticles was half as 
fast as the clearance of 170 and 240 nm particles [100].  Presumably, this effect is due to 
non-specific protein adsorption on the surface of larger nanoparticles, leading to 
opsonization and subsequent clearance by the RES [99].   
Clearly, particles with longer circulation times have superior ability to reach the 
tumor site through passive targeting.  As opsonization is an integral step in the removal of 
foreign macromolecules by the RES, many efforts for increasing serum stability and 
extending circulation time have focused on blocking absorption of opsonins onto the 
nanoparticle surface [59].  Hydrophobic and charged nanoparticles associate readily with 
opsonins and serum proteins.  Attachment of polyethylene glycol (PEG), or PEGylation, 
has been a popular approach for conferring “stealth” properties to circulating 
nanoparticles.  PEG is highly flexible, hydrophilic, non-degradable, and non-toxic [101].  
PEGylation helps shield hydrophobic or charged nanoparticles and slows the process of 
opsonization through steric hindrance [59].   
3.6.1.2. Active targeting 
The primary goal of a targeted therapeutic is to eliminate diseased cells while 
leaving normal cellular activities unimpaired.  Therefore, it is highly advantageous for a 
polymer delivery system to preferentially localize in the disease tissue rather than normal 
tissue in the body.  Through careful engineering of polymer nanoparticles, various 
targeting ligands can be displayed to enhance selective delivery to a disease sites, thereby 




tumor sites, these organs allow passage of macromolecules, generally up to 200 nm in 
size.  Unchecked accumulation of non-degradable compounds may lead to undesired 
toxicity.  Attachment of antibody fragments has been explored as a potential strategy to 
enhance tumor targeting due to their high binding specificity.  By incorporating a 
fragment, specificity is retained and the antibody region responsible for eliciting an 
immune response is not present [71].  Despite some early success in antibody targeting 
[103], more recent attention has been focused on exploiting transport receptors 
upregulated in tumors, such as transferrin and folate.  In normal cells, transferrin 
receptors exist to facilitate the endocytosis of transferrin, an iron-binding glycoprotein.  
Folate receptors function to allow transport of folic acid, a vitamin required for synthesis 
of purines and pyrimidines [71].  Transferrin and folate receptors are constitutively over 
expressed in many tumor cell types due to their increased metabolic demand.  Active 
targeting continues to command significant attention because many cancer-cell types 
display tumor-specific receptor upregulation.  Strategies are being developed to 
specifically target breast, colorectal, lung, and prostate cancer by way of tumor-specific 
ligands [71].  As new genetic and physiological anomalies in cancer cells are discovered, 
incorporation of active targeting agents will play an important role in the local delivery of 
specialized therapeutic agents.   
Targeted, functional delivery of therapeutic agents is a significant unmet need in 
drug delivery. Despite tremendous effort in targeted carriers and directed drug delivery 
systems, true targeting remains elusive. While surface conjugation of various peptide 
sequences, proteins, antibodies, and other small molecules can effectively enhance the 




probabilistic (i.e., more receptors per unit area increases the chance of receptor–ligand 
interaction and subsequent internalization). Given adequate circulation time, the current 
generation of nanoparticles will ultimately traffic to highly perfused tissue such as the 
liver, lungs, pancreas, kidneys, tumors, and sites of angiogenesis.  The next generation of 
intelligent delivery systems should be deterministic rather than probabilistic; capable of 
tunable pharmacokinetics and biodistribution whereby the carriers will localize at, and 
only at, the intended disease targets and in response to the diseased environment will 
release their therapeutic payload. In addition, they should be able to seek, find, and 
persist in disease sites while providing concomitant treatment and noninvasive 
monitoring. 
3.7. RNA INTERFERENCE 
The landmark discovery of RNA mediated interference (RNAi) in 1998 has 
sparked a massive research effort in all fields of biological science and redefined our 
understanding of gene regulation mechanisms[104, 105].  RNAi pathways are guided by 
the presence of small interfering RNA (siRNA), short strands of duplex RNA capable of 
selective, potent, and reversible silencing of target genes3.  These nucleotide strands are 
part of an endogenous regulatory pathway present in a variety of eukaryotic organisms to 
control gene expression.  RNA interference pathways have been demonstrated in 
protozoa, plants, fungi, and animals, indicating a conserved pathway which serves to 
protect the genome from viral pathogens, transposons and aberrant messenger RNA 
(mRNA)[106].  Theoretically, siRNA could be used as a powerful and versatile 
therapeutic to treat nearly any disease resulting from aberrant gene expression.  




of the molecular and genetic nature of disease enable siRNA technology to be rapidly 
adapted for disease treatment.  Owing to its remarkable potency and low therapeutic 
dosage, siRNA holds extraordinary promise as a new biological therapeutic[107, 108].  
Inefficient delivery and immunostimulation concerns have been implicated as the major 
hurdles to its widespread clinical implementation[92, 109].   
3.7.1. Mechanism of RNAi 
siRNAs are formed by cleavage of long double-stranded RNA into 21 - 23 
nucleotide fragments by the enzyme Dicer, a member of the Ribonuclease III 
family[110].  In most therapeutic applications, siRNA is produced synthetically and 
presented directly to the cell.  This method mitigates the possibility of an innate immune 
interferon response as previous reports have indicated that cytoplasmic dsRNA > 30 
nucleotides triggers interferon synthesis in mammalian cells[111].  siRNA subsequently 
associates with a multi-protein complex termed RNA induced silencing complex (RISC) 
after which the duplex is unwound through the action of RISC protein Argonaute 2 
(Figure 3.4)[112, 113].  Following unwinding, the sense strand is cleaved while the anti-
sense strand directs the activated RISC complex to selectively target and degrade 
complementary mRNA[114].  Each activated RISC complex can catalyze degradation of 
multiple target mRNA strands, making RISC-mediated mRNA degradation a prolific 
gene-silencing mechanism.  Recent reports have demonstrated the sustained potency of 
siRNA silencing.  Bartlett and Davis observed knockdown of a luciferase reporter gene 
lasting 4 - 7 days in rapidly dividing cells and over 3 weeks in non-dividing cells[107], 
and a study by Elbashir showed that 21 nt synthetic siRNA effectively mediated gene 




Because of its broad therapeutic potential and sustained, sequence-specific gene 
silencing, siRNA has been identified as a treatment modality for a variety of diseases, 
including many viruses and cancers.  Following a pioneering study by Song, et al., which 
demonstrated the first in vivo evidence of siRNA efficacy[115], many investigations have 
shown successful knockdown of disease targets.  More recently, Davis and colleagues 
reported evidence of nanoparticle-mediated delivery of functional siRNA in 
humans[116].  Many RNAi-based therapeutics are currently undergoing clinical trials, 
predominantly for indications in ophthalmology and oncology (Figure 3.5). 
3.7.2. Key Challenges and Opportunities in siRNA therapeutics 
Although siRNA should not be considered a panacea for all disease, its broad 
therapeutic applicability and promising success both in vitro and in vivo cannot be 
ignored.  Many disease treatments stand to benefit from the clinical implementation of 
siRNA therapeutics.  However, translating this therapeutic value into a clinical reality is 
hampered by the lack of an efficient delivery system.  This is due primarily to the 
combination of extracellular and intracellular barriers which limit the access of 
exogenous siRNA to the cytoplasm of target cells. 
Interference with viral RNA genomes or replicative intermediates has proven 
effective, particularly with hepatitis viruses[117].  Several groups have demonstrated 
significant siRNA-mediated inhibition of hepatitis B virus replication in vivo[118-121] 
and in vitro studies indicate that siRNA may be an attractive antiviral therapy for 
hepatitis C (HCV) [122, 123].  Targeted siRNA holds promise in the treatment of other 




based treatments for hypercholesterolaemia[124], a formulation for which Alnylam 
Pharmaceuticals has applied to initiate Phase I clinical trials.   
siRNA has been hypothesized as a potential treatment strategy for several types of 
cancer.  Numerous studies present compelling evidence for siRNA as a novel therapeutic 
approach, but work remains to be done to elucidate the precise anti-tumor activity of 
siRNA.  Reports have indicated siRNA may induce off-target effects, activating immune 
responses and stimulating production of cytokines and interferons, which could enhance 
innate anti-tumor activity[125].  Other diseases, such as liver cirrhosis and human 
papillomavirus have shown promising response to siRNA treatment in vivo[92].   
The development of RNAi technologies has largely been driven by innovation in 
small biotechnology and pharmaceutical companies, like Alnylam, Marina, Tekmira, Isis, 
Rxi, Calando, and others.  Prior to 2008, much of the news around  RNAi focused on 
lucrative acquisitions and development partnerships.  Traditional large pharmaceutical 
companies invested heavily in RNAi, with $500M from Roche, $200M from Pfizer, and 
$1.5B+ from Merck.  Since then, these announcements have been followed by a series of 
high-profile realignments, with both Roche (November 2010) and Pfizer (February 2011) 
abandoning internal RNAi efforts. 
This model is expected to continue as traditional pharmaceutical companies shy 
away from lengthy and expensive exploratory R&D.  Rather, recent trends suggest big 
pharma companies are becoming more conservative with their research efforts; content to 
acquire technical expertise and intellectual property through acquisition of companies 




marketing and distribution of new drug candidates, shifting the onus for innovation to 
smaller companies. 
In many ways, the future for RNAi, for scientists, funding agencies, and private 
investors, has never been brighter.  The recent announcements by Roche and Pfizer 
served to deflate what was perhaps an RNAi bubble from 2006 – 2008.  It should be 
noted, however, that both Merck and Novartis continue to quietly invest in RNAi 
development programs.  Furthermore, recent clinical data from the recent meeting of the 
American Society for Clinical Oncology in June 2011 indicate that meaningful clinical 
progress is being made with siRNA-based therapies.  Both Atu027 (advanced solid 
cancer, Silence Therapeutics) and ALN-VSPO2 (liver cancer, Alnylam) achieved 
important safety endpoints in Phase I clinical trials.  These developments, combined with 
recent advances in RNA chemistry that significantly reduce immunostimulation, suggest 










Figure 3.2 - Illustrative examples of responsive behavior. (a) Coil-to-globule transition of 
a linear polymer chain in solution. (b) Responsive swelling/deswelling of a 
surface-grafted crosslinked hydrogel particle. (c) Stimuli-responsive 
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 Figure 3.5 - Delivery vehicles and disease indication for RNAi products in clinical 
trials.  Data adapted from ref. [126].  Abbreviations: AMD: Age-related macular 
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Chapter 4:  Tunable, responsive nanogels containing tert-butyl 
methacrylate and 2-(tert-butylamino)ethyl methacrylate 
4.1. INTRODUCTION 
Responsive polymers are a class of functional materials capable of undergoing a 
discrete behavioral change when subjected to chemical (pH, redox potential, ionic 
strength) or physical (temperature, light, ultrasound, electrical field) stimuli.  Distinct 
transitions in solubility, hydrophilic/hydrophobic balance, and physical conformation 
result from these stimuli and are commonly manifested as coil-globule transitions; 
network swelling and deswelling; sol-gel transitions; and self-assembly [1, 2]. Tailoring 
these critical phenomena and resultant physicochemical properties of polymers by tuning 
copolymer composition is an attractive strategy that has been routinely employed for 
materials in drug delivery [3-7], tissue engineering [8-10], diagnostics and sensing [11, 
12], and “smart” optical [13, 14] applications.    
A particularly well-studied example of the influence of copolymer composition on 
critical phenomena is in the thermoresponsive polymer poly(N-isopropyl acrylamide) 
(PNIPAAm).  Temperature has been widely used to induce phase transitions in polymer 
networks because of its ease of modulation and applicability in biomedical applications 
[15] and PNIPAAm is capable of undergoing a reversible, temperature-dependent phase 
transition near 32°C [16].  This lower solution critical temperature (LCST) can be 
depressed through the inclusion of hydrophobic moieties in the polymer chain as 
demonstrated by copolymerizing NIPAAm with t-butyl acrylamide (TBAm) [17], n-butyl 
methacrylate (BMA) [18], and 5,6-benzo-2-methylene-1,3-dioxepane [19].  Conversely, 




[20] or ionic monomers such as 2-(dimethylamino)ethyl methacrylate (DMAEMA) [21] 
or (meth)acrylic acid (MAA ) [22].   
Inclusion of hydrophobic or hydrophilic moieties in pH-responsive polymers has 
been explored in analogous fashion.  Monomers containing ionizable tertiary amine 
groups, such as DMAEMA or 2-(diethylaminoethyl) methacrylate (DEAEMA), are 
typically used in pH-responsive polymers.  Armes and co-workers [23-25] created a 
variety of DEAEMA-based polymers through several polymerization methods; 
synthesizing responsive microgels via emulsion polymerization [23], diblock copolymers 
via group transfer polymerization [25], and triblock copolymer micelles via atom transfer 
radical polymerization (ATRP)[24].  Stayton and collaborators [6, 26, 27] employed a 
polymerization to create well-controlled block copolymers of DEAEMA and BMA to 
create responsive micelles for delivery of plasmid DNA [27] or small interfering RNA 
[6].  These copolymer micelles possess tunable pH-responsiveness and membrane-
disruptive activity depending on polymer composition and block length.   
Siegel and Cornejo-Bravo [28] examined copolymerization of PDEAEMA gels 
with BMA or 2-hydroxyethyl methacrylate (HEMA) and resultant impact on buffering 
range.  As the hydrophobic character of the polymer increased (via inclusion of BMA), 
the buffering pH was depressed.  This observation can be explained by relative strength 
of polymer/polymer interactions to that of polymer/solvent/ion interaction.  In addition to 
directly impacting critical phenomena and physical properties like size and surface 
charge, copolymer composition also influences circulation time [29, 30], protein binding 
[31], cellular internalization [32], cytocompatibility [33, 34], and drug loading and 




Recent focus on biomedical applications of responsive hydrogels has prompted 
examination of these bulk critical phenomena in nanoscale systems [36-38].  Nanoscale 
hydrogels, or nanogels, are particularly attractive as drug delivery agents owing to their 
facile manufacture, tunable physicochemical characteristics, and repeatable release [39].  
Furthermore, their covalent crosslinking endows them with mechanical integrity not 
available in their self-assembled counterparts.  Several recent efforts have explored the 
utility of responsive nanoscale hydrogel carriers in drug delivery [33, 40, 41], 
demonstrating release of biological therapeutics such as insulin and imaging agents such 
as gold.    
We have previously reported the development of a UV-initiated, oil-in-water 
photoemulsion polymerization [33, 42] that allows for the facile synthesis of sub-100 nm 
hydrogel particles without specialized conditions requisite for RAFT or ATRP.  
Analogous work in thermal-initiated emulsion polymerizations of DEAEMA has resulted 
in sub-50 nm nanogels [43].  We have used the UV-initiated photoemulsion method as  a 
robust synthesis for a panel of tunable, responsive polymer networks.  As mentioned in 
the preceding text, BMA, both n-butyl methacrylate and t-butyl methacrylate, have been 
used in conjunction with tertiary amine methacrylates to modulate physicochemical 
properties.  TBAEMA, a secondary amine methacrylate, is less well studied.  Morse, et 
al. [44] recently provided a thorough characterization of TBAEMA latex particles and 
highlighted their applicability as Pickering emulsifiers.  Previously, TBAEMA was 
evaluated in copolymer coatings for surgical instruments and orthopedic implants 




In the present study, we examine the influence of TMBA and TBAEMA on the 
aqueous solution properties of poly(ethylene glycol) methyl ether methacrylate 
(PEGMA)-grafted DEAEMA nanogels.  This represents, to the best of our knowledge, 
the first known examples of P(DEAEMA-co-TBAEMA-g-PEGMA) nanogels 
synthesized via aqueous photoemulsion polymerization.  We also provide a direct 
comparison of physicochemical properties with a P(DEAEMA-co-TMBA-g-PEGMA) 
nanogel system.  This polymerization method represents a platform from which abundant 
combinations of methacrylate-based hydrogels could be produced to create responsive 
hydrogels with nanoscale dimensions and tunable physicochemical properties (Figure 
4.1).   
4.2. MATERIALS AND METHODS 
4.2.1. Polymer synthesis 
Hydrogel particles of nanoscale dimensions were synthesized via UV-initiated 
free radical photoemulsion polymerization/crosslinking according to previous reports 
from our laboratory [33, 42].  Briefly, 2-(diethylamino) ethyl methacrylate (DEAEMA, 
Sigma-Aldrich, St. Louis, MO), 2-(tert-butylamino)ethyl methacrylate (TBAEMA, 
Polysciences, Inc., Warrington, PA), tert-butyl methacrylate (TBMA, Sigma-Aldrich, St. 
Louis, MO), and tetra(ethylene glycol) dimethacrylate (TEGDMA, Sigma-Aldrich, St. 
Louis, MO) were passed through a column of basic alumina powder to remove inhibitor 
prior to use.  Poly(ethylene glycol) methyl ether methacrylate (PEGMA), Mn ~ 2080, 
(Sigma-Aldrich, St. Louis, MO) was used as received.  DEAEMA, TEGDMA, and 




Irgacure 2959 (Ciba Geigy, Tarrytown, NY) at 0.5 wt% of total monomer, 4 mg mL-1 
Brij-30 (Acros Organics, Fair Lawn, NJ) and 1.16 mg mL-1 (3.4 mM) ionic surfactant 
myristyltrimethylammonium bromide (MyTAB, Sigma-Aldrich, St. Louis, MO).  The 
reaction pH was routinely pH 8.5.  The mixture was emulsified using a Misonix 
Ultrasonicator (Misonix, Inc., Newtown, CT).  The emulsion was purged with nitrogen 
gas and exposed to a UV source for 2.5 hr with constant stirring.   
4.2.2. Polymer Purification 
MyTAB, Brij 30, and unreacted monomers were removed by repeatedly inducing 
polymer-ionomer collapse, separating particles by centrifugation for 10 min at 3,200×g, 
and resuspending in 0.5 N HCl.  Polymer particles were dialyzed against ddH2O for at 
least 7 days in 12 – 14 kDa molecular weight cutoff dialysis tubing (Spectrum Labs, 
Rancho Dominguez, CA) with water changes twice daily.  Following dialysis, polymers 
were flash frozen in liquid N2 and lyophilized for 5 days.   
4.2.3. 1H- NMR Spectroscopy 
The composition of uncrosslinked polymer formulations and purification fractions 
were investigated using a Varian (Palo Alto, CA) DirectDrive 400 MHz nuclear magnetic 
resonance spectrometer equipped with automatic sampler.  Deuterium oxide (D2O, 
99.9%) was obtained from Cambridge Isotope Laboratories (Andover, MA).  Deuterium 
chloride (DCl, 100.0%) and methyl sulfoxide-d6 (DMSO, 99.5%) with 0.03% 
tetramethyl silane (TMS) were obtained from Acros Organics (Fairlawn, NJ). All 
glassware, including NMR Tubes (Wilmad Lab Glass, Vineland, NJ), 2 mL sample vials, 




samples of approximately 50 mg were weighed directly in sample vials and D2O was 
added to bring the final polymer concentration to 25 mg mL-1.  Samples were briefly 
sonicated in a sonic bath and transferred to NMR tubes for subsequent analysis.  Aliquots 
of the purification supernatants were frozen at -80°C and lyophilized with a Labconco 
FreeZone -105°C benchtop lyophilizer (Kansas City, MO) for 48 hours.  The resulting 
dry residue was dissolved in 0.75 ml deuterated DMSO and transferred to NMR tubes.  
All NMR Spectra were analyzed using SpinWorks 3
TM
 software. 
4.2.4. Dynamic Light Scattering Analysis 
The hydrodynamic diameter in aqueous suspension of the polymer networks was 
measured using a measured using a Brookhaven ZetaPlus instrument (Brookhaven 
Instruments Corp.) operating with a 659 nm diode laser source.  Dynamic light scattering 
(DLS) measurements of particle size and its response to dynamic pH were conducted by 
resuspending lyophilized particles in PBS at 0.75 mg mL
-1
.  The suspension pH was 
adjusted to 10.5 using 1 N NaOH and gradually lowered to pH 3.5 using 1 N HCl. 
Measurements of the z-average particle size were collected at 23°C.  Subsequent studies 
employed a Malvern Zetasizer NanoZS (Malvern Instruments Corp., Malvern, UK) 
operating with a 633 nm laser source equipped with MPT-2 Autotitrator.  DLS 
measurements of particle size and pH-responsive behavior were conducted by 
resuspending lyophilized particles in PBS at 0.5 mg mL
-1
.  The suspension pH was 
adjusted to 10.5 using 1 N NaOH and gradually lowered to pH 3.5 using 1 N HCl.  





4.2.5. Transmission Electron Microscopy 
Transmission electron micrographs were collected using a FEI Tecnai (Hillsboro, 
OR) Transmission Electron Microscope (80 kV) at magnifications from 16,500× to 
160,000×.  Lyophilized particles were diluted in ddH2O and stained with 2% uranyl 
acetate immediately prior to imaging.  Typically, 5 µL of 0.02 w/v% of particle 
suspension was dropped onto a 400-mesh Formvar-coated copper TEM grid (Electron 
Microscopy Sciences, Hatfield, PA) and excess liquid wicked off using filter paper.  An 
equivalent volume of 2 w/v% uranyl acetate was then added to the grid and allowed to 
stain for 60 seconds before excess liquid was wicked away with filter paper.  Particle 
volume in the dry state was taken as the cube of mean diameter from TEM images.  
Particle diameters were calculated from the particle area as determined by an ImageJ 
particle sizing algorithm.  Reported values represent the mean ± standard deviation (n > 
50).  
4.2.6. Electrophoretic Light Scattering 
The effective surface ζ-potential of the polymer networks was measured using a 
Brookhaven ZetaPlus instrument (Brookhaven Instruments Corp.) operating with a 659 
nm diode laser source.  Measurements of ζ-potential as a function of pH were conducted 
by resuspending lyophilized particles in 5 mM phosphate buffer at 0.5 mg mL
-1
.  The 
suspension pH was adjusted to 10.5 using 1 N NaOH and gradually lowered to pH 3.5 
using 1 N HCl. Electrophoretic light scattering measurements of the surface ζ-potential 




4.2.7. Fluorescence Spectroscopy 
Pyrene (Puriss grade, >99.0%, Sigma-Aldrich, St. Louis, MO) was used without 
further purification.  Disodium phosphate heptahydrate (Na2HPO4 • 7H2O) and sodium 
phosphate monohydrate (NaH2PO4 • H2O) were purchased from Fisher Chemical.  
Phosphate buffer solutions from pH 5.8 – pH 8.0 were prepared by combining solutions 
of 0.2M NaH2PO4 • H2O and 0.2M Na2HPO4 • 7H2O.  Polymer solutions were prepared 
by suspending dry nanoparticles in ultrapure DI water at a concentration of 1 mg mL
-1
.  
These preceding two solutions were then mixed in equal volumes to give a final 
concentration of nanoparticles at 0.5 mg mL
-1
 in 100 mM phosphate buffer.  Pyrene was 
dissolved in methanol at 1 mM.  Fluorescence spectra were collected on a Fluorlog-3 
Spectrofluorometer (Jobin Yvon, Horiba Scientific, Edison, NJ).  Emission spectra were 
collected with λex = 339 nm, 1 nm increments, 1.5 nm slit with for excitation, 1 nm slit 
width for emission, and 0.8 s integration time.  Excitation spectra were collected with λem 
= 390 nm, 1 nm increments, 1 nm slit for excitation, and 1.5 nm for emission, and 0.8 s 
integration time.   
4.3. RESULTS AND DISCUSSION 
4.3.1. Polymer Synthesis 
A series of tunable, polycationic nanoscale hydrogels comprised of a crosslinked 
core of PDEAEMA surface grafted with PEG was synthesized using photoemulsion 
polymerization.  Polymer composition was varied from 0 ~ 25 mol% TBMA or 




physicochemical properties.  A methoxy-terminated poly(ethylene glycol) methacrylate 
(PEGMA, MW ~ 2080) was employed as an emulsion stabilizer and to provide grafted 
PEG chains on the nanogel surface.  PEGMA is commercially available and routinely 
used as a reactive stabilizer in the aqueous emulsion polymerization of methacrylate 
copolymers [23, 44]  The MW 2080 PEGMA was chosen because previous work has 
indicated a minimum PEG graft size of 2 kDa was needed to minimize nonspecific 
protein adsorption [46]. 
As this polymerization method is a UV-initiated free radical polymerization, the 
copolymer could be optimally assumed to be random, whereby monomers are 
incorporated into the copolymer based on their relative feed concentrations and 
reactivities in no preferential order.  This assumption can be evaluated by examining the 
reactivity ratios (r1, r2) for constituent monomer pairs (M1 and M2).  Generally, 
copolymerizations with r1r2 = 0.5 – 2 can be considered to obey moderate ideal behavior 
[47].  To estimate the reactivity ratios between monomer pairs, the Q-e scheme [47, 48] 
was used to calculate r1 and r2 values.   Reported Q-e values and resulting reactivity ratios 
are tabulated in Table 4.2.  
From these data, it can be seen that all estimated values for r1 and r2 lie between 
0.4 – 2.0, suggesting that the resultant copolymer can be described as ideal, with 
copolymer compositions closely related to the feed concentration.  For the purpose of this 
analysis, the ratio between hydrophobic (TBMA or TBAEMA) and ionizable 
(DEAEMA) monomer was considered to be the key ratio in modulating network 
hydrophobicity and its influence on resultant physicochemical properties, such as 




composition and altering polymer-solvent interactions can impact various critical 
phenomena, including temperature (LCST/UCST) or pH at which polymer chains 
undergo phase transitions [15, 49].  For this reason, polymer formulation nomenclature 
was established such that the numerical suffix on the polymer name (e.g. PDETB30 or 
PDETBA20) refers to the moles of hydrophobic monomer (TBMA or TBAEMA) per 100 
moles of DEAEMA.   
4.3.2. Polymer Purification 
As described in our previous reports [33, 42], purification was achieved by 
repeatedly inducing a polyelectrolyte-ionomer transition.  Following polymerization, 1 N 
HCl was added directly to the reaction flask at 1:1 (vol/vol) ratio with the reaction 
mixture to protonate DEAEMA pendant groups.  Following this step, the acidified 
reaction mixture was added to acetone to bring the final acetone concentration to 80 
vol%.  The addition to an organic solvent was used to lower the dielectric strength (ε) of 
the suspension and facilitate the transition from polyelectrolyte regime to ionomer regime 
[50].  In the polyelectrolyte regime, counterions diffuse freely through polymer networks, 
while in the ionomer regime, counterions are bound to ionized groups on the polymer 
network in ion pairs.  This transition is shown schematically in Fig.  The energy gain (E) 
from electrostatic attraction of ions can be described by the equation: 
     𝐸 =
𝑒2
𝜀∙𝑎
     (4.1) 
where e is the charge of the ion species, ε is the dielectric strength, and a is the 




The ionomer regime is rare in solvents with a sufficiently high dielectric constant 
(e.g. water, ε = 81).  As the solvent dielectric strength is lowered, however, the formation 
of ion pairs decreases the concentration of mobile counterions and concomitantly the gel 
osmotic pressure.  Moreover, these ion pairs attract one another through dipole-dipole 
interactions and form multiplets.  These mutliplets act as additional physical crosslinks in 
the gel and support gel collapse.  By using the polymer-ionomer transition, these 
nanogels can be simultaneously collapsed and ionized, a state that resulted in rapid 
flocculation and sedimentation.  The ionomer phase was then separated from the solvent 
by centrifugation.  Surfactant removal was monitored by analyzing the supernatant from 
each purification cycle via 
1
H-NMR.  A purification cycle is defined as (1)  protonation 
of DEAEMA with 0.5 N HCl, (2) ionomer phase transition by addition of 4 vol. 
equivalents of acetone (80 vol% acetone total), and (3) centrifugation of ionomer/solvent 
mixture.  The progressive removal of surfactant from the purification supernatant can be 
seen in Figure 4.4 and Table 4.3. 
In Figure 4.4, the peaks at 3.3 ppm and 2.5 ppm can be attributed to the solvent 
residual peak and HDO, respectively.  The strong peak near 3.5 ppm disappears rapidly 
following the Cycle 1, signifying the loss of unreacted PEGMA and/or Brij-30, both of 
which possess oxyethylene protons (-CH2-CH2-O-) with δ = 3.50 in DMSO.  
Additionally, the peaks near δ = 1.15 – 1.30 diminished significantly following Cycle 1.  
This likely indicates the loss of Brij-30 and MyTAB, both of which possess aliphatic 
protons (-CH2-CH2-) near 1.2 ppm.  Following purification cycle 6, any residual 




The uncrosslinked polymer chains were purified in a similar fashion, albeit with 
much higher relative centrifugal force (RCF).  Sedimentation of uncrosslinked polymer 
chains following polyelectrolyte-ionomer transition required RCF of 30,000×g or greater.  
The absence of a oxyethylene peak (δ = 3.6 ppm) in the polymer synthesized without 
PEGMA, P(DEAEMA-co-TBMA) (PDB30),  serves as additional evidence that Brij-30 
was successfully removed during the purification process. 
4.3.3. 1H-NMR Spectroscopy 
To verify polymer composition, the 
1
H NMR spectra of uncrosslinked nanoscale 
hydrogels were collected and analyzed (Figure 4.5 and Figure 4.6). The results are 
summarized in Table 4.4.  The resultant copolymer ratio of t-butyl (either from TBMA or 
TBAEMA) to DEAEMA closely mirrors that of the comonomer ratio in the feed.  This 
result is expected given the reactivity ratios of constituent comonomers, all containing 
methacrylate groups, are relatively similar, as previously shown in Table 4.2.  
Furthermore, the pairwise products of reactivity ratios (r1r2) lie within the region 
described by ideal radical polymerizations, resulting in a random copolymer.   
The peak assignments and spectra for both TBMA- and TBAEMA-containing 
copolymers are shown in Figure 4.5 and Figure 4.6.  For this analysis, the [-N-(CH2-
CH3)2-] (peak d, 3.1 ppm) was selected as the basis for determining the relative molar 
quantity of DEAEMA, the [-C-(CH3)3-] (peak h, 1.3 ppm) for determining the relative 
molar quantities of TBMA (Figure 4.5) and TBAEMA (Figure 4.6), and the [-O-CH2-




A notable observation of the data in Table 4.4 is the poor efficiency with which 
PEGMA was incorporated into the copolymer; below 10% of PEGMA in the feed was 
detected in the copolymer.  PEGMA is a large (MW ~ 2,080) and highly hydrophilic 
macromonomer and consequently may not partition into the oil phase of the emulsion, 
where DEAEMA, TBMA, and TBAEMA reside.  Rather, it is far more likely that the 
PEG macromonomer adsorbed to the oil droplet surface along with Brij®-30 and 
MyTAB, serving to reduce interfacial tension at the oil-water boundary.  Based on the 
relative molar compositions determined in Table 4.4, the copolymer contains 
approximately 5 wt% PEG.  Other reports involving emulsion-based polymerizations of 
DEAEMA/PEGMA to form microgels [23] or nanogels [42]  have reported PEG 
incorporation of 5 - 7 wt% polymer.  A consequence of the PEG macromonomer’s 
preferential association with the emulsion interface and water phase is that it will 
predominantly graft to the particle surface, with incorporated PEG chains protruding in 
the surrounding aqueous media.  .  Indeed, 
1
H-NMR studies of crosslinked nanogels 
(Figure 4.7) revealed a strong peak at 3.6 ppm (peak a), indicative of oxyethylene protons 
from PEG.  Protons from the ethlyamino groups of DEAEMA  (peak c, 3.2 ppm and peak 
d, 1.25 ppm) are also present, although suppressed relative to their uncrosslinked spectra 
(Figure 4.5 and Figure 4.6).  Similar observations were reported by Fisher et al. [42] in 
our initial reports of crosslinked nanogels synthesized via photoemulsion polymerization.  
These results suggest that the vast majority of DEAEMA and TBMA/TBAEMA protons 
are sequestered in the network core, unavailable for solvation and detection by 
1
H-NMR.  
This PEG coating may serve to impart colloidal stability and minimize opsonization 




4.3.4. Electron Microscopy 
Nanoscale hydrogels of varying composition were initially subjected to TEM and 
DLS measurements to confirm nanoscale dimensions and pH-responsive behavior.  
Analysis of TEM micrographs revealed successful formation of nanoscale hydrogel 
networks.  Nearly all preparations appear to have a narrow particle size distribution with 
a mean diameter of approximately 50 nm, as seen in Figure 4.8.  Diameters of the dry 
nanogels are tabulated in Table 4.5. 
 The particle area was determined using ImageJ software to identify particles 
based on relative contrast between particle and background.  This measurement was then 
used to obtain the dry diameter of nanoscale hydrogels.  Images obtained at 26,500× and 
43,000× magnification were used most frequently to construct the number-average 
particle size distribution, as they offered to best combination of particle number, typically 
40 – 50 particles/image, and resolution.  In practice, however, images obtained at 
magnifications of 16,500× – 60,000× could be used with little variation in the calculated 
diameter and standard deviation.  Both PDETBA20 (Figure 4.8, Panel F) and 
PDETBA30 (Figure 4.8, Panel G) exhibit a mean particle size greater than that of the 
other formulations, 63 nm and 66 nm.  This can perhaps be ascribed to the staining 
procedure.  A staining time of 1 minute was determined sufficient for uranyl acetate to 
penetrate nanogels of TEGDMA-crosslinked P(DEAEMA-co-TBMA-g-PEGMA) 
(PDETB30), providing homogenous staining and high contrast.  However, this staining 
time was not sufficient for copolymers with 20 mol% TBAEMA (PDETBA20) and 30 
mol% TBMA (PDETBA30) and is most evident in Figure 4.8, Panel G, where a hazy 




Panel F.  This blurred boundary made identification of particle perimeter more inaccurate 
and likely resulted in an overestimation of the true particle area.  In all cases, the number-
average particle size distribution was roughly Gaussian, an example of which is seen in 
Figure 4.9. 
4.3.5. Dynamic Light Scattering 
Dynamic light scattering was used to probe physicochemical properties of the 
nanoscale hydrogels, including their hydrodynamic diameter, swelling ratio, and critical 
swelling pH.  The latter is of particular interest in hydrogel-mediated intracellular drug 
delivery because this parameter is an indication of when the network swells and will 
permit drug efflux to the surrounding milieu.   
In the pH-dependent phase transitions described in the following text, nanogels 
were first adjusted to pH 10.5 and titrated to progressively lower pH values using HCl, as 
described in the Materials and Methods.  The justification is that acidification (via the 
action of endosomal ATP-dependent proton pumps) is the most prevalent pH-dependent 
pathway an intracellular drug delivery carrier would experience.  In our tests, the pH-
dependent swelling response was completely reversible with no evidence of hysteresis 
upon titrating from pH 10.5 to pH 3.5 and back to pH 10.5.  No salt induced flocculation 
was observed in these studies over the course of two titration cycles. 
The hydrodynamic diameter and polydispersity index reported represent those 
determined by Cumulant analysis as outlined in ISO 13321 [52].  Other analysis 
algorithms exist, such as CONTIN and NNLS, but the cumulant analysis is the readily 




assumption of this method is a single distribution of spherical particles.  The method 
returns a single z-average particle size, which represents a hydrodynamic diameter based 
on the intensity-weighted particle size distribution.  Figure 4.10 shows representative 
distributions for nanoscale hydrogels in the swollen and collapsed state, suggesting the 
Cumulant analysis is applicable for these measurements.  It should be noted that both 
CONTIN and NNLS are mathematically equipped to describe multimodal particle 
distributions.   
The colloidal stability of nanoparticle dispersions is a function of both surface 
charge [53] and/or any steric stabilization [23, 54] from adsorbed or bound molecules 
protruding from the surface.  A net surface charge, or ζ-potential, of ± 30 mV is generally 
regarded as the minimum for purely electrostatic stabilization.  PEG has been widely 
used as a steric stabilizer [55, 56] in biomaterials to impart colloidal stability and prevent 
protein adsorption in biological applications [51].  The resistance to particle-particle 
aggregation was tested in a copolymer containing a hydrophobic co-monomer, TBMA, 
after 4 weeks and 8 weeks in aqueous suspension.  The TBMA was incorporated to 
increase network core hydrophobicity, and as such, these nanoparticles should display the 
highest propensity for aggregation or flocculation.  According to DLVO theory [57], this 
process in colloidal suspensions is driven largely by Van der Waals attractions between 
approaching particles undergoing Brownian motion.  The results, shown in Figure 4.11 
demonstrate that the nanogels are able to resist aggregation for at least 8 weeks in 
aqueous suspension.  The hydrodynamic diameter remains at approximately 93 – 96 nm 
in the deswollen state (pH > 7.5) and 119 – 122 nm in the swollen state (pH < 6.0).  The 




 The polydispersity index (PdI), is given by a ratio of the second (µ2) and first 
moment (Γ) of the Cumulants analysis (µ2/Γ
2
)1 and describes the apparent width of the 
size distribution [52] .  It should be noted that this PdI, as defined in the Cumulants 
analysis, does not describe a true particle size distribution, but rather the width of an 
assumed Gaussian distribution around a single exponential fit of the generated 
autocorrelation function.  Little variation is seen in the PdI between 4 weeks and 8 weeks 
in aqueous suspension.  Moreover, nearly all PdI values, except measurements in the 
hydrophobic to hydrophilic phase transition around pH 7.0, lie below 0.2.  These data 
suggest our nanogels are stable in aqueous suspension and are able to resist significant 
particle aggregation over the course of at least 8 weeks.  In a previous report [42], we 
replaced reactive PEGMA (MW ~ 2080) with a non-reactive PEG monomethyl ether 
(MW ~ 1900) in the photoemulsion reaction mixture.  The resultant nanogels (w/o PEG 
graft) demonstrated poor stability and underwent visible flocculation and sedimentation 
within 1 h.  As a result, we infer that the PEG graft is important to conferring colloidal 
stability to these nanogels.   
Figure 4.12 illustrates the influence of hydrophobic moiety incorporation on pH-
dependent volume swelling of the nanogel formulations.  Swelling in ionizable hydrogel 
systems is driven by a balance of thermodynamic and physical forces; namely the free 
energy of polymer and solvent interactions, osmotic pressure generated by mobile 
counterions inside the gel, and elastic contractile response to gel deformation [58].  As 
hydrophobic content increases, greater proton activity or greater ionization (i.e. lower 
pH) is required to promote polymer/solvent/ion interaction over polymer/polymer 
                                                 





interaction.  As expected, this effect also leads to a decrease in the onset of pH-dependent 
gel swelling [33, 59].    
The addition of TBMA (Figure 4.12A) clearly shifts the onset of pH-dependent 
swelling from ~ pH 7.8 to pH 7.0.  The critical swelling pH can be defined by fitting a 
hyperbolic tangent or sigmoidal function to the measured hydrodynamic diameter (DH) 
and determining the inflection point. In this case, data were fit to a hyperbolic tangent 
function of the form [60] 
 
 𝐷𝐻 = 𝐴 + 𝐵 ∙ 𝑡𝑎𝑛ℎ(𝐶 ∙ 𝑝𝐻 + 𝐷)            (4.2) 
Taking the second derivative of Equation 1 yields the inflection point of the 





     (4.3) 
In networks containing TBMA, the pHc trend decreased as follows: PDET (pHc = 
7.37) ~ PDETB20 (pHc = 7.36) ~ PDETB10 (pHc = 7.31) > PDETB30 (pHc = 6.65). 
Additionally, PDET, PDET10, and PDET20 have reached maximum swelling volume by 
~ pH 6.8, while PDETB30 reaches maximum volume swelling near pH 6.0.  This pH is 
characteristic of the early endosomes in mammalian cells, suggesting these networks may 
have utility as vehicles for intracellular drug delivery.   
The degree of volume swelling is decreased as the gel concentration of TBMA is 
increased.  Both PDETB10 and PDETB20 exhibit a lower volume swelling ratio than the 




network expansion.  This observation may be ascribed to two effects, (1) the persistence 
of hydrophobic associations in the polymer network that resist solvation and limit elastic 
deformation of the network, and (2) a reduction in ionizable amine content and 
consequent decrease in osmotic pressure generated by salts migrating into the network 
core.    
In order to maintain the total monomer concentration constant throughout various 
formulations, an increase in TBMA concentration required a concomitant decrease in 
DEAEMA concentration.  Simply, the PDETB30 contains less tertiary amines than 
PDETB, and therefore, the capacity for electrostatic repulsion and osmotic swelling 
decreases proportionally with decreasing DEAEMA content.  These data suggest that 
there may be a critical [TBMA]:[DEAEMA] ratio, below which hydrophobic TBMA 
groups are not present in sufficient concentration to segregate into hydrophobic domains 
and counterbalance the effects of amine-group ionization and osmotic swelling.    
Incorporation of TBAEMA (Figure 4.12B) also lowers the onset of pH-dependent 
swelling, though the effect is less pronounced.  In these copolymers, the decrease in pHc 
does not follow any particular compositional trend: PDET (pHc = 7.37) >  PDETBA30 
(pHc = 7.13) > PDETBA10 (pHc = 7.01) ~ PDETBA20 (pHc = 6.98).  These formulations 
also display similar capacity for volumetric swelling.  As TBAEMA contains a secondary 
amine, the network charge density (and resultant osmotic pressure) should remain 
relatively constant between PDET, PDETBA10, PDETBA20 and PDETBA30. Moreover, 
this suggests the ionizable secondary amine group in TBAEMA likely precludes the 
formation of discrete domains of hydrophobic t-butyl groups.  Hydrophobic domains in 




reduce volumetric swelling [61].  These data suggest that the presence of a t-butyl-R 
group is not necessary and sufficient to depress pHc, but rather a more general, 
hydrophobic effect governs the modification of phase change behavior.   
4.3.6. Electrophoretic Light Scattering 
Measurements of the effective surface ζ-potential reveal insignificant differences 
between the various formulations.  These data are consistent with the expectation that the 
PEG-grafted surface of these nanoscale hydrogels are very similar and that the 
modifications in monomer composition primarily affect the network core.  All 
formulations possess a reversible surface charge, with an isoelectric point (IEP) at 
approximately pH 8.0, slightly positive ζ-potential at pH 7.4, and a maximum ζ-potential 
of 25 - 30 mV at pH 3.50 (Figure 4.13).  These observations are consistent with those by 
Amalvy, et al. [23], who noted the nature of grafted stabilizer was more important in 
determining IEP than the nature of core particles in PDEAEMA microgels.   
At physiological pH, the slightly positive ζ-potential may help facilitate non-
specific cell-uptake.  The negative ζ-potential observed from pH 10.5 to ~ pH 8.0 can be 
ascribed to the adsorption of negatively charged hydroxyl ions on the PEG-coated surface 
[62] and has been noted previously in similar DEAEMA-based materials [23, 41].  
Likewise, the positive ζ-potential can be ascribed the surface adsorption of hydronium 
ions and protonation of amine-containing groups in the network core, which serve to 
establish an electrical double layer around the particles.  While the measured ζ-potential 
for all formulations fall outside the limits for electrostatically-driven colloidal stability (± 




where nanoscale hydrogels possessed a net surface charge of ± 5 mV.  This provides 
additional evidence of the steric stabilization afforded by PEG surface grafts.  Moreover, 
previous work [41] has estimated the ζ-potential of neat PDEAEMA nanogels to be 
approximately -45 mV at pH 10 and 75 mV at pH 4.  Thus, the surface layer of PEG was 
indeed effective at shielding surface charge. 
4.3.7. Pyrene Fluorescence Spectroscopy 
The ratio of the first to third vibronic peak (I1/I3) in the fluorescence emission 
spectra of pyrene was used to study the pH-dependent conformational transition of 
responsive nanoscale hydrogels.  The fluorescence spectra of pyrene undergoes a 
characteristic shift depending on the polarity of pyrene microenvironment.  When 
dissolved in highly polar, aqueous solvents the I1/I3 ratio in the emission spectra is 
approximately 1.59 while this ratio decreases to 0.61 in nonpolar, aliphatic hydrocarbons 
such as n-hexane or dodecane [63].  Therefore, a decrease in the emission I1/I3 ratio 
indicates pyrene is preferentially partitioned in hydrophobic domains.  Figure 4.14 shows 
a representative change in pyrene fluorescence in aqueous suspensions of PDETB30 
between collapsed hydrophobe (pH 8.0) and swollen hydrophile (pH 6.0).  Consequently, 
the fluorescence spectra of pyrene can be used to probe the polarity of aqueous 
suspensions of nanoscale hydrogels and determine the influence of polymer composition 
on relative network hydrophobicity and the critical pH required to induce a 
conformational transition.  Figure 4.15A clearly demonstrates that inclusion of TBMA 
causes, in a composition-dependent fashion, a decrease in the pH required to induce a 




This value decreases from approximately pH 7.5 in PDET to below pH 7.0 in 
PDETB30, with both PDETB10 and PDETB20 exhibiting intermediate values.  
Additionally, whereas PDET displays a rather abrupt transition from hydrophobe to 
hydrophile, the networks containing TBMA transition over a substantially wider pH 
range.  In previous investigations of hydrophobic polybasic gels, Siegel and Firestone 
[59] postulated increasing chain stiffness served to increase the breadth of the pH-
dependent swelling transition.  In bulk gels of similar monomeric composition 
P(DMAEMA-co-TBMA) to our polymer system P(DEAEMA-co-TBMA-g-PEGMA), 
the persistence of hydrophobic microdomains resulted in 35% increase in shear modulus 
at 20% TBMA content and a 245% increase at 40% TBMA content [61].   In the present 
study, a similar stiffening effect could be imparted by TBMA in DEAEMA-based 
nanogels and result in a more broad swelling transition.  These studies also provide 
additional insight into the relative hydrophobicity of the network core.  For example, at 
pH 8.0, the I1/I3 ratio for collapsed PDET is 1.15 whereas the I1/I3 ratio for collapsed 
PDETB30 is approximately 1.09.  Upon suspension in pH 5.8 buffers, these ratios 
increased to 1.58 and 1.49 for PDET and PDETB30, respectively.  These values for I1/I3 
correspond well with previous reports of pyrene fluorescent probes in DEAEMA-based 
polymeric materials [64]. 
Our understanding of the impact of TBAEMA on pH-dependent swelling 
transition is less clear, however.  Nanoscale hydrogels containing TBAEMA did not 
exhibit the same type of composition-dependent phase transition displayed by the TBMA 
copolymers (Figure 4.15B).  When copolymerized in DEAEMA-based nanogels at low 




scattering (Figure 4.12B) and pyrene (Figure 4.15B) studies.  The breadth of the 
transition remains relatively constant when compared to PDET, which contains neither 
TBAEMA nor TBMA.  When copolymerized with DEAEMA at 20 mol% and 30 mol% 
(PDETBA20 and PDETBA30), TBAEMEA raises the pHc as determined by DLS and 
significantly increases the breadth of the hydrophobe-hydrophile phase transition as 
determined by pyrene fluorescence.  This observation is seemingly inconsistent with the 
chain stiffness argument applied to TBMA-containing nanogels.  If chain stiffness and 
mobility were the dominant factors governing the breadth of the hydrophobe-hydrophile 
phase transition, one would expect PDET, PDETBA10, PDETBA20, and PDETBA30 to 
have phase transitions of similar breadth.  DEAEMA and TBAEMA have identical 
molecular weights and similar end-group bulkiness.  We therefore expect that TBAEMA 
will have little impact on the chain stiffness.  One possible explanation for the broad 
nature of the TBAEMA-induced hydrophobe-hydrophile phase transition may be the 
heterogeneous distribution of ionizable amine species in the network core.  PTBAEMA 
has pKa ~7.6 - 8.0 [44] while PDEAEMA has pKa ~ 7.0 – 7.3 [23].  Thus, PDETBA30 
should possess a greater network charge density at elevated pH and create an increasingly 
polar environment (indicated by increasing I1/I3 in Figure 4.15B) that is distributed over 
the pKa range of the multiple ionizable species.  This effect is less notable in PDETAB20 
and nearly absent in PDETBA10.   
4.4.   CONCLUSIONS 
Nanoscale, pH-responsive polycationic networks were successfully synthesized 




hydrophobic moieties, TBMA and TBAEMA, was verified using 
1
H-NMR.  Hydrogel 
nanoparticles exhibit a dry diameter of approximately 50 - 65 nm as determined by TEM 
and a collapsed, yet hydrated, diameter of approximately 90 nm.  Dynamic light 
scattering reveals a single distribution of particle sizes that remain stable in aqueous 
suspension for at least 8 weeks.  In P(DEAEMA-g-PEGMA) copolymers, the onset of 
pH-dependent swelling occurs ~ pH 7.8 - 8.0 and networks have reached maximum 
volume swelling ~ pH 6.7 - 7.0.  In P(DEAEMA-co-TBMA-g-PEGMA) copolymers, the 
onset of pH-dependent swelling decreasing with increasing TBMA content, reaching ~ 
pH 7.2 with maximum volume swelling ~ pH 5.50 in PDETB30.  Moreover, TBMA 
broadens the transition from collapsed hydrophobe and swollen hydrophile in light 
scattering and pyrene fluorescence spectroscopy studies.  In P(DEAEMA-co-TBAEMA-
g-PEGMA) copolymers, the compositional dependence is less obvious and may be 
complicated by the presence of multiple ionizable species in TBAEMA and DEAEMA.  
The polymerization described in this report and in our previous work [33, 42] permits the 
reliable formation of hydrogel nanoparticles with utility in diverse applications that 
require tailoring material properties.  In particular, PDETB30 possesses size (dH ~ 100 
nm) responsive characteristics (pHc ~ 6.6) well-suited for intracellular drug delivery 
applications. Our future efforts will focus on evaluating the safety and efficacy of 

















Table 4.1 - Reagents used for nanoscale hydrogel synthesis 




















PDETB P(DEAEMA-g-PEGMA) 0 2.500 5.000 - - 0.121 50 0.1 
PDETB10 P(DEAEMA-co-TBMA-g-PEGMA) 10 2.322 5.000 0.178 - 0.124 50 0.1 
PDETB20 P(DEAEMA-co-TBMA-g-PEGMA) 20 2.168 5.000 0.332 - 0.126 50 0.1 
PDETB30 P(DEAEMA-co-TBMA-g-PEGMA) 30 2.033 5.000 0.467 - 0.128 50 0.1 
PDETBA10 P(DEAEMA-co-TBAEMA-g-PEGMA) 10 2.273 5.000 - 0.227 0.121 50 0.1 
PDETBA20 P(DEAEMA-co-TBAEMA-g-PEGMA) 20 2.084 5.000 - 0.416 0.121 50 0.1 







Table 4.2 - Reactivity data of comonomers in photoemulsion polymerization for fixed 
M1 of DEAEMA 





 r1 r2 r1r2 
M2 
DEAEMA 2.08 0.42 1.0 1.0 1.0 
TBMA 1.18 -0.35 1.28 0.43 0.55 









Figure 4.3 - Polyelectrolyte to ionomer transition in tertiary amine-containing gels.  







Figure 4.4  - 
1
H-NMR Analysis of nanogel purification supernatants.  Purification 
aliquots were analyzed following 1, 3, or 6 cycles of polyelectrolyte-
ionomer transition and centrifugation.  Supernatant samples were frozen, 










Table 4.3 – Relative area of contaminant peaks in the supernatant following a purification 
cycle of (1)  protonation of DEAEMA with 0.5 N HCl, (2) ionomer phase 
transition by addition of 4 vol. equivalents of acetone (80 vol% acetone 
total), and (3) centrifugation of ionomer/solvent mixture.  Supernatant 












(δ = 1.15 - 1.35) 
1 42.6 10.3 
2 3.3 1.7 
3 0.7 1.4 
4 0.8 1.5 
5 1.3 1.9 
6 0.7 0.5 
 
1






Figure 4.5 -  NMR Spectra of uncrosslinked copolymers containing TBMA in D2O.  (1) 
P(DEAEMA-g-PEGMA) (PDE), (2) P(DEAEMA-co-TBMA) (PDB30) and 
(3) P(DEAEMA-co-TBMA-g-PEGMA) (PDEB30). Inclusion of TBMA is 
verified by the presence of the t-butyl proton peak at 1.3 ppm.  Inclusion of 






Figure 4.6 - NMR Spectra of uncrosslinked copolymers containing TBAEMA in D2O.  
(1) P(DEAEMA-g-PEGMA) (PDE), (2) P(DEAEMA-co-TBMA) (PDB30) 
and (3) P(DEAEMA-co-TBAEMA-g-PEGMA) (PDEBA20).  Inclusion of 
TBMA is verified by the presence of the t-butyl proton peak at 1.3 ppm.  






Table 4.4 - Polymer composition as determined by 
1
H-NMR for linear copolymers 




t-butyl  (TBMA or 
TBAEMA) 
DEAEMA PEGMA 












mol% in feed 
mol% in 
polymera 
P(DEAEMA-g-PEGMA) 0 - - 91.8 99.5 8.2 0.48 
P(DEAEMA-co-TBMA) 30 23.1 24.6 76.9 75.4 - - 
P(DEAEMA-co-TBMA-g-PEGMA) 
30 21.6 21.4 72 78.1 6.4 0.45 
P(DEAEMA-co-TBAEMA-g-PEGMA) 











Figure 4.7 – 
1
H-NMR Analysis of crosslinked P(DEAEMA-co-TBMA-g-PEGMA) 






 Figure 4.8 - Representative transmission electron microscopy images of TEGDMA-
crosslinked nanogels.  PDET (A), PDETB10 (B), PDETB20 (C) PDETB30 
(D), PDETBA10 (E), PDETBA10 (F), PDETBA30 (G).  Particles stained 






Table 4.5 - Calculated dry diameters of nanogels from TEM micrographs.  Reported 
values represent the mean  ±  s.d.  (n > 150). 
Name Calculated diameter (nm) 
PDET 47 ± 13 
PDETB10 60 ± 26 
PDETB20 50 ± 22 
PDETB30 52 ± 17 
PDETBA10 50 ± 18 
PDETBA20 63 ± 21 






Figure 4.9 - Sample number-average particle size distribution of dry P(DEAEMA-co-
TBMA-g-PEGMA) (PDETB30) generated by quantitative particle sizing 
from TEM micrographs.  Distribution mean = 52.0, Std Dev = 17.3, n = 200.  
Bars represent observed data and line represents best fit Gaussian 
























Figure 4.10 – Representative intensity-weighted particle size distribution for 
P(DEAEMA-co-TBMA-g-PEGMA) crosslinked with 2.5 mol% TEGDMA 























Figure 4.11 – Colloidal stability of nanoscale hydrogels.  Hydrodynamic diameter (left 
axis) and polydispersity index (right axis) of P(DEAEMA-co-TBMA-g-
PEGMA) networks crosslinked with 2.5 mol% TEGDMA after 4 weeks 
(filled symbols) and 8 weeks (empty symbols) in aqueous suspension.  Data 
points represent mean of 12 measurements and lines represent a best fit to the 
data. A hyperbolic tangent fit was applied to the measurements of 













































Figure 4.12 - Influence of hydrophobic moiety incorporation on pH-dependent swelling 
properties in nanoscale hydrogels containing TBMA (A) or TBAEMA (B).  
Symbols indicate 0 mol% (□), 10 mol% (◊), 20 mol% (Δ), or 30 mol% (●) 
comonomer based on DEAEMA.  Data points represent mean of 12 





































































Figure 4.13 - Effective surface zeta-potential of polymer formulations synthesized with 
varying TBMA (A) and TBAEMA (B). Data points represent the mean of 
10 measurements ± SD.  
pH









































Figure 4.14 – Normalized fluorescent emission spectra of pyrene in 100 mM phosphate 
buffer and 0.5 mg mL
-1
































Figure 4.15 - Influence of t-butyl incorporation on fluorescence emission spectra of 
nanogels synthesized with TBMA (A) or TBAEMA (B).    Nanogels 
suspended at 0.5 mg mL
-1
 and pyrene dissolved at 6×10
-7
 M in 100 mM 
phosphate buffers.  Symbols designate PDET (●), PDETB10 (▼),  
PDETB20 (■),  or PDETB30 (◊) in (A) and PDET (●), PDETBA10 (▼), 
PDETBA20 (■), or PDETBA30 (◊)  in (B).  Points represent measured data 
and lines represent best-fit sigmoidal curves. 
pH































Figure 4.16 - Influence of hydrophobic moiety on fluorescence emission spectra of 
pyrene.  Pyrene dissolved at 6×10
-7
 M in 100 mM phosphate buffers with 
PDET (●), PDETB30 (▼), or PDETBA30 (■) at 0.5 mg mL
-1
.  Points 
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Chapter 5:  Membrane Disruptive Properties of Hydrophobic Polybasic 
Nanoscale Hydrogels 
5.1. INTRODUCTION 
Compositional considerations, such as the balance between cationic and nonionic, 
hydrophilic components and ratio of hydrophobic monomers have significant impact on 
resultant drug delivery properties (i.e. transfection efficiency, complex stability, etc.)  [1].  
These parameters must be carefully investigated and optimized in the development of 
polymer drug delivery systems.  It is generally understood that increasing cationic 
content leads to increased nucleic acid condensation.  Previous work on the interaction 
between poly(dimethylaminoethyl methacrylate) (PDMAEMA) or poly(aminoethyl 
methacrylate) (PAEMA) and DNA showed that PAEMA interacts more strongly with 
DNA while PDMAEMA exhibited superior buffering capacity [1], which should lead to 
increased endosomolytic activity.  However, excess cationic content in polymer delivery 
systems can have deleterious effects.  High cationic charge density is frequently 
correlated with toxicity of conventional cationic polymers like poly(ethyleneimine) (PEI) 
[2] and may host of undesirable consequences in vivo [3].  
Thus, hydrophobically-modified polymers with decreased charged density have 
been investigated as substitutes in polynucleotide (e.g. DNA, siRNA) delivery 
applications.  Hydrophobic modifications to gene-delivery polymers serve to, among 
others, enhance the physical encapsulation of genetic material, increase non-specific 
adsorptive endocytosis, facilitate unpacking of gene-polymer complexes, and potentially 
increase cytocompatibility [4].  High molecular weight polymers with decreased charge 




Recently, Saltzman and coworkers [6] described a series of lactone-based terpolymers 
with tunable hydrophobicity based on lactone ring size.   The best-performing terpolmyer 
was susceptible to serum aggregation and subsequently required a surface coat of an 
RGD-terminated polyglutamic acid to enhance colloidal and in vivo stability.  This 
polymer subsequently enabled the delivery of the pro-apoptotic TRAIL gene to tumor 
xenografts and slowed tumor growth. 
 Chapter 4 outlined a facile strategy to tune the polymer hydrophobicity and 
critical swelling pH by incorporating tert-butyl methacrylate in the nanogel.    This 
synthetic strategy has been employed by Peppas and coworkers [7-9] to decrease critical 
swelling pH and others to increase endosomolytic [10] and gene transfection [11] 
efficiency.  The previous studies in Chapter 4 compared the pH-dependent aqueous 
solution behavior of P(DEAEMA-g-PEGMA) and P(DEAEMA-co-TBMA-g-PEGMA) 
nanogels.  TBMA-modified networks exhibited a more tightly collapsed network at 
elevated pH [7], which could theoretically provide improved protection of encapsulated 
siRNA.  Moreover, a decrease in the pH required to induce a critical transition (as 
demonstrated by PDETB30) may minimize premature siRNA release before the intended 
site of action.   
However, the optimum balance between hydrophobic and cationic core monomers 
must be carefully considered.  Excessive core hydrophobicity could result in limited 
siRNA encapsulation, poor buffering capacity, and perhaps inefficient endosomolysis due 
to lack of cationic core groups.  Decreased swelling observed with increased core 
hydrophobicity may also limit the diffusion of siRNA in to and out of the nanogel below 




This work builds upon the studies performed in Chapter 4 and seeks to understand 
the role of hydrophobicity in modulating membrane destabilization.  To study this 
interaction, three model membrane systems were used.   Sheep erythrocytes were used to 
assess the pH- and concentration-dependent membrane destabilization of lipid bilayers, 
lactate dehydrogenase (LDH) leakage was measured from Caco-2 and RAW 264.7 cells 
to evaluate the non-specific membrane destabilization in live cells, and giant unilammelar 
vesicles (GUVs) were used to gain insight into the mechanism of membrane 
destabilization.  Cytotoxicity of each copolymer was also investigated as a function of 
concentration and exposure time. 
5.2. MATERIALS AND METHODS 
5.2.1. Polymer synthesis and purification 
Polymer synthesis and purification proceeded as described in Section 4.3.1 and 
Section 4.3.2.   Briefly, 2-(diethylamino) ethyl methacrylate (DEAEMA, Sigma-Aldrich, 
St. Louis, MO), 2-(tert-butylamino)ethyl methacrylate (TBAEMA, Polysciences, Inc., 
Warrington, PA), tert-butyl methacrylate (TBMA, Sigma-Aldrich, St. Louis, MO), and 
tetra(ethylene glycol) dimethacrylate (TEGDMA, Sigma-Aldrich, St. Louis, MO) were 
passed through a column of basic alumina powder to remove inhibitor prior to use.  
Poly(ethylene glycol) methyl ether methacrylate (PEGMA), Mn ~ 2080, (Sigma-Aldrich, 
St. Louis, MO) was used as received.  DEAMA, TEGDMA, and TBMA or TBAEMA 
were added to an aqueous solution containing 5 wt% PEGMA, Irgacure 2959 (Ciba 
Geigy, Tarrytown, NY) at 0.5 wt% of total monomer, 4 mg mL
-1
 Brij-30 (Acros 




(MyTAB, Sigma-Aldrich, St. Louis, MO).  The reaction pH was routinely pH 8.5.  The 
mixture was emulsified using a Misonix Ultrasonicator (Misonix, Inc., Newtown, CT).  
The emulsion was purged with nitrogen gas and exposed to a UV source for 2.5 h with 
constant stirring.  MyTAB, Brij 30, and unreacted monomers were removed by 
repeatedly inducing polymer-ionomer collapse, separating particles by centrifugation, and 
resuspending in 0.5 N HCl.  Polymer particles were dialyzed against ddH20 for 7 days 
with the water changed twice daily.  Following dialysis, polymers were flash frozen in 
liquid N2 and lyophilized for 5 days.   
5.2.2. Fluorescence Spectroscopy 
Pyrene fluorescence measurements were conducted in similar fashion to those 
described in Section 4.2.7.  Pyrene excitation spectra were collected on a Fluorlog-3 
Spectrofluorometer (Jobin Yvon, Horiba Scientific, Edison, NJ).  Excitation spectra were 
collected with λem = 390 nm, 1 nm increments, 1 nm slit for excitation, and 1.5 nm for 
emission, and 0.8 s integration time.   
5.2.3. Cell Culture 
Human colorectal adenocarcinoma cells (Caco-2) and murine macrophages 
(RAW 264.7) were maintained in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 100 U mL
-1
 penicillin, 100 μg mL
-1
 streptomycin, 0.25 µg mL
-
1
Amphotercin B,  and 10% FBS.  Caco-2 cells were used between passage 34 and 62.  
RAW 264.7 cells were used between passage 9 and 16.  Caco-2 cells were passaged by 
washing with pre-warmed Dulbecco’s phosphate buffered saline (DPBS) and subsequent 




fresh, prewarmed DMEM and cells were separated by centrifugation.  The resulting pellet 
was suspended in 10 mL DMEM and cell count was determined using a Scepter 
Automated Cell Counter (Millipore, Billerica, MA) with 60 µm tips.  The cell suspension 
was diluted as necessary and added to tissue-culture treated flasks or multi-well plates.  
Caco-2 cells were typically passaged at 1:5 ratio with media replenished every 2-3 days.  
RAW 264.7 cells were passaged by washing with prewarmed DPBS and replacing the 
original culture volume with fresh DMEM.  Cells were removed from the flask surface 
by gentle scraping with a 25 cm cell scraper (BD Falcon, Franklin Lakes, NJ).  The 
number of suspended cells was counted using a Scepter Automated Cell Counter and 
diluted as necessary for addition to tissue culture flasks or multi-well plates.  RAW 264.7 
cells were typically passaged every 2 days.    
5.2.4. Cytocompatibility 
In vitro cytocompatibility of polycationic nanoscale hydrogels was evaluated 
using commercially available cytotoxicity assays.  MTS assays were performed using the 
CellTiter 96 AQueous One Solution Cell Proliferation Assay kit (Promega Corp., 
Madison, WI) in which the soluble tetrazolium salt [3-[4,5-dimethylthiazol-2-yl]-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) is reduced to a purple 
formazan product.  The absorbance of the formazan product is proportional to the number 
of viable cells.  Stock solutions of polymer were suspended in PBS and allowed to 
equilibrate overnight.  Caco-2 cells were seeded in 96-well plates at 15,000 cells/well and 
incubated for 36 hours prior in 200 μL DMEM.  RAW 264.7 cells were seeded in 96-well 




Media was aspirated and cells were washed 2× with DPBS and incubated in 160 µL 
serum-free DMEM for 90 minutes.  Following this incubation period, polymer stock 
solutions at 5× were added to cells for another designated exposure times.  Media and 
polymer were aspirated and replaced with a DMEM/MTS solution.  Absorbance at 490 
nm was recorded after 4 hours incubation in the DMEM/MTS solution.   
5.2.5. Membrane Destabilization 
5.2.5.1. Hemolysis 
Sheep blood in sodium citrate was obtained from Hemostat Laboratories (Dixon , 
CA) and used for up to two weeks after receipt.  Phosphate buffers (0.15 M) from pH 5.0 
– 8.0 were prepared by dissolving predetermined amounts of monosodium phosphate and 
disodium phosphate in ultrapure DI water.  The buffer pH was adjusted as needed using 1 
N HCl or 1 N NaOH.  Dry nanoscale hydrogels were suspended in 150 mM phosphate 
buffer at the desired pH at a concentration of 2.5 mg ml
-1
 and allowed to equilibrate 
overnight.  Erythrocytes were isolated from whole sheep blood by 3 successive washes 
with freshly prepared 150 mM NaCl.  Red blood cells (RBCs) were separated by 
centrifugation from 10 minutes at 2,000×g.  The supernatant and remaining buffy coat 
were carefully aspirated and discarded.  After removing the supernatant following the 
final wash, RBCs were suspended in a volume of 150 mM phosphate buffer identical to 
that of the original blood aliquot at the pH matching that of the suspended polymers.  
This solution was diluted 10-fold in 150 mM phosphate buffer to yield an RBC 
suspension of approximately 5×10
8
 cells/mL.  In a typical experiment, 1×10
8
 RBCs were 




Cornelius, OR) pre-equilibrated at 37°C.   Following a 60 min incubation period, samples 
were centrifuged at 14,500 RPM for 5 min to separate cells and membrane fragments.  
An aliquot of each sample was transferred to a clear 96-well plate and hemoglobin 
absorbance was measured at 541 nm.  Negative controls (0% lysis) consisted of 150 mM 
phosphate buffer at experimental pH and positive controls (100% lysis) consisted of 
RBCs incubated in ultrapure DI water.  
The pH values tested in this analysis range from pH 5.0 – pH 8.0; experiments 
performed at pH 5.00, 5.50, 6.00, 6.50, 7.40, 7.60, 7.80, and 8.00.  The concentrations 
tested range from 1 – 2000 µg ml
-1
; with experiments performed with 2000, 1000, 500, 
250, 100, 50, 25, 10, 5, 2.5, and 1 µg ml
-1
 nanogel suspended in 150 mM phosphate 
buffer at the specified pH.   
5.2.5.2. Lactate Dehydrogenase Release 
LDH assays were performed using a CytoTox-ONE™ Homogeneous Membrane 
Integrity Assay (Promega Corp., Madison, WI ) to measure release of lactate 
dehydrogenase (LDH) from cells with damaged membranes.  Cells were seeded to 96-
well plates and polymer solutions added as previously described.  At designated time 
points, 50 µL aliquots of media was aspirated and combined with 50 µL LDH assay 
buffer in a black-walled 96-well plate.  Following 10 minutes incubation at room 
temperature, the fluorescence was measured at 530 ex/590 em.  Generally, cell culture 




5.2.5.3. Giant Unilammelar Vesicle Disruption 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dihexadecanoyl-
sn-glycero-3-phosphoethanolamine (DHPE) labeled with BODIPY® FL, cholesterol, and 
Texas Red-sucrose were kindly donated by Prof. Jeanne Stachowiak (University of Texas 
at Austin, Austin, TX).  Giant unilammelar vesicles (GUVs) were synthesized via 
electroformation as previously described [12, 13].  Briefly, lipid/cholesterol solutions 
were combined in the following ratio: 7:3:0.01 POPC:Cholesterol:Bodipy FL DHPE and 
drop-cast onto clean glass slides.  The lipid solutions were allowed to dry and were then 
assembled into electroformation chambers.  Vesicles were electroformed at 60°C in 
Texas Red-sucrose (∼350 milliosmole(mOsm)) solution.    
GUVs were placed in 35 mm glass-bottom petri dishes for real-time confocal 
microscopy imaging.  PDET and PDETB30 were prepared at 2 mg ml
-1
 in 100 mM 
phosphate buffer adjusted to pH 6.50.  The osmolarity of the resulting suspensions was 
measured and adjusted with sucrose to ~350 mOsm as needed.  1 ml of GUV suspension 
was transferred to the glass-bottom petri dish and was allowed to sediment for 5 min.   25 
µL of the nanogel suspension was carefully injected into the dish so as not to disturb the 
spatial distribution of focused GUVs.  Images were collected every 5 s at a fixed focal 
plane.   
5.3. RESULTS AND DISCUSSION 
5.3.1. Pyrene Fluorescence Spectroscopy 
Analogous to the pyrene emission studies performed in Section 4.3.7, pyrene 




hydrophobe to hydrophile.  The maximum excitation wavelength of pyrene red-shifts 
from 333 nm to 338 nm upon transition from polar to nonpolar environment.  Therefore, 
an increase in the excitation I338/I333 ratio indicates pyrene is preferentially partitioned in 
hydrophobic domains.  Figure 5.1 shows a representative change in pyrene fluorescence 
in aqueous suspensions of PDETB30 between collapsed hydrophobe (pH 8.0) and 
swollen hydrophile (pH 6.0).  Consequently, the fluorescence excitation spectra of pyrene 
can be used to probe the polarity of aqueous nanogel suspensions and determine the 
influence of polymer composition on nanogel hydrophobicity and the critical pH required 
to induce a conformational transition.   
Increasing the proportion of TBMA causes a clear decrease in the onset for the 
pH-dependent phase transition, as seen in Figure 5.2.  These observations follow the 
expected trend - increasing TMBA composition progressively lowers the apparent pH 
(pHapp) for the hydrophobic – hydrophilic transition.  Moreover, these data corroborate 
the pH-responsive swelling profiles presented in Figure 4.12A and are in excellent 
agreement with the pyrene emission studies shown in Figure 4.16A.   
Likewise, increasing the proportion of TBAEMA from 0 mol% of DEAEMA to 
30 mol% of DEAEMA causes a clear increase in the onset of the pH-dependent phase 
transition, as seen in Figure 5.3.  This trend is also expected, given that TBAEMA 
contains a secondary amine that should increase the pKa, and thus the onset of pH-
dependent phase transition, to higher pH values.  The broad transitions observed for 
PDETBA20 and PDETBA30 for pyrene emission studies (Figure 4.16B) are notably 




transition is quite similar for PDET, PDETBA10, PDETBA20, and PDETBA30.  A direct 
comparison of the effects of TBMA and TBAEMA on pH of hydrophobe-hydrophile 
phase shift can be seen in Figure 5.4 
5.3.2. Membrane Destabilization 
This series of experiments was constructed to identify nanogels capable of 
selective membrane destabilization.  An optimal nanogel would be relatively inert and 
non-disruptive under normal physiological conditions.  Upon transition to endosomal 
conditions, this optimal nanogel would undergo a conformational transition to render it 
capable of potent membrane destabilization.  Conversely, a non-optimal nanogel would 
mediate membrane disruption under physiological conditions and/or be non-disruptive in 
endosomal conditions.   
5.3.2.1. Hemolysis 
Hemolysis experiments were used to approximate the endosomolytic ability of 
these nanogels.  The pH- and concentration-dependent hemolysis was determined 
according to Equation 5.1: 
 
% 𝑯𝒆𝒎𝒐𝒍𝒚𝒊𝒔 =  
𝑨𝒔𝒂𝒎𝒑𝒍𝒆 −𝑨𝒃𝒍𝒂𝒏𝒌
𝑨𝒎𝒂𝒙−𝑨𝒃𝒍𝒂𝒏𝒌
    (5.1) 
Where Asample represents RBCs exposed to polymer at a given pH and 
concentration, Ablank is the absorbance of the supernatant after RBC exposure to 




exposure to DI water.  The relative lysis for nanoscale hydrogels containing varying 
amounts of TBMA or TBAEMA is shown in contour plot form in Figure 5.5.  These data 
demonstrate that polymer composition has a clear impact on membrane-disruptive 
capabilities.  As demonstrated previously with dynamic light scattering studies (Figure 
4.12), the simple presence of a t-butyl group alone in the copolymer is not the critical 
parameter for exerting control over resultant physicochemical properties.  Rather, the 
increased network hydrophobicity of TBMA-containing nanogels seems to govern the 
interactions with biological membranes.   
As seen in Figure 5.5, inclusion of TMBA in the nanogels markedly expands both 
the pH and concentration range at which these networks effectively disrupt erythrocyte 
membranes.  For example, PDET demonstrates efficient hemolysis at high concentrations 
(> 0.25 mg mL-1) and between pH 7.0 and pH 7.6.  In contrast, PDETB30 demonstrates 
highly efficient hemolysis in the pH range of early endosomes (pH 5.5 – pH 6.5) at 
concentrations as low as 1 µg mL
-1
.  The enhanced hemolytic ability of PDETB30 at pH 
6.0 is depicted in Figure 5.6, along with that of PDET and PDETBA30.  Notably, 
PDETB30 is 10× more efficient (on a mass basis) than previously reported polycationic 
block copolymer systems with demonstrated efficacy in in vitro siRNA delivery[10] and 
25× more efficient than phenylalanine-grafted pseudo-peptides[14] with demonstrated 
utility in intracellular protein delivery[15].  These data indicate that the membrane-
disruptive properties of these nanogels can be tuned by adjusting hydrophobic monomer 




5.3.2.2. Lactate dehydrogenase leakage 
The influence of polymer composition and exposure time on membrane 
destabilization in live cells was investigated using an LDH membrane integrity assay.  In 
this assay, the percentage of LDH leakage from permeabilized or damaged cell 
membranes can be given by an equation analogous to Equation 5.2.   
 
% 𝑳𝑫𝑯 𝑹𝒆𝒍𝒆𝒂𝒔𝒆 =  𝟏𝟎𝟎 ∗
𝑹𝑭𝑼𝒔−𝑹𝑭𝑼𝑷𝑩𝑺
𝑹𝑭𝑼𝒎𝒂𝒙−𝑹𝑭𝑼𝑷𝑩𝑺
   (5.2) 
Where RFUS is the fluorescent reading from the sample, RFUPBS is the 
fluorescent reading from cells exposed only to PBS (0% lysis) and RFUmax (100% lysis) 
is the maximum fluorescent reading from the plate.  In typical applications, RFUmax is 
given by a commercial lysis buffer.  In practice, however, the fluorescent reading 
generated by the greatest polymer concentration (2 mg/mL) generated fluorescent values 
that exceeded that of the kit lysis buffer and 1% w/v solutions of Triton-X100.  Thus, 
LDH release is occasionally reported as >100% at polymer concentrations 1 – 2 mg ml
-1
.  
LDH leakage as a function of nanogel concentration and exposure time is shown 
for PDET (Figure 5.7), PDETB30 (Figure 5.8), and PDETBA30 (Figure 5.9).  For PDET 
(Figure 5.7), the LDH leakage increases with longer exposure time (60 min to 180 min) 
and remains relatively constant from 180 min to 360 min.  For PDETB30 (Figure 5.8), 
the LDH leakage is negligible at concentrations up to 250 µg ml
-1
 for 60 min and 180 min 
exposure.  However, the leakage increases considerably following 360 min exposure. 
LDH release following exposure to PDETBA30 (Figure 5.9) follows no clear time 




underscore the need for careful consideration of incubation time in future cytotoxicity 
and siRNA delivery experiments to minimize the non-selective disruption of cellular 
membranes.   
The influence of nanogel composition on LDH leakage, shown in Figure 5.10A 
for TBMA-containing polymers and Figure 5.10B for TBAEMA-containing polymers, 
show that PDETB30 is less damaging to Caco-2 cell membranes than PDET, PDETB10, 
and PDETB20.  The general trend for inducing LDH membrane leakage is PDET ~ 
PDETB10 ~ PDETB20 > PDETB30.  For the TBAEMA-containing polymers (Figure 
5.10B), the general trend is as follows: PDETBA30 > PDETBA20 ~ PDETBA10 > 
PDET.  Notably, these trends are in excellent agreement with the trends in hydrophobic-
hydrophilic phase transition shown in Figure 5.2 and Figure 5.3 and summarized in Table 
5.1.   
Therefore, the pH-responsive transition regime (from collapsed hydrophobe to 
swollen hydrophile) is critical factor in determining the membrane-disruptive ability of 
these nanogels.  In all cases, nanogels were demonstrated maximum hemolysis at or near 
the pHapp determined by pyrene fluorescence studies (Table 5.1).  If this pHapp is near 
physiological pH, this membrane-disruptive effect was obvious in hemolysis (at pH 7.4) 
and LDH leakage assays.  However, if the pHapp is decreased through increased polymer 
hydrophobicity (e.g. PDETB30), the nanogels are less disruptive at physiological 




5.3.2.3. Giant Unilammelar Vesicle Disruption 
Visualizing a model lipid bilayer during the destabilization can provide some 
insight into the mechanism of membrane disruption.  Prevailing theories for membrane 
disruptive mechanisms by cationic polymers include reorientation of lipid head groups 
through ammonium-phosphate interactions [21],  transient nanopore formation [22, 23] 
following electrostatic attraction between polycation and cell membrane, or even 
catastrophic membrane disruption [24].  Naturally, size, surface charge, and ligand 
functionalization play important roles in modulating membrane interaction [25].  
However, many of these studies rely on biophysical measurements of controlled model 
systems such as supported lipid bilayers.  In reality, mammalian cell membranes are far 
more complex than these model systems.  Mammalian cell membranes typically contain 
dynamic combinations of surface- and transmembrane proteins, sugar coatings, diverse 
lipid combinations, and cholesterol.   Unfortunately, a mechanistic comprehension of 
membrane destabilization in mammalian cell membrane is currently underdeveloped.   
The micrographs in Figure 5.11 suggest that transient nanopore formation is the 
predominant mechanism through which PDETB30 exerts a membrane-destabilizing 
effect.  For these initial studies, pH 6.50 was selected to approximate the pH of an early 
endosomal environment.  Based on the hemolysis studies presented in Figure 5.5, PDET 
should be non-disruptive and PDETB30 should be highly-disruptive at these conditions.  
Following an injection to bring the PDET to 50 µg ml
-1
 in the buffered GUV solution, no 
discernible change was detected in membrane integrity.  The sucrose-Texas Red remains 
entrapped in the GUV for several minutes after injection, confirming the persistence of 




due to a mechanical disturbance displacing the GUVs from the focal plane.  Shifting the 
focal plane revealed that many GUVs had been forced downward by the force of the 
PDET injection. 
In contrast, the micrographs in Figure 5.11, Panels B and D, reveal substantial 
PDETB30-mediated destabilization of lipid membranes.  Exposure to 50 ug ml
-1
 
PDETB30 in pH 6.50 buffered solution resulted in a rapid and complete efflux of 
sucrose-Texas Red from the vesicle interior.  These data concur with the hemolysis data 
for PDETB30 at this concentration and pH, which indicate complete (~100%) disruption 
of erythrocytes.  Further efforts in this area will determine if the mechanism of membrane 
destabilization exhibits a dependence on polymer concentration.  Additionally, the 
molecular weight of the entrapped fluorescent solute (currently sucrose) will be varied to 
estimate the average pore size formed by membrane-disruptive nanogels.   
5.3.3. Cytocompatibility 
The effect of polymer concentration and composition on cellular proliferation was 
assessed using MTS assays.  These data are important to determine the non-toxic polymer 
doses for future drug delivery experiments.  In this assay, the metabolic activity of an 
experimental population relative to control populations can be given by the ratio: 
 
 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑃𝑟𝑜𝑙𝑖𝑓𝑒𝑟𝑎𝑡𝑖𝑜𝑛 =  
𝐴𝑠−𝐴𝑏𝑘𝑔
𝐴𝑃𝐵𝑆−𝐴𝑏𝑘𝑔




Where As is the absorbance (λ = 490 nm) from sample wells, Abkg is the 
background absorbance from DMEM/MTS solution, and APBS is the absorbance from 
wells in which cells were incubated only with DPBS. 
5.3.3.1. Caco-2 Cells 
As seen in Figure 5.12, PDETB20 and PDETB30 are non-toxic to Caco-2 cells at 
concentrations below 0.5 mg mL
-1
.  From 0.05 mg mL
-1
 - 2 mg mL
-1
, these formulations 
are significantly less toxic than the base formulation of P(DEAEMA-g-PEG) (PDET).  It 
has been well documented that free amino groups contribute to the untoward cytotoxicity 
of many polycationic delivery agents and that increased cationic charge density correlates 
with increased cytotoxicity [2].  As expected, polymers with similar cationic charge 
densities, e.g. nanogels with 20 mol% and 30 mol% TBAEMA, as well as PDET, exhibit 
similar toxicity profiles.  By nature of the polymer composition, nanogels with 20 mol% 
and 30 mol% TBMA have less cationic charge density and thus result in decreased 
toxicity. 
5.3.3.2. RAW 264.7 Cells 
In order to assess the concentration- and time-dependent toxicity of polymer 
carriers in model cells of intestinal phagocytes, MTS assays were conducted on murine 
macrophage cells.  As seen in Figure 5.13, the composition-dependent trend in toxicity 
profile remains consistent with observations in Caco-2 cells, though the magnitude of 
difference in toxicity was less pronounced.  The general trend across the concentration 




PDETB30 was significantly less toxic (p < 0.05) than the base formulation of PDET from 
5 – 500 µg mL
-1
.   
Comparison the polymer dose-dependent toxicity between Caco-2 cells and RAW 
264.7 cells reveals that the macrophages are more sensitive to the presence of nanogels 
than are the Caco-2 cells.  This disparity may be due to the relative amount of nanogel 
uptake demonstrated by each cell type.  Macrophages are phagocytic cells and will more 
readily imbibe macromolecules from their environment, thereby amplifying any harmful 
effects of the nanogels on cellular membranes or processes.  
In order to develop a conservative estimate for nontoxic nanogel concentrations in 
further experiments, RAW 264.7 cells were exposed to nanogels for 24 h and the 
metabolic activity compared to untreated control cells via MTS assay.  This comparison, 
shown in Figure 5.14 for PDET and PDETB30, reveals that PDETB30 is non-toxic below 
nanogel concentrations of 50 µg ml
-1
.   
5.4. CONCLUSIONS 
Physicochemical properties of nanoscale hydrogel networks, including critical 
phase transition pH, membrane disruption, and cytocompatibility can be modulated by 
tuning polymer composition.  PDETB30 nanogels exhibit favorable pH-responsive phase 
transition behavior for intracellular delivery and offer an excellent combination of 
hemolytic ability and cytocompatibility.  Additionally, the breadth of the pH range for 
maximum membrane disruption is related to the pH range for hydrophobic-hydrophilic 
transition.  PDETB30 is membrane-disruptive over a broader pH range than other 




and PDETBA30).  For these reasons, TBMA-containing nanoscale hydrogels, 
particularly PDETB30, possess attractive characteristics for intracellular drug delivery 





Table 5.1 – Comparison of critical pH values for phase transition and pH of maximum 
hemolysis. 
Name Copolymer mol t-butyl/ 








PDET P(DEAEMA-g-PEGMA) 0 7.37 7.39 7.4 
PDETB10 P(DEAEMA-co-TBMA-g-PEGMA) 10 7.31 7.24 7.4 
PDETB20 P(DEAEMA-co-TBMA-g-PEGMA) 20 7.36 7.04 6.5  
PDETB30 P(DEAEMA-co-TBMA-g-PEGMA) 30 6.65 6.78 6.5 
PDETBA10 P(DEAEMA-co-TBAEMA-g-PEGMA) 10 7.01 7.30 7.4 
PDETBA20 P(DEAEMA-co-TBAEMA-g-PEGMA) 20 6.98 7.54 7.4 
PDETBA30 P(DEAEMA-co-TBAEMA-g-PEGMA) 30 7.13 7.66 7.6 
 
1
Critical swelling pH determined by dynamic light scattering in Chapter 4, Figure 4.12. 
2
pH value for apparent hydrophobe-hydrophile phase transition (pHapp) determined by pyrene fluorescence 
spectroscopy.  Determined by calculating the inflection point of sigmoidal fit in Figures 5.2 and 5.3. 
3







Figure 5.1 - Normalized fluorescent excitation spectra of pyrene in 100 mM phosphate 
buffer and 0.5 mg mL
-1




























Figure 5.2 – Influence of TBMA incorporation on pyrene excitation (I338/I333 ratio) in 
P(DEAEMA-co-TBMA-g-PEGMA) nanogels.  Nanogels suspended at 0.5 
mg mL-1 and pyrene dissolved at 6×10-7 M in 100 mM phosphate buffers 
at designated pH values.  Symbols designate PDET (●), PDETB10 (▼),  



































Figure 5.3 – Influence of TBAEMA incorporation on pyrene excitation (I338/I333 ratio) in 
P(DEAEMA-co-TBAEMA-g-PEGMA) nanogels.  Nanogels suspended at 
0.5 mg mL
-1
 and pyrene dissolved at 6×10-7 M in 100 mM phosphate 
buffers at designated pH values.  Symbols designate PDET (●), PDETB10 
(▼),  PDETB20 (■),  or PDETB30 (◊). 
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Figure 5.4 - Influence of hydrophobic moiety on fluorescence excitation spectra of 
pyrene.  Pyrene dissolved at 6×10
-7
 M in 100 mM phosphate buffers with 
PDET (●), PDETB30 (▼), or PDETBA30 (■) at 0.5 mg mL
-1
.  Points 
represent measured data and lines represent best-fit sigmoidal curves.
pH


























Figure 5.5 – Hemolysis as a function of nanogel concentration and solution pH.  Contour plots for PDET, PDETB20 and PDETB30 
(top) and PDET, PDETBA20, and PDETBA30 (bottom).  
0 mol%  20 mol%  30 mol%  























































Figure 5.6 – Concentration-dependent hemolytic activity of PDET (□), PDETB30 (●), 
and PDETBA30 (□) in 150 mM phosphate buffer at early endosomal pH 
(pH 6.0).  Erythrocytes exposed to various polymer concentrations for 60 





















Figure 5.7 – Representative time-dependent LDH leakage from Caco-2 cells following 60 
min (●), 180 min (○), or 360 min (▼) exposure to PDET.  Data points 
represent the sample mean ± std error (n=4).  LDH leakage calculated 
relative to untreated cells and surfactant-lysed cells.   
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Figure 5.8 - Representative time-dependent LDH leakage from Caco-2 cells following 60 
min (●), 180 min (○), or 360 min (▼) exposure to PDETB30.  Data points 
represent the sample mean ± std error (n=4).  LDH leakage calculated 
relative to untreated cells and surfactant-lysed cells.   
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Figure 5.9 – Representative time-dependent LDH leakage from Caco-2 cells following 60 
min (●), 180 min (○), or 360 min (▼) exposure to PDETBA30.  Data points 
represent the sample mean ± std error (n=4).  LDH leakage calculated 




Polymer Concentration (mg ml
-1
)

































Figure 5.10 – Polymer-mediated LDH leakage from Caco-2 cells following exposure to 
PDET (●), PDETB10 (▼), PDETB20 (■), or PDETB30 (◊) for 60 min (A) 
or PDET (●), PDETBA10 (▼), PDETBA20 (■), or PDETBA30 (◊) for 60 
min (B). 
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Figure 5.11 - Destabilization of GUV membranes.  Intravesicle red fluorescence indicates 
sucrose-Texas Red.  Green fluorescence indicates membrane lipid DHPE-
Bodipy FL.  GUVs were suspended in 100 mM phosphate buffer at pH 6.5.  
PDET (A) or PDETB30 (B) in isosmotic phosphate buffer was added at 
achieve a final concentration of 50 µg ml
-1
.  GUVs after 30 seconds 
incubation (C and D).  Images captured using Zeiss spinning disc confocal 







Figure 5.12 - Cytocompatibility of polycationic nanogels as a function of polymer 
concentration.  Symbols represent PDET (●), PDETB20 (▼), PDETB30 
(■), PDETBA20 (◊), or PDETBA30 (▲).  The relative viability of Caco-2 
cells was determined by MTS assay following 90 min nanogel exposure and 
is expressed as a fraction of the control (untreated) cells.  Data are expressed 
as means ± SEM, n = 8.  Lines are to guide the eye.  Statistical significance 
determined via pairwise t-test between cells exposed to PDETB20 and 
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Figure 5.13 - Cytocompatibility of P(DEAEMA-g-PEGMA) and P(DEAEMA-co-
TBMA-g-PEGMA) nanogels as a function of polymer concentration.  The 
relative proliferation of RAW 264.7 cells was determined by MTS assay 
following 3 h nanogel exposure and is expressed as a fraction of the control 
(untreated) cells.  Data are expressed as means ± SEM, n = 4.  Statistical 
significance determined via pairwise t-test between cells exposed to 
PDETB30 or PDET (# p < 0.05). 
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Figure 5.14 - Cytocompatibility of PDET and PDETB30 nanogels as a function of 
polymer concentration following 24 h exposure.  The relative proliferation 
of RAW 264.7 cells was determined by MTS assay and is expressed as a 
fraction of the control (untreated) cells.  Data are expressed as means ± 
SEM, n = 4.  Statistical significance determined via pairwise t-test between 
cells exposed to PDET or PDETB30 (# p < 0.05). 
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Chapter 6:  Internalization pathways of membrane-disruptive, pH-
responsive nanogels 
6.1. INTRODUCTION 
Cellular internalization of polymer nanoparticles is a complex phenomenon that 
depends on size [1, 2], shape [3, 4], polymer chemistry [5], and surface characteristics of 
drug delivery vehicles.  Understanding the mechanism of internalization is critical 
because the internalization pathway influences subcellular trafficking, sorting, and 
exposure to variable enzymatic and pH conditions.  In mammalian cells, the principal 
pathways of internalization are clathrin-mediated endocytosis, caveloae-mediated 
endocytosis, macropinocytosis, or other energy-independent pathways [6].  Phagocytic 
cells, such as macrophages and dendritic cells can ingest material through phagocytosis.   
Clathrin-mediated endocytosis is a ubiquitous internalization pathway that serves 
as the primary mode of internalization for macromolecules.  Endocytic vesicles evolving 
from clathrin-coated pits will deliver their contents to early endosomes and will 
subsequently experience vesicular acidification.  Caveloae-mediated endocytosis occurs 
in membrane invaginations lined with the protein caveloae and cholesterol.  Vesicles 
generated from caveloae-mediated endocytosis do not undergo acidification.  
Macropinocytosis, similar to phagocytosis, occurs via actin-dependent membrane 
protrusions.  This pathway is common to many cell types and results in the formation of 
large macropinosomes approximately 1 – 5 µm in diameter [6].  In macrophages, 
macropinosomes typically become acidified, shrink, and subsequently fuse with 
lysosomes [7].   The fate of macropinosomes is less clear in other cell types.  Studies of 
macropinosome-endosome mixing in A431 cells revel little fluid or membrane exchange 




Historically, the constitutive endocytic activity of the clathrin-mediated pathway 
has been the most attractive mechanism for internalization.  Caveloae-mediated 
internalization is comparatively slow [9] and the small vesicle size (50 – 60 nm) 
precludes the entry of many nanoparticle delivery systems.  As this pathway generally 
avoids non-productive lysosomal accumulation, it holds promise as target for drug 
delivery of biomacromolecules.  Some recent evidence [10] suggests caveloae-mediated 
internalization plays a critical role in transfection efficiency of cationic polymer-DNA 
complexes for gene delivery gene delivery.   
Many mechanistic studies of nanoparticle uptake rely on the parallel analysis of 
flow cytometry and confocal microscopy to evaluate internalization and subcellular fate.  
While powerful when used in combination, both flow cytometry and confocal 
microscopy are subject to individual limitations.  Uncertainty in  the internalization (vs. 
surface adsorption) of fluorescent probes is a limitation of conventional flow cytometry 
whereas the statistical analysis of confocal micrographs can be laborious due to limited 
sample throughput.  This chapter describes the use of imaging flow cytometry as a robust 
technique to simultaneously gather statistical cytometry data and high-resolution images 
of thousands of cells.  This technique is used to study the uptake and intracellular 
localization of fluorescent PDET30 nanogels to elucidate the principal mechanisms of 
internalization in the model cell lines, Caco-2 and RAW 264.7. 
6.2. MATERIALS AND METHODS 
6.2.1. Fluorescent Polymer Synthesis 
PDETB30 was synthesized and purified as described in Section 4.2.1 and 4.2.2.  




hydrochloride (AEMA) was included in the pre-polymer feed mixture at 5 mol% of 
DEAEMA.  The resulting copolymer was named PDETB30f to signify the amine 
functionality.  The primary amine of AEMA was verified with a fluorescamine assay 
after synthesis and purification.   
Oregon Green 488 carboxylic acid, succinimdyl ester (OG488) was purchased 
from Molecular Probes (Eugene, OR).  The solid dye was dissolved in DMSO to yield a 
10 mg ml
-1
 solution.  To form the fluorescent polymer conjugate, PDETB30f was 
suspended at 10 mg ml
-1
 in 150 mM sodium bicarbonate buffer, pH 8.30.  OG488 was 
added to the PDETB30f suspension to give a 1:1 mol ratio between AEMA and OG488.  
The reaction was stirred gently in the dark for 6 h.  Following reaction completion, 
unreacted dye was separated from labeled PDETB30f through dialysis against DI water.  
Dialysis proceeded for 3 days in 12,000 – 14,000 MWCO dialysis tubing (Spectrum 
Labs, Rancho Dominguez, CA) for 3 days.  Labeled nanogels, PDETB30-OG488, were 
lyophilized in the dark for 3 days.  
6.2.2. Cell Culture 
General cell culture reagents and cell maintenance/passaging procedures are 
found in Section 5.2.3.   
6.2.3. Mechanism of Nanogel Uptake 
Chlorpromazine hydrochloride (98%), Nystatin, and Wortmannin (98%) were 
purchased from Sigma-Aldrich (St. Louis, MO).  5-N,N-dimethyl amiloride was 
purchased from Enzo Life Sciences (Farmingdale, NY). Filipin III was purchased from 
Cayman Chemical (Ann Arbor, MI).  Inhibitor toxicity to Caco-2 cells and RAW 264.7 




RAW 264.7 cells or Caco-2 cells were seeded at 1× 10
5
 cells/well in 6-well plates 
and allowed to grow to 80% confluence before exposure.  Immediately prior to exposure 
to inhibitors, cells were washed 1× with 2 mL DPBS and media was replaced with 1.8 
mL serum-free DMEM.  Concentrated suspensions (20×) of inhibitors were added to 
wells in 100 µL increments and allowed to incubate with cells for 30 min in a 37°C, 5% 
CO2 atmosphere.  Cells inhibited by refrigeration were placed at 4°C for 30 min prior to 
nanogel exposure.   
Following the 30 min equilibration period, 100 µL of PDETB30-OG488 at 500 
µg ml
-1
 in PBS was added to test well to yield a final concentration of 25 µg ml
-1
.  
Control wells received 100 µL PBS. Nanogel exposure occurred for 60 min at 37°C or 
4°C.  Following the exposure period, cells were rinsed 3× DPBS (with calcium and 
magnesium) and the media was replaced with 2 mL serum-free DMEM.  Hoechst 33342 
was added to each well for nuclear staining at a final concentration of 2.5 µg ml
-1
.  The 
nuclear staining process was completed for 30 min for RAW 264.7 cells and 45 min for 
Caco-2 cells at 37°C, 5% CO2.  Following Hoechst incubation, cells were rinsed 3× with 
DPBS (w/out calcium and magnesium).   
RAW 264.7 cells were isolated by replacing the final DPBS wash with 1 mL flow 
cytometry buffer and gently scraping the cells.  Cell suspensions from each well were 
transferred to microfuge tubes and centrifuged for 5 min at 500×g.  The supernatant was 
discarded and cell pellet re-suspended in 100 µL flow cytometry buffer.  Flow cytometry 
buffer was prepared by combining FBS, DPBS, and N3Na to form 1% FBS and 0.1% 




Caco-2 cells were isolated by replacing the final DPBS wash with 500 µL 0.25% 
trypsin-EDTA and incubating at 37°C, 5% CO2 for 8 min.  Trypsin was neutralized by 
adding 3 mL DMEM with 10% FBS and without phenol red.  Cell suspensions were 
centrifuged for 5 min at 500×g.  The supernatant was discarded and cell pellet re-
suspended in 100 µL flow cytometry buffer.   
All cell suspensions were kept on ice until analysis with Image Stream 
Cytometry. Propidium iodide (PI) was used as a live/dead discriminator and was added to 
cell suspensions immediately before analysis at a final concentration of 1 µg mL
-1
. 
6.2.4. Image Stream Cytometry 
Analysis of uptake mechanisms and siRNA delivery was conducted using an 
Amnis ImageStream (Seattle, WA) imaging flow cytometer equipped with lasers at 405 
nm, 488 nm, 658 nm, and 785 nm.  For uptake studies, fluorescent data were collected 
using Channel 1 (430 – 505 nm, Hoechst), Channel 2 (505 – 595 nm, OG488), Channel 4 
(595 – 660 nm, PI), and Channel 6 (745 – 800 nm, side scatter).  Brightfield images were 
collected in Channel 5.  Cells were imaged with a 60× objective.  Fluid velocity was set 
to a nominal value of 40 mm/sec.  Fluorescent compensation matrices were constructed 
using Amnis IDEAS® software and verified manually for proper fit.  At least 5,000 cells 
were collected for analysis.  Dead cells (PI positive) were excluded from analysis.  Out-
of-focus cells were also excluded from further analysis by gating the Gradient RMS 
feature in IDEAS® software. This feature detects image sharpness by calculating large 
changes in pixel values across the brightfield image.    Typically, cells with Gradient 




6.2.5. Statistical Analysis 
Statistical comparisons between experimental and control groups were made with 
two-tailed, unpaired, Student’s t-test.  Differences were accepted as statistically 
significant with p < 0.05.   
6.3. RESULTS AND DISCUSSION 
6.3.1. Fluorescent Polymer Synthesis 
To enable visualization of nanogel subcellular localization in siRNA delivery 
experiments, a fluorescent version of the PDETB30 nanogel was necessary.  A primary 
amine-containing analogue of PDETB30, termed PDETB30f, was successfully 
synthesized through the inclusion of AEMA in the nanogel core.   Following previous 
work [11], solid AEMA was added to the pre-polymer mixture immediately before 
sonication.  While this monomer is stable in its hydrochloride salt form, it readily 
undergoes a cyclic rearrangement to 2-hydroxyethyl methacrylamide upon neutralization 
[12].  Moreover, AEMA can undergo a Michael addition to the polymer chain.  Thus, the 
use of AEMA inevitably results in a mixture of reaction products.  While AEMA served 
as a suitable functionalization site for a fluorescent conjugate, future generations of 
fluorescent nanogels will utilize a more stable and predictable reactant.   
Oregon Green 488 (OG488), an amine reactive dye, was conjugated to primary 
amines in the nanogel core.  Prior to the conjugation reaction, the primary amine content 
of PDETB30f was determined to be47.5 ± 0.6µmol g
-1
, which represents a 32% 
incorporation efficiency.   OG488 was subsequently added to PDETB30f at 1:3 mol ratio 
of dye to amine.   This ratio was used to maintain consistency in the fluorescent loading 




Oregon Green 488 functionalization was tested with fluorescence spectroscopy and the 
percent functionalization calculated with UV absorbance and comparison to an Oregon 
Green 488 standard curve.   
The fluorescence emission (λex = 465 nm) spectra of the labeled nanogel 
(PDETB30-OG488) is shown in Figure 6.1.  The fluorescent labeling was estimated at 
19.1 ± 0.4 µmol g
-1
 using a standard curve of OG488 in PBS and at 17.1µmol g
-1
 using 





.   
6.3.2. Mechanism of Cellular Internalization 
6.3.2.1. Toxicity of Endocytosis Inhibitors 
Prior to testing the uptake inhibition of PDETB30-OG488, the specific 
pharmacological inhibitors were tested for toxicity against the two model cell lines, RAW 
264.7 and Caco-2.  Cytotoxicity was determined using an MTS assay as described in 
Section 5.2.4.  Toxicity data for specific inhibitors is seen in Figure 6.2.  To ensure 
inhibitory activity, the concentration used in inhibition experiments was selected as the 
maximum possible concentration before the onset of cytotoxicity.   
6.3.2.2. Nanogel Uptake 
In this study, several uptake inhibitors (Table 6.1) were applied to Caco-2 and 
RAW 264.7 cells to elucidate the primary uptake pathways into enterocytes and 
phagocytes, respectively.  As demonstrated in the previous chapter, the membrane-
disruptive activity of PDETB30 is highly dependent on environmental conditions (e.g. 




delivery of encapsulate cargoes, these polybasic nanogels must be exposed to a slightly 
acidic environment.  Some internalization pathways, such as caveloae-mediated 
endocytosis and lipid raft endocytosis, do not result in vesicular acidification.  Thus, 
these trafficking pathways are both undesirable and unproductive, as PDETB30 is far less 
membrane disruptive at pH values of the extracellular milieu.  In contrast, pathways such 
as clathrin-mediated endocytosis or macropinocytosis are preferred because of their 
progressive vesicular acidification; a process that will enable PDETB30 to undergo a 
volume phase transition and destabilize the surrounding vesicular membrane. 
In the mechanistic studies of nanogel internalization, it was particularly important 
to verify that the Oregen Green 488 (OG488)-labeled nanogels were located inside the 
cell rather than on the periphery.  In order to accomplish this, two image masks were 
created in the cell brightfield channel.  The total cell mask (Figure 6.3) encompasses the 
entire cell contents.  The cell interior mask (Figure 6.3) is slightly smaller than the total 
cell mask and encompasses cell contents inside the cell membrane.   
The internalization coefficient is a ratio of the OG488 floursence inside the cell 
and OG488 fluoresence inside and around the cell, where the cell boundaries are 
determined by masks shown in Figure C.5.  Two representative images illustrate the 
difference between extracellular or membrane-bound fluoresncence (Internalization 
Coefficeint < 0) and intracellular fluoresence (Internalization Coefficient < 0).  The 
population formed by live, focused, single cells with internalized OG488 was used as the 




6.3.2.3. Nanogel uptake Caco-2 cells 
Figure 6.4 shows the intracellular fluorescence of PDETB30-OG488 (relative to 
uninhibited control) in Caco-2 cells.  Corresponding fluorescent and brightfield 
micrographs are seen in Figure 6.5.  Incubation with chlorpromazine did not have a 
significant effect on the uptake of PDETB30-OG488, indicating that clathrin-mediated 
endocytosis is not a dominant uptake pathway for these nanogels in Caco-2 cells.  
Inhibitors of caveloae-mediated endocytosis, Filipin III and Nystatin, resulted in a 14% 
and 12%, respectively, reduction in intracellular fluorescence of PDETB30-OG488.  
Inhibitors of macropinocytosis, wortmannin and amiloride, resulted in the greatest 
decrease in intracellular fluorescence.  Wortmannin caused a 39% reduction in 
intracellular fluorescence and amiloride caused a 31% reduction.  
Inhibition of energy-dependent processes by incubation at 4°C caused a 63% 
reduction in the intracellular fluorescence.  Notably, an appreciable portion of PDETB30-
OG488 uptake in Caco-2 cells occurs through an energy-independent process.  Other 
reports have noted energy-independent transport of nanoparticles, specifically with 
respect to cationic lipids and breast cancer cells [13] and PLGA nanoparticles and Caco-2 
cells[14].  This process is thought to be due to particle fusion with the cell membrane and 
has been reported in several types of cationic delivery vectors, including lipoplexes [15], 
dendrimers [16], and crosslinked poly(ethyleneimine) nanogels [17].  PDETB30 is mildly 
membrane-disruptive under physiological conditions and may permit the cellular influx 
of nanogel particles through the transient membrane perturbation and nanopore formation 




6.3.2.4. Nanogel uptake RAW 264.7 cells 
Figure 6.6 shows the intracellular fluorescence of PDETB30-OG488 (relative to 
uninhibited control) in RAW 264.7 cells and corresponding fluorescent and brightfield 
micrographs are seen in Figure 6.7.  These data suggest that a multiple internalization 
pathways are responsible for PDETG30-OG488 uptake in RAW macrophages.   
The dominant uptake pathways are clathrin-mediated endocytosis and 
macropinocytosis.  The inhibition of clathrin-mediated endocytosis with chlorpromazine 
decreased the uptake of PDETB30-OG488 by 45% and the inhibition of 
macropinocytosis with amiloride reduced uptake by 68%.  The caveloae-mediated 
endocytic pathway is active, albeit less than clathrin-mediated endocytosis or 
macropinocytosis, as inhibition of caveloae-mediated endocytosis with nystatin caused a 
slight decrease in the nanogel uptake (~18%).  Notably, uptake was not significantly 
inhibited by cholesterol-sequestering agent Filipin III.  This suggests that caveloae-
mediated endocytosis plays a minor role in the internalization of PDETB30-OG488 by 
macrophages.  The energy-independent internalization of PDETB30-OG488 was 
appreciable in RAW 264.7 cells, though this pathway was less prominent than in Caco-2 
cells.   
Although macrophages are capable of phagocytosis, the inhibition of PI3K, 
required for actin polymerization and phagosome and macropinosome formation [18],  
with  wortmannin resulted in a ~25% decrease in PDETB30-OG488 internalization. The 
lack of phagocytic uptake from RAW 264.7 macrophages may be ascribed to their ~100 
nm size.  The generally accepted lower size limit for phagocytosis is approximately 500 




culture media.  Macrophages rely on the adsorption of opsonin proteins to cell surface 
receptors such as Fc receptors and complement receptors to initiate phagocytosis.  The 
lack of serum proteins in the cell culture media may limit initiation of phagocytic 
internalization.   
The presence of multiple internalization mechanisms is consistent with other 
reports of hydrophobically modified particles [20].  Banquy et al. [21] observed a 
difference in uptake of hydrogel nanoparticles depending on nanoparticle modulus.  
RAW 264.7 macrophages internalized soft particles preferentially through 
macropinocytosis and stiff particles through clathrin-dependent endocytosis.   
6.3.2.5. Intracellular staining  
Intracellular punctate staining of PDETB30-OGG488 was analyzed in a semi-
quantitative fashion using Amnis IDEAS® software.  The intracellular spot mask was 
created by identifying staining patterns with spot pixel values at least 10 times greater 
than the surrounding cell background.  A software algorithm was used to count the 
number of spots per cell.  A demonstrative example of 0 spots, 3 spots (low spot count), 
and 9 spots (high spot count) is shown in Figure 6.8.   
Figure 6.9 and Figure 6.10 show the spot count distributions for Caco-2 cells and 
RAW 264.7 cells, respectively.  Unfortunately, this analysis reveals limited insight into 
the subcellular fate of PDETB30-OG488 as a function of uptake mechanism.  The 
number of counted spots is primarily a function of population fluorescent intensity.  For 
example, when macropinocytosis of PDETB30-OG488 is inhibited by amiloride in RAW 




uninhibited uptake (Figure 6.10, Panel A).  Similar observations were noted for Caco-2 
cells.   
6.4. CONCLUSIONS 
The mechanisms of cellular internalization of fluorescent nanogels were studied 
using ImageStream cytometry in Caco-2 cells and RAW 264.7 cells.  Despite the lack of 
any targeting moieties, these nanogels are internalized readily by both Caco-2 cells and 
RAW 264.7 macrophages.  After 60 min exposure, the intracellular PDETB30-OG488 
fluorescence increased over 25× in Caco-2 cells and over 80× in RAW cells.   
Macropinocytosis is the dominant mechanism of nanogel internalization in Caco-2 cells 
while clathrin-mediated endocytosis and macropinocytosis are the dominant mechanism 
of internalization in RAW 264.7 cells.  Membrane vesicles arising from clathrin-
mediated endocytosis and macropinocytosis both undergo acidification.  As PDETB30 
requires a slightly acidic pH to exert its membrane-destabilizing effects, these 
internalization pathways are desirable for uptake and subsequent endosomal escape of 
PDETB30 and encapsulated therapeutics.  Further efforts will analyze the ability of 
PDETB30 (and fluorescent analogue PDETB30-OG488) to enable cytoplasmic delivery 






Figure 6.1 – Fluorescent emission spectra of PDETB30-OG488 at 0.125 mg ml
-1
 in PBS. 





































Table 6.1 – Uptake Inhibitors and their inhibitory effects 





Chlorpromazine Clathrin-mediated endocytosis by 
dissociating clathrin lattice 
10 µM 1 – 100 µM 
Filipin III Caveloae via cholesterol binding 1.5 µM 0.05 – 50 µM 
Nystatin Caveloae/Lipid Raft Endocytosis 50 µg/mL 1 – 1000 µg/mL 
Wortmannin Macropinocytosis/phagocytosis by 
inhibiting PI3K 
100 nM 0.5 – 500 nM 
Amiloride Macropinocytosis via preventing 
Na+/H+ exchange 






Figure 6.2 – Cytotoxicity of inhibitors on Caco-2 cells following 90 min exposure.  
Cellular proliferation relative to untreated control was determined via MTS 
assay.  Data represent the mean of quadruplicate samples ±s.e.m.  Dashed 







Figure 6.3. – Internalization coefficient of fluorescent nanogels.  Fluorescent intensity of 
PDETB30-OG488 in uptake inhibition studies was calculated from cells 








Figure 6.4 – Uptake inhibition in Caco-2 cells.  Intracellular PDETB30-OG488 
fluorescence relative to non-inhibited control.  Caco-2 cells pre-incubated 
with inhibitors for 30 min prior to 60 min exposure to 25 µg ml
-1
 PDETB30-
OG488.  Bars represent the mean of 2 pooled experiments ±s.e.m.  *p < 





Figure 6.5 – Representative fluorescent micrographs of Caco-2 cells exposed to 
endocytosis inhibitors and PDETB30-OG488.Images sampled from median 






Figure 6.6 – Uptake inhibition in RAW 264.7 cells.  Intracellular PDETB30-OG488 
fluorescence relative to non-inhibited control.  RAW 264.7 cells pre-
incubated with inhibitors for 30 min prior to 60 min exposure to 25 µg ml
-1
 
PDETB30-OG488.  Bars represent the mean of 2 pooled experiments 





Figure 6.7 – Representative fluorescent micrographs of RAW 264.7 cells exposed to 
endocytosis inhibitors and PDETB30-OG488.  Images sampled from 
median intensity region of OG488 fluorescent histogram.  Scale bar 







Figure 6.8. – Spot counting of intracellular nanogels.  Left images show fluorescent 
intensity (white) of fluorescently-labeled PDESSB30-OG488.  Three 
representative images of low (1 spot) count (A), intermediate (5 spots) count 
(B), and high (9 spots) count.  Spot masks are shown in turquoise overlaid 





Figure 6.9 – Frequency distributions of intracellular staining of PDETB30-OG488 in 
Caco-2 cells. Cellular internalization examined in the presence of no 
inhibitor (A), chlorpromazine (B), filipin III (C), nystatin (D), wortmannin 
(E), amiloride (F), or 4°C (G).  Untreated (no PDETB30-OG488) is shown 
in panel H.  Caco-2 cells were pre-incubated with inhibitors for 30 min, 
exposed to 25 µg ml
-1
 PDETB30-OG488 for 60 min, and imaged via 
ImageStream cytometry after 60 min further incubation.  Histograms 





Figure 6.10 – Frequency distributions of intracellular staining of PDETB30-OG488 in 
RAW 264.7 cells. Cellular internalization examined in the presence of no 
inhibitor (A), chlorpromazine (B), filipin III (C), nystatin (D), wortmannin 
(E), amiloride (F), or 4°C (G).  Untreated (no PDETB30-OG488) is shown 
in panel H.  RAW 264.7 cells were pre-incubated with inhibitors for 30 min, 
exposed to 25 µg ml
-1
 PDETB30-OG488 for 60 min, and imaged via 
ImageStream cytometry after 60 min further incubation.  Histograms 
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Chapter 7:  Cytoplasmic delivery of functional siRNA using pH-
responsive nanoscale hydrogels 
7.1. INTRODUCTION 
The landmark discovery of RNA interference (RNAi) in 1998 has sparked a 
massive research effort in all fields of biological science and redefined our understanding 
of gene regulation mechanisms [1].  Theoretically, RNAi mediated by siRNA could be 
used as a powerful and versatile treatment modality to treat nearly any disease resulting 
from aberrant gene expression.  Owing to its remarkable potency and reversible 
therapeutic effect, siRNA holds extraordinary promise as a new biological therapeutic.  
As with many biotherapeutics, efficient delivery has been implicated as the major hurdle 
to its widespread clinical application [2].   
Several materials-based strategies exist to circumvent the delivery challenges 
associated with cytoplasmic delivery of small interfering RNA.  The most common 
classes of materials are lipids and lipidoids, polycationic polymers, and siRNA 
conjugates [2].  Lipids are perhaps the most widely studied class of materials for siRNA 
delivery and lipid-based formulations for RNAi have progressed to the clinic in greater 
number than other delivery systems [3].  The first evidence of RNAi in humans was 
demonstrated using a polycationic cyclodextrin nanoparticles [4].  Recently, alternative 
strategies have emerged to enable siRNA delivery to target cells and tissues.  Khormaee, 
et al. [5] recently reported the use of a membrane-disruptive anionic pseudo-peptide to 
deliver siRNA in vivo.  Polysaccharides from yeast cell walls have been used to deliver 
inflammation-suppressing siRNA via oral administration [6] 
Amine-containing methacrylates, such as 2-(diethylaminoethyl) methacrylate 




foundations for polymeric nucleic acid-delivery systems because of their ability to form 
cooperative electrostatic interactions with polyanionic siRNA.  Chapters  4 – 6 have 
explored the aqueous solution properties, membrane-disruptive properties, and 
internalization mechanisms of pH-responsive nanoscale hydrogels (nanogels).   
The nanogel with the most promising attributes for siRNA delivery consists of a 
(1) ionizable core of 2-(diethylaminoethyl methacrylate) (DEAEMA), (2) hydrophobic 
comonomer of tert-butyl methacrylate (TBMA), and (3) grafted corona of poly(ethylene 
glycol).  This nanogel (PDETB30) undergoes a volume phase transition from collapsed 
hydrophobe to swollen hydrophile at approximately pH 6.5 and is highly disruptive to 
model membrane systems in this transition region.  Additionally, PDETB30 displays 
excellent biocompatibility to Caco-2 cell and RAW 264.7 cells in in vitro toxicity assays.   
However, a critical aspect of intracellular delivery systems is a mechanism for 
elimination or degradation.  Disulfide linkers can be cleaved by the reductive tripeptide 
glutathione (GSH); present at intracellular concentrations of 1 - 11 mM [9].  By 
incorporating these linkers into polycationic nanogels, we can impart degradability to the 
network while retaining their mechanical integrity and pH-responsive behavior (Figure 
7.1). 
This chapter describes the synthesis and characterization of nanogels with 
reducible disulfide crosslinks and compares their suitability as siRNA carriers with non-




7.2. MATERIALS AND METHODS 
7.2.1. Synthesis of disulfide crosslinker 
Dichloromethane (>99.5%) was purchased from Fisher Scientific (Plainfield, NJ).  
Methacryloyl chloride (97%) and anhydrous pyridine (99.8%) were purchased from 
Sigma-Aldrich (St. Louis, MO).  2-Hydroxyethyldisulfide (90%) was purchased from 
Acros (Geel, Belgium). 
The homobifunctional disulfide crosslinker, bis(2-methacryloyloxyethyl) disulfide 
(SSXL), was synthesized according to the method reported by Gao, et al. [10].  Briefly, 
organic solvents were dried over MgSO4 before use.  Dichloromethane was purged with 
N2 for 15 min and placed in a dry nitrogen atmosphere (O2 < 0.1 ppm, H2O < 0.1 ppm).  
Pyridine (15.8 mL, 0.195 mol) and bis(2-hydroxyethyl) disulfide (10.00 g, 0.065 mol) 
were added to cold (4°C) dichloromethane and agitated briefly.  Methacryloyl chloride 
was added dropwise to the stirring organic mixture over the course over 20 min.  The 
flask was then sealed and removed from the ice bath and the reaction was allowed to 
proceed for 12 h in a nitrogen atmosphere.   
The crude reaction product, in dichloromethane, was successively washed with 1 
N HCl, 1 N NaOH, and DI water.  The organic phase was retained and dried to a viscous 
yellow liquid via rotary evaporation.  The product was then dissolved in diethyl ether and 
passed through a column of sodium carbonate and basic alumina. Diethyl ether was 
removed through rotary evaporation, again yielding a viscous yellow liquid.   
Additional flash chromatography purification was performed using a Teledyne-
Isco Companion Automated Flash Chromatography Instrument (Lincoln, NE) equipped 




hexanes, Solvent B- ethyl acetate.  The gradient was adjusted from 0 – 15% B over 40 
minutes and then from 15 – 100% B over 10 minutes.  Fractions of interest were 
determined by monitoring absorbance at 258 nm.  Product fractions were pooled and 
solvent was removed by rotary evaporation to yield a viscous, yellow liquid. 
 
7.2.2. Characterization of disulfide crosslinker 
The composition of raw materials, purification fractions, and final product of the 
SSXL synthesis were investigated using a Varian (Palo Alto, CA) DirectDrive 400 MHz 
nuclear magnetic resonance spectrometer equipped with automatic sampler.  Chloroform-
d (CDCl3, 99.8%) was obtained from Acros Organics (Fairlawn, NJ). All glassware, 
including NMR Tubes (Wilmad Lab Glass, Vineland, NJ), 2 mL sample vials, and 
Pasteur pipettes were dried overnight in a vacuum oven.  SSXL was dissolved at 1% 




Mass spectrometry was performed courtesy of the Mass Spectrometry Facility in 
the Department of Chemistry and Biochemistry, University of Texas at Austin. 
7.2.3. Polymer Synthesis 
7.2.3.1. Synthesis of degradable nanogel 
To impart a mechanism for biodegradation to the responsive nanogel PDETB302, 
SSXL was used as a replacement for tetra(ethylene glycol) dimethacrylate (TEGDMA) in 
the photoemulsion polymerization.  SSXL was added to pre-polymer mixture at 2.5 
                                                 




mol% of total monomer and photoemulsion polymerization and nanogel purification 
proceeded as described in Section 4.2.1 and Section 4.2.2. The resulting nanogel, termed 
PDESSB30, was stored in a desiccator at -20°C until further use.   
7.2.3.2. Fluorescent Polymer Synthesis 
A fluorescent version of PDESSB30 was synthesized and purified as in identical 
fashion to the description in Section 6.2.1.  Like the synthesis of PDETB30-OG488, the 
covalent conjugation of Oregon Green 488 (OG488) was enabled by the incorporation of 
primary amines in the PDESSB30 core.  Again, 2-aminoethyl methacrylate hydrochloride 
(AEMA) was included in the pre-polymer feed mixture at 5 mol% of DEAEMA.  The 
resulting copolymer was named PDESSB30f to signify the amine functionality.  The 
primary amine of AEMA was verified with a fluorescamine assay after synthesis and 
purification.   
Oregon Green 488 carboxylic acid, succinimdyl ester (OG488, Molecular Probes, 
Eugene, OR) was dissolved in DMSO to yield a 10 mg ml
-1
 solution.  To form the 
fluorescent polymer conjugate, PDESSB30f was suspended at 10 mg ml
-1
 in 150 mM 
sodium bicarbonate buffer, pH 8.30.  OG488 was added to the PDESSB30f suspension to 
give a 1:1 mol ratio between AEMA and OG488.  The reaction was stirred gently in the 
dark for 6 h.  Following reaction completion, unreacted dye was separated from labeled 
PDESSB30-OG488 through dialysis against DI water.  Dialysis proceeded for 3 days in 
12,000 – 14,000 MWCO dialysis tubing (Spectrum Labs, Rancho Dominguez, CA) for 3 




7.2.4. Degradable Nanogel Characterization 
Several characterization techniques were employed to study the physicochemical 
properties of the PDESSB30 nanogels in comparison to the TMBA analogue, PDETB30.  
Dynamic light scattering was used to determine the hydrodynamic diameter of 
PDESSB30 as a function on environmental pH and was performed as described in 
Section 4.2.4.  Measurements of the ζ-potential were performed to evaluate the effective 
surface charge as function of environmental pH and were performed as described in 
Section 4.2.6.  Transmission electron microscopy (TEM) was used to determine the 
diameter of the dry nanogels and was conducted as described in Section 4.2.5.  
Evaluations of RAW 264.7 metabolic activity upon exposure to PDESSB30 and 
PDETB30 were conducted using a commercially-available MTS assay kits as described 
in Section 5.2.4. 
7.2.5. RNA Binding 
RNA complexation buffer was prepared by dissolving 3.15 g sodium phosphate 
dibasic heptahydrate, 0.02 g potassium phosphate monobasic monohydrate, 0.20 g 
potassium chloride, and 8.01 g sodium chloride in Milli-Q purified water.  Following salt 
dissolution, the solution pH was adjusted to pH 5.50 using 1 N HCl and ultrapure water 
was added to bring the final solution volume to 100 mL.  To remove nucleases, 
diethylpyrocarbonate (DEPC) was added at 0.1% and incubated at room temperature 
overnight.  The buffer solution was then autoclaved to remove DEPC.  Polymer-siRNA 
complexes were formed by combining aqueous solutions of nanogels, siRNA, 10x 




Silencer® GAPDH siRNA, Quant-iT™ Ribogreen® RNA Assay Kit, and RNAse 
Free H2O were purchased from Life Technologies (Carlsbad, CA).  Free siRNA in 
solution was measured using the Ribogreen® assay according to manufacturer’s 
instructions.  Nanogel suspensions were diluted in RNAse free complexation buffer (pH 
5.50).  Concentrated siRNA was added to yield 500 ng ml
-1
 RNA in a nanogel suspension 
at designated concentrations.  Measurements of the free siRNA were taken after 60, 120, 
and 180 minute complexation periods.   
7.2.6. Cell Culture 
General cell culture reagents and cell maintenance/passaging procedures are 
found in Section 5.2.3.  In all cytometry studies, Caco-2 cells or RAW 264.7 cells were 
seeded to 6-well plates and allowed to grow to 80% confluency before use.   
7.2.7. siRNA delivery 
DyLight 647-labeled small interfering RNA (Sense: DY647-
UAAGGCUAUGAAGAGAUACUU) was purchased from Thermo Scientific (Lafayette, 
CO). Cy3-labeled Silencer® Negative Control No. 1 siRNA was purchased from Life 
Technologies (Carlsbad, CA).  Fluorescent nanogels, PDETB30-OG488 and PDESSB30-
OG488 were synthesized and purified as described in Section 6.2.1 and Section 7.2.3.2, 
respectively.   
Concentrated suspensions (20×) of fluorescent nanogels (PDETB30-OG488 or 
PDESSB30-OG488), fluorescent siRNA (DY647-siRNA or Cy3-siRNA), or fluorescent 
nanogels and fluorescent siRNA were prepared to contain 0.5 mg mL
-1
 nanogel, 26.5 µg 
mL
-1




samples (nanogel or siRNA) were prepared in a similar fashion, replacing the volume of 
the absent component(s) with RNAse free H2O.   
To separate nanogel/siRNA complexes from complexation buffer, 4 vol 
equivalents of acetone was added to the suspension following the designated 
complexation period.  The acetone serves to induce a polyelectrolyte-ionomer transition 
[11].  Suspensions were centrifuged at 15,000 rpm for 5 min and supernatant was 
discarded.  Residual solvent evaporated after 15 min in a laminar flow hood.  
Polymer/siRNA complexes were resuspended in the original complexation volume of 
RNAse free PBS at pH 7.40. 
Following resuspension, 100 µL of nanogel/siRNA complexes at 500 µg ml
-1
 in 
PBS were added to each test well to yield a final concentration of 25 µg ml
-1
.  Control 
wells received 100 µL PBS or100 µL of the corresponding nanogel-only or siRNA-only 
solution. Nanogel exposure occurred for designated time points at 37°C or 4°C.  
Following the exposure period, cells were rinsed 3× DPBS (with calcium and 
magnesium) and the media was replaced with 2 mL serum-free DMEM.   
For Image Stream cytometry, Hoechst 33342 was added to each well for nuclear 
staining at a final concentration of 2.5 µg ml
-1
.  The nuclear staining process was 
completed for 30 min for RAW 264.7 cells and 45 min for Caco-2 cells at 37°C, 5% CO2.  
Following Hoechst incubation, cells were rinsed 3× with DPBS (w/out calcium and 
magnesium).  No nuclear stain was used in conventional flow cytometry experiments.   
RAW 264.7 cells were isolated by replacing the final DPBS wash with 1 mL flow 
cytometry buffer and gently scraping the cells.  Cell suspensions from each well were 




discarded and cell pellet re-suspended in flow cytometry buffer.  Flow cytometry buffer 
was prepared by combining FBS, DPBS, and N3Na to form 1% FBS and 0.1% N3Na in 
DPBS. 
Caco-2 cells were isolated by replacing the final DPBS wash with 500 µL 0.25% 
trypsin-EDTA and incubating at 37°C, 5% CO2 for 8 min.  Trypsin was neutralized by 
adding 3 mL DMEM with 10% FBS and without phenol red.  Cell suspensions were 
centrifuged for 5 min at 500×g.  The supernatant was discarded and cell pellet re-
suspended in flow cytometry buffer.   
All cell suspensions were kept on ice until analysis with Image Stream 
Cytometry. Propidium iodide (PI) was used as a live/dead discriminator and was added to 
cell suspensions immediately before analysis at a final concentration of 1 µg mL
-1
. 
7.2.7.1. Flow cytometry 
Efficiency of PDETB30- and PDESSB30-mediated Cy3-siRNA delivery was 
compared using a BD FACSCalibur (San Jose, CA) flow cytometer equipped with lasers 
at 488 nm and 635 nm.  Fluorescent data were collected using FL-2 (570 – 600 nm, Cy3) 
and FL-3 (653 - 669 nm, PI).  Dead or dying cells were identified with propidium iodide.  
Typically, 40,000 cells were collected per sample.   
7.2.7.2. Image Stream Cytometry 
Analysis of uptake mechanisms and siRNA delivery was conducted using an 
Amnis Image Stream (Seattle, WA) imaging flow cytometer equipped with lasers at 405 
nm, 488 nm, 658 nm, and 785 nm.  Fluorescent data were collected using Channel 1 (430 




Channel 5 (660 – 745 nm, DY647), and Channel 6 (745 – 800 nm, side scatter).  
Brightfield images were collected in Channel 3. 
Cells were imaged with a 60× objective.  Fluid velocity was set to a nominal 
value of 40 mm/sec.  Fluorescent compensation matrices were constructed using Amnis 
IDEAS® software and verified manually for proper fit.  At least 5,000 cells were 
collected for analysis.  Dead cells (PI positive) were excluded from analysis.  Out-of-
focus cells were also excluded from further analysis by gating the Gradient RMS feature 
in IDEAS® software. This feature detects image sharpness by calculating large changes 
in pixel values across the brightfield image.    Typically, cells with Gradient RMS value 
<40 were considered out of focus3. 
7.2.8. siRNA-Mediated Gene Silencing 
GAPDH Positive Control siRNA, KD Alert Assay Kits, and 10× Phosphate 
Buffered Saline (RNAse free) were purchased from Life Technologies (Carlsbad, CA).  
Caco-2 cells were seeded to tissue-culture treated 96-well plates at 2,500 cells/well and 
allowed equilibrate 24 hours before use.  GAPDH siRNA was loaded into PDETB30 or 
PDESSB30 nanogels as outlined in Section 7.2.5.  Following 60 min incubation in 
complexation buffer, nanogel/siRNA complexes were precipitated through the addition of 
acetone and centrifuged at 15,000 rpm for 5 min.  Supernatant was discarded and 
complexes were resuspended in RNAse free PBS.  Prior to use, Caco-2 cells were washed 
1× with PBS and media replaced with serum free DMEM.  Concentrated (20×) 
nanogel/siRNA complexes or control suspensions were added to test wells and incubated 
at 37°C, 5% CO2 for 60 min.   Following the 60 min exposure period, cells were washed 
                                                 




3× with pre-warmed PBS and media replaced with complete DMEM.  Cells were 
incubated at 37°C, 5% CO2 prior to conducting the KD Alert gene silencing assay 
according the manufacturer’s instructions.  Care was taken to adjust the microplate reader 
sensitivity to remain within the GAPDH enzyme calibration curve established according 
to the manufacturer’s instructions.   
7.2.9. Statistical Analysis 
Statistical comparisons between experimental and control groups were made with 
two-tailed, unpaired, Student’s t-test.  Differences were accepted as statistically 
significant with p < 0.05.   
7.3. RESULTS AND DISCUSSION 
7.3.1. Synthesis of disulfide crosslinker 
A homobifunctional crosslinker 2-bis-(2-methacryloyloxyethyl disulfide) was 
synthesized (Figure 7.2) to endow responsive DEAEMA-based nanogels with a 
mechanism for biodegradation, namely reductive cleavage of the disulfide bonds.  At the 
time of this study, this bifunctional linker was not commercially available.  However, this 
crosslinker is now available commercially (with hydroquinone inhibitor) from Sigma-
Aldrich (CAS No. 36837-97-5). 
The synthesis and purification of 2-bis-(2-methacryloyloxyethyl disulfide) 
(SSXL) was successful; the reaction resulted in a molar yield of approximately 50%.  The 
structure of SSXL was verified with 
1
H-NMR.  The spectra, shown in Figure 7.3, show 




5.60 ppm (2H, -O-CH2-CH2-), and 6.14 ppm (3H, CH3-C=).  Analysis of the mass 
spectra (Figure 7.4) reveals a product of the expected molecular weight, 290 Da.   
7.3.2. Degradable Nanogel Synthesis and Characterization 
Disulfide-crosslinked nanogels containing an ionizable core of DEAEMA-co-
TBMA and PEG corona were successfully synthesized via photoemulsion 
polymerization.  This synthesis was conducted in identical fashion to our previous reports 
[11-13] and resulted in a similar yield (~1.2 g of nanogel) to previous syntheses.  
Replacing the non-degradable linker TEGDMA (as used in PDET, PDETB30, etc.) with 
SSXL had no identifiable change on physicochemical properties like pH-dependent 
swelling (Figure 7.5.), ζ-potential (Figure 7.6), and cytotoxicity to RAW 264.7 cells 
(Figure 7.7).    
As shown in Figure 7.5, the critical swelling pH for PDESSB30 is 6.55.  These 
nanogels have a z-average diameter of 96 nm at pH 8.5 and 126 nm at pH 6.0.  The 
breadth of the volume phase transition is similar to PDETB30, occurring over 1.45 pH 
units.  The value reported for PDETB30 in Chapter 4 is 1.56 pH units.  PDESBB30 
nanogels exhibit a PdI of 0.12 – 0.15 throughout the volume phase transition. 
The nanoscale dimensions of PDESSB30 were verified by TEM and the dry 
particle size was determined to be 50 ± 17 nm.  As shown in Figure 7.8 and tabulated in 
Table 4.5., this is quite similar to previous nanogel syntheses.  
After confirming that size, swelling, and surface charge of the nanoscale 
hydrogels were unaffected by the change in crosslinker, studies were conducted to 




tripeptide. Previous experiments4  served to establish a linear relationship between 
observed count rate (counts per second) and particle concentration (mg mL
-1
) in dynamic 
light scattering experiments.  This relationship was used to conduct a semi-quantitative, 
real-time measurement of degradation of SSXL-crosslinked nanoscale hydrogels in 
reductive aqueous suspension.  The experiments were conducted using a Malvern 
ZetaSizer Nano ZS with the sample cell set to 37°C and measurements collected 
approximately every 3 minutes.  After a brief equilibration period, sample cuvettes were 
injected with PBS or aqueous glutathione to bring the final concentration to 1 mM or 10 
mM glutathione in PBS.   
The degradation profiles, as seen in Figure 7.9, offer insight on the apparent 
glutathione sensitivity and kinetics of polymer degradation. A reduction in observed 
count rate is taken as a reduction in particle concentration and is an indicator of 
glutathione-induced degradation.  Interestingly, the concentration of glutathione required 
to induce significant polymer degradation lies between the average minimum (1 mM) and 
maximum (11 mM) concentrations of intracellular glutathione.  This attribute is 
compelling because it gives SSXL-crosslinked nanoscale hydrogels the ability to remain 
intact in the extracellular milieu and degrade in the intracellular environment.  These data 
indicate the time-scale for degradation is fairly rapid, on the order of minutes.   
Upon exposure to 10 mM glutathione, nearly 50% of the PDESSB30 degradation 
exposed to 10 mM GSH occurs within 15 min.  Nearly all degradation is completed by 60 
minutes.  Similar results for count rate degradation were observed for dithiothreitol 
                                                 




(DTT), but are not shown here.  For comparison, the observed count rate for PDESSB30 
in PBS remained constant over the time-course of the experiment.   
These observations were confirmed using Nanosight (Amesbury, UK) 
nanoparticle tracking analysis.  At an identical glutathione:PDESSB30 to that employed 
in light scattering studies, exposure to 10 mM glutathione for 15 min at 37°C caused a 









 (data not shown).   
After 2 hours exposure to GSH, samples were inspected visually via TEM for 
evidence of degradation.  As seen in Figure 7.10, discrete particles were not detected at 
any region on the TEM grid, indicating near complete degradation of polymer networks.  
This application of light scattering to monitor PDESSB30 degradation kinetics 
worked well for this initial application, though other methods may provide 
complementary insight into the degradation kinetics and extent of disulfide degradation.  
Analysis of degradation fragments using gel permeation chromatography (GPC) was 
problematic due to the high polydispersity of the linear polymer chains and incomplete 
nanogel degradation at intermediate time points.  Colorimetric methods, such as Ellman’s 
assay [14], were not sufficiently sensitive to detect free sulfhydryl groups in degraded 
PDESSB30.  The theoretical maximum (assuming 100% conversion) for sulfhydryl 
groups at 1 mg mL
-1
 PDESSB30 in aqueous suspension is approximately 150 nM.  
Increasing the nanogel concentration beyond this concentration resulted in significant 




7.3.3. Fluorescent Nanogel Synthesis 
To enable visualization of nanogel subcellular localization in siRNA delivery 
experiments, a fluorescent version of the PDESSB30 nanogel was necessary.  A primary 
amine-containing analogue of PDESSB30, termed PDESSB30f, was successfully 
synthesized and purified using the methods outlined in Sections 6.2.1.   
Oregon Green 488 (OG488), an amine reactive dye, was conjugated to primary 
amines in the nanogel core.  Prior to the conjugation reaction, the primary amine content 
of PDESSB30f was determined to be 17.0 ± 0.4 µmol g
-1
, which represents a 11.5% 
incorporation efficiency.   OG488 was subsequently added to PDESSB30f at 1:1 mol 
ratio of dye to amine.   Following dialysis and lyophilization, the Oregon Green 488 
functionalization was tested with fluorescence spectroscopy and the percent 
functionalization calculated with UV absorbance and comparison to an Oregon Green 
488 standard curve.   
The fluorescence emission (λex = 465 nm) spectra of the labeled nanogel 
(PDESSB30-OG488) is shown in Figure 7.13.  The fluorescent labeling was estimated at 
16.9 ± 0.3 µmol g
-1
 using a standard curve of OG488 in PBS and at 19.5 µmol g
-1
 using 





, suggesting near 100% conjugation efficiency. 
7.3.4. siRNA Loading Efficiency of pH-responsive nanogels 
The ability of nanogels to encapsulate siRNA is an important determinant in their 
ability to deliver therapeutically relevant dosages of RNA to disease sites and initiate 
gene silencing.  PDETB30 clearly displays the most desirable attributes for an 




than PDET or PDETBA30.  Previous work [15] demonstrated that cationic polymer were 
able to bind DNA more efficiently with increasing cationic density.  Thus, the RNA 
binding capacity was evaluated in a high-throughput fashion analogous to that described 
by Siegwart et al. [16].  RNA binding was evaluated as a function of nanogel 
composition, RNA:nanogel mass ratio, and complexation time to determine the loading 
efficiency of each nanogel.   
The fraction of free RNA (Ff) was calculated by taking the ratio of fluorescent 
intensity of sample solutions to fluorescent intensity of a polymer-free control RNA 
solution.  Both measurements were corrected for background fluorescence and the 
fraction of bound RNA, Fb =  1 - Ff.  These data for a 60 min complexation period are in 
Figure 7.11.  These results indicate that all formulations can efficiently bind free siRNA 
until a 1:1 mass ratio of polymer and siRNA and this binding is relatively independent of 
polymer composition.  Nearly identical results were obtained for complexation periods of 
120 and 180 min.   
  One limitation of this experimental technique is that it cannot distinguish the 
difference between RNA bound through surface adsorption or electrostatic encapsulation.  
Of these two, the latter is the more desirable as encapsulation and entrapment will afford 
better protection of RNA cargoes.  As discussed previously, all polymer networks exhibit 
a positive surface charge at pH 5.50, so it is highly probable that anionic RNA can be 
adsorbed onto the particle surface through electrostatic interactions.  Thus, this initial 
experiment likely overestimates the true RNA loading capacity of the nanogels. 
To separate the effects of surface adsorption and electrostatic encapsulation, 




(PBS, pH 5.50) for 60 minutes and were subsequently transferred to 3× volume of serum 
free DMEM.  By immersing the polymer/siRNA complexes in a more basic solution, the 
effective surface charge can be reduced from approximately 30 mV to nearly neutral (0 ± 
5 mV).  This step change in surface charge serves to electrostatic interactions between 
nanogel surface and siRNA, permitting desorption of RNA from the surface.   
According to the light scattering data presented in Chapter 4, this pH will 
completely or partially (depending on nanogel composition) collapse the network 
structure, serving to entrap RNA in the network core and limit diffusion out of the 
network.  As seen in Figure 7.12 for a 10:1 mass ratio of polymer to siRNA, 
approximately 70% of the RNA is retained in the bound state following immersion in 
DMEM.  Sample loading efficiencies for each nanogel formulation are tabulated for 
100:1 and 1:1 nanogel:siRNA ratios (g/g) in Table 7.1.   
Qualitative evidence of nanogel/siRNA binding can be seen in Figure 7.14.  
Complexes of PDETB30-OG488 and DY647-siRNA (prepared as described in Section 
7.2.7.) were visualized using Image Stream cytometry.  As expected, the siRNA-loaded 
nanogels are too small to visualize with brightfield microscopy, but the fluorescent signal 
from PDETB30-OG488 and DY647-siRNA was visible.   As seen in the DY647 vs. 
OG488 intensity plot in Figure 7.14, nearly all PDETB30-OG488 nanogels contain 
DY647-siRNA.  Analogous observations were made for complexes of PDESSB30-





7.3.5. Nanogel-mediated delivery of siRNA 
7.3.5.1. Flow cytometry 
The ability of PDETB30, and its degradable analogue PDESSB30, to deliver 
fluorescent siRNA to Caco-2 cells was evaluated using flow cytometry.  Figure 7.15 
shows the influence of exposure time on uptake of Cy3-siRNA.  As expected, the naked 
siRNA is not able to efficiently enter Caco-2 cells.   However, by complexation with 
PDETB30 or PDESSB30, the median fluorescence is increased by a factor of 5× after 5 
min of exposure.  Notably, siRNA delivery via PDETB30 and PDESSB30 result in a 
rapid increase in siRNA fluorescence from 0 – 5 min, followed by an approximately 
linear increase in median fluorescence from 5 min – 60 min.   
As discussed in Chapter 6, the mechanism of internalization in Caco-2 cells is 
primarily macropinocytosis.  This is an energy dependent internalization pathway and 
uptake of nanogel/Cy-3siRNA complexes is predictably inhibited by uptake at 4°C 
(Figure 7.16).  Moreover, these data corroborate the observations of Chapter 6 (Figure 
6.4 and Figure 6.6), whereby PDETB30 can be internalized through an energy-
independent pathway.  Following 60 min uptake at 4°C, cells exposed to PDETB30/Cy3-
siRNA and PDESSB30/Cy3-siRNA exhibit greater median fluorescence than cells 
exposed to Cy3-siRNA alone.   
These data suggest that PDETB30 and PDESSB30 are capable of delivery siRNA 
to Caco-2 cells.  This work served as the basis for further study of the intracellular 
distribution of fluorescent nanogel/siRNA complexes and evaluation of the gene 




7.3.5.2. Image Stream Cytometry 
As described in Chapter 6, Image Stream cytometry was used to simultaneously 
acquire statistical flow cytometry data and high-resolution fluorescent micrographs.  
Additionally, the imagine analysis capabilities of Image Stream cytometry permit the 
sorting and gating of events with particular image features, such as cellular 
internalization (vs. surface adsorption) or probe colocalizaition.   
As shown in Figure 7.17A, PDETB30-OG488 is an efficient delivery vehicle for 
DY647-siRNA in RAW macrophages.  Both PDETB30-OG488 and PDESSB30-OG4885 
enhance the cytoplasmic fluorescence of DY647-siRNA relative to the siRNA only (blue 
histogram) and untreated control (gray histogram) cells.  Figure 7.17B shows the OG488 
fluorescent intensity histogram in untreated (gray), PDETB30-OG488 (green), and 
PDETB30-OG488/DY647-siRNA (red) treated samples.  Notably, the fluorescent signal 
in the cells treated with nanogels only is greater than that of cells treated with 
nanogels/siRNA.  This suggests that the internalization of nanogel/siRNA complexes is 
less efficient than nanogels alone.    
Figure 7.18 shows representative fluorescent micrographs of RAW 264.7 cells.  
Cell nuclei are shown in blue (Hoechst), PDETB30-OG488 in green, and siRNA in red 
(DY647).  Areas of nanogel/siRNA colocalizaition appear yellow on the fluorescent 
overlay. 
Panels A - C show representative images of cells exposed only to 100 nM 
DY647-siRNA for 60 min, panels  D - F show representative images of cells exposed 
only to 25 µg mL
-1
 PDETB30-OG488 for 60 min,  and panels G – I show representative 
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images of cells exposed 25 µg mL
-1
 PDETB30-OG488 and 100 nM DY647-siRNA for 
60 minutes.  As expected due to its high MW (~13 kDa) and negative charge, little to no 
internalization was observed by the naked siRNA.  In panels G – I (PDETB30-
OG488/DY647-siRNA), the siRNA staining pattern appears mostly diffuse and 
distributed near the cell membrane.  Several bright, colocalized spots appear in panels H 
and I, suggesting some vesicular entrapment of polymer/siRNA complexes.  Vesicular 
entrapment, and/or lysosomal accumulation, is expected in a portion of the 
nanogel/siRNA complexes due to the heterogeneous internalization pathways presented 
by RAW 264.7 cells.   
Similar observations were made for Caco-2 cells exposed to PDETB30/DY647-
siRNA or DY647-siRNA under identical conditions.  The fluorescent intensity 
histograms for DY64 and OG488 are shown in Figure 7.19A and Figure 7.19B, 
respectively.  Comparing the median fluorescent values from Figure 7.17 (RAW 264.7 
cells) and Figure 7.19 (Caco-2 cells) suggests a comparable level of nanogel and siRNA 
internalization in to these two cell types.  The notable exception to this observation is the 
decreased PDETB30-OG488 intensity in RAW cells exposed to PDETB30-
OG488/DY647-siRNA.  This effect is not present in Caco-2 cells, which rely primarily 
on macropinocytosis to internalize PDETB30-OG488.  As shown in Figure 6.6, RAW 
264.7 cells uptake PDETB30-OG488 through a combination of clathrin-mediated 
endocytosis and macropinocytosis.  This suggests that the clathrin-dependent uptake of 






7.3.6. siRNA-Mediated Gene Silencing 
Delivery efficacy of functional siRNA to model cells lines is an important 
parameter in the assessment of polymeric delivery systems.  In these studies, GAPDH 
was chosen as the target gene for siRNA knockdown.  GAPDH is a well-known 
housekeeping gene, ubiquitously expressed in nearly all cell types, and is involved in the 
reduction of NAD
+
 to NADH in the glycolysis pathway.  Knockdown was assessed using 
a KDAlert™ GAPDH Assay Kit and monitoring the increase in fluorescence 
(em:520/ex:590) over a 4 minute period.  This gene target was originally selected to 
facilitate a broad comparison of gene knockdown and transfection conditions for the cell 
types (Caco-2 and RAW 264.7) chosen for these studies.   
GAPDH knockdown, shown in Figure 7.20, reveal that GAPDH siRNA delivered 
via PDETB30 induces a robust gene silencing effect, reducing GAPDH expression by 60 
– 85%.  This knockdown effect occurred at multiple polymer:siRNA ratios ranging from 
8:1 – 1000:1.     
Figure 7.21 compares the siRNA-mediated gene silencing in Caco-2 cells treated 
with PDETB30/siRNA or PDESSB30/siRNA at a 200:1 nanogel:siRNA ratio.  Both 
nanogel formulations are capable of delivering functional siRNA.  Knockdown efficiency 
was 53% for cells treated with PDESSB30/siRNA and 83% for cells treated with 
PDETB30/siRNA.  Based on flow cytometry data in Figure 7.15, Caco-2 cells treated 
with PDETB30/siRNA exhibited characteristically higher siRNA fluorescence than did 
cells treated with PDESSB30/siRNA.  Therefore, the superior knockdown efficiency of 
PDETB30/siRNA relative to PDESSB30/siRNA is likely due to increased siRNA 




While GAPDH siRNA and KD Alert assays were suitable for initial studies of 
gene silencing in Caco-2 cells, this assay did not transfer well to RAW 264.7 
macrophages.  The linear range for detecting GAPDH enzyme activity can typically 
accommodate approximately 2,000 – 10,000 cells/well.  In Caco-2 cells (doubling time ~ 
60 h), the cell density at the time of assay (~48 h after transfection) is expected to be 1 - 
2× the seeding density.  In contrast, RAW 264.7 cells grow much more rapidly, with a 
doubling time ~15 h.  Therefore, RAW 264.7 cells will undergo 3 – 4 doubling cycles 
between transfection and assay.  Thus, RAW 264.7 cells were typically seeded at a low 
density (1,000 cells/well in 96-well plates) for these studies.  Any variations in the cell 
seeding density were then amplified by successive rounds of RAW division.  This 
becomes problematic because the KD Alert relies on comparison of experimental wells to 
external control wells.  In practice, high variability in the RAW cell density at assay time 
limited the utility of the KD Alert assay kit in evaluating any PDETB30/siRNA-mediated 
gene silencing in RAW cells.  Analysis methods that provide an internal control, such as 
qPCR, are better suited for evaluation of gene silencing. 
7.4. CONCLUSIONS 
A disulfide crosslinker was synthesized to allow degradation of pH-responsive 
nanogels in reductive environments.  This crosslinker was incorporated into responsive 
nanogels, termed PDESSB30, with little to no changes on physicochemical properties 
including critical swelling pH, nanogel size, or in vitro biocompatibility.  These nanogels 
degrade within minutes upon exposure to physiological levels of glutathione as 
determined by light scattering and electron microscopy.  Analysis of cellular 




(PDESSB30) and non-degradable (PDETB30) nanogels.  Moreover, both PDESSB30 and 
PDETB30 are capable of delivering functional siRNA to Caco-2 cells, achieving gene 
silencing of 47% and 83%, respectively.  The combination of attractive physicochemical 
properties and siRNA delivery efficiency make PDETB30 and PDESSB30 attractive 








Figure 7.1–Degradable nanogel in response to glutathione.  Disulfide crosslinks are 








































Figure 7.3 - 
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Figure 7.4 - Mass spectrum of purified bis(2-methacryloyloxyethyl) disulfide.  Anticipated molecular weight of the bis(2-









Figure 7.5 - pH-responsive behavior of nanogels in suspended in PBS. PDET (□),  













































Figure 7.6 - Effective surface ζ-potential of various polymer formulations PDET (●),  
PDETB30 (▼), and PDESSB30 (□).  Data points represent the mean of 3 




























Figure 7.7. - Relative proliferation of RAW 264.7 cells upon exposure to PDESSB30 (●) 
or PDETB30 (○) for 360 min. The relative proliferation of RAW cells was 
determined by MTS assay and is expressed as a fraction of the control 







Figure 7.8  - Representative transmission electron microscopy images of PDET,  
PDETBA30 (B), PDETB30 (C), and PDESSB30 (D).  Particles stained with 
uranyl acetate and images collected at 43,000×.  Scale bar represents 200 





Figure 7.9 - Light scattering analysis of glutathione-induced degradation.  Nanogels 
dissolved in PBS and exposed to 1 mM (gray) and 10 mM (black) 
















Figure 7.10 - Representative transmission electron microscopy images of PDESSB30 
incubated for 2 hours in (A) DI water and (B) 10 mM glutathione solution 
(left).   Particles stained with uranyl acetate and images collected at 26,500× 







Figure 7.11. - RNA Loading capacity of poly(DEAEMA-g-PEGMA) (PDET), and 
poly(DEAEMA-co-BMA-g-PEGMA) (PDETB10), (PDETB20), and 














































Figure 7.12 - RNA loading of poly(DEAEMA-g-PEGMA) (PDET), and poly(DEAEMA-
co-BMA-g-PEGMA) (PDETB10), (PDETB20), and (PDETB30) in PBS, 
pH 5.50 (gray) and in serum-free DMEM, pH 7.40 (white).  Polymer and 
siRNA were combined at a ratio of 10:1 [polymer]:[siRNA].  Fraction of 
bound RNA determined by Ribogreen assay following 180 min incubation 

















































































Table 7.1 –Loading efficiencies for nanogels and siRNA.  Fraction of bound RNA 
determined by Ribogreen assay following 60 min complexation with 
nanogels.  Data represent mean of triplicate samples ± s.d.  
  Loading Efficiency 
Nanogel 
Nanogel:siRNA 
(g/g) pH 5.50 pH 7.40 
PDET 100 0.99 ± 0.003 0.72 ± 0.02 
PDETB10 100 0.98 ± 0.002 0.71 ± 0.01 
PDETB20 100 0.97 ± .0003 0.63 ± 0.01 
PDETB30 100 0.97 ± 0.001 0.67 ± 0.05 
PDET 1 0.97 ± 0.001 0.58 ± 0.06 
PDETB10 1 0.94 ± 0.001 0.51 ± 0.09 
PDETB20 1 0.96 ± 0.002 0.50 ± 0.12 








Figure 7.15 – siRNA delivery to Caco-2 cells as a function of incubation time.  
Nanogel/Cy3-siRNA complexes were prepared at a 20:1 nanogel/siRNA 
ratio (g/g) and incubated with cells for designated time points.  Data points 
represent the median fluorescence of live cells as determined by flow 





Figure 7.16 – siRNA delivery to Caco-2 cells as a function of nanogel composition and 
incubation temperature.  Nanogel/Cy3-siRNA complexes were prepared at a 
20:1 nanogel/siRNA ratio (g/g) and incubated with Caco-2 cells for 60 min.  
Data points represent the median fluorescence of live cells as determined by 





Figure 7.17 - Fluorescence intensity of RAW 264.7 cells in siRNA delivery experiments.  
Fluorescence intensity histograms of DY647-siRNA (A) and PDETB30-
OG488 (B).  Fluorescence histograms generated from live, focused, single 
cells exposed to PBS (untreated, gray), DY647-siRNA alone (blue), 
PDETB30-OG488 alone (green), or PDETB30-OG488/DY647-siRNA 





Figure 7.18 - DY647-siRNA delivery to RAW 264.7 cells.  Nuclear stain (Hoechst 
33342) shown in blue, PDETB30-OG488 (Oregon Green 488) shown in 
green, and DY647-siRNA (DyLight 647) shown in red.  Three 
representative examples of RAW 264.7 cells exposed to DY647-siRNA 
alone (A-C), PDETB30-OG488 along (D – F), or PDETB30-
OG488/DY647-siRNA (G – I) are shown.  Images sampled from median 






Figure 7.19 - Fluorescence intensity of Caco-2 cells in siRNA delivery experiments.  
Fluorescence intensity histograms of DY647-siRNA (A) and PDETB30-
OG488 (B).  Fluorescence histograms generated from live, focused, single 
cells exposed to PBS (untreated, gray), DY647-siRNA alone (blue), 
PDETB30-OG488 alone (green), or PDETB30-OG488/DY647-siRNA 





Figure 7.20 - DY647-siRNA delivery to RAW 264.7 cells.  Nuclear stain (Hoechst 
33342, blue), PDETB30-OG488 (Oregon Green 488, green), and DY647-
siRNA (DyLight 647, red) are shown.  Three representative examples of 
RAW 264.7 cells exposed to DY647-siRNA alone (A-C), PDETB30-
OG488 alone (D – F), or PDETB30-OG488/DY647-siRNA (G – I) are 
shown.  Images sampled from median region of DY647 histogram.  Scale 






Figure 7.21 – GAPDH knockdown in Caco-2 cells following exposure to 
PDETB30/siRNA. Cells exposed to siRNA-loaded nanogels at designated 
concentrations of PDETB30 and 250 ng mL
-1
 (~20 nM, gray) or  1250 ng 
mL
-1
 (~100 nM, black) GAPDH siRNA.  Expression levels measured 48 hrs 
after transfection.   Bars represent the mean of % remaining expression 




















































Figure 7.22 – GAPDH knockdown in Caco-2 cells following exposure to 
PDETB30/siRNA or PDESSB30/siRNA. Cells exposed to siRNA-loaded 
nanogels at 200:1 nanogel:siRNA ratio (g/g, 50 µg mL
-1
 nanogel and 0.25 
µg ml
-1
 siRNA).  Expression levels measured 48 hrs after transfection.   
Bars represent the mean of % remaining expression GAPDH expression  ± 
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Chapter 8:  Nanogels with bio-inspired pseudo-peptides to impart 
network hydrophobicity and enable intracellular delivery of small 
interfering RNA 
8.1. INTRODUCTION 
Synthetic polymers with reduced charge density, high molecular weight, and 
hydrophobic comonomers have received recent attention as high-efficiency, low-toxicity 
drug delivery vehicles [1].  Zhou et al. [2], recently described a series of lactone-based 
terpolymers of varying hydrophobicity and cationic charge density. Other previous 
reports [3-5] have explored the incorporation of hydrophobic amino acid grafts to pH-
responsive linear polymers and their utility in therapeutic protein delivery [6].  These 
studies found that phenylalanine grafts were particularly effective at enhancing the 
membrane-disruptive capabilities of the polymer while remaining relatively 
biocompatible.   
To investigate whether a phenylalanine moiety can impart similar hydrophobicity 
to P(DEAEMA-g-PEGMA) nanoscale hydrogels while enhancing relative 
biocompatibility, a methacrylamide-derivatized phenylalanine was synthesized.  This 
functional monomer, N-methacryloyl L-phenylalanine methyl ester (MAPA), has been 
used previously in to increase the hydrophobicity of poly(hydroxyethyl methacrylate) 
P(HEMA) microparticles in hydrophobic interaction chromatography applications [7].  In 
a related study, Türkmen, et al. [8] synthesized circa 150 nm P(HEMA-co-MAPA) 
nanospheres and explored their utility in adsorption of the model antibody 




This chapter investigates the use of MAPA as a hydrophobic comonomer in pH-
responsive nanoscale hydrogels for intracellular delivery of siRNA.  The aqueous 
solution properties, membrane-disruptive properties, cytocompatibility, and siRNA 
delivery efficiency are evaluated.  Where relevant, the in vitro and physicochemical 
properties are compared to the unmodified P(DEAEMA-g-PEGMA), PDET, or the best-
performing P(DEAEMA-co-TBMA-g-PEGMA) analogue, PDETB30.   
8.2. MATERIALS AND METHODS 
8.2.1. Materials 
L-phenylalanine methyl ester hydrochloride, anhydrous triethylamine, 
methacryloyl chloride, hexanes, 2-(diethylamino) ethyl methacrylate (DEAEMA), 
Tetra(ethylene glycol) dimethacrylate (TEGDMA), Poly(ethylene glycol) methyl ether 
methacrylate (PEGMA), Mn ~ 2080 – 50 wt% solution in H2O,  myristyltrimethyl 
ammonium bromide (MyTAB) and diethylpyrocarbonate (DEPC) were purchased from 
Sigma-Aldrich (St. Louis, MO).  Irgacure 2959 was donated by Ceiba Geigy (Tarrytown, 
NY). 
Sodium hydroxide solution (NaOH, 1N), hydrochloric acid solution (HCl, 1N), 
methylene chloride, basic alumina – 300 mesh, sodium chloride (NaCl), disodium 
phosphate heptahydrate (Na2HPO4 • 7H2O) sodium phosphate monohydrate 
(NaH2PO4 • H2O), sodium azide (N3Na), and Thermo Scientific HyClone USDA Tested 
Fetal Bovine Serum (FBS) were purchased from Fisher Chemical (South Plainfield, NJ).  




Dulbecco’s Modified Eagles Medium (DMEM) with 4500 mg L
-1
 glucose and 
sodium bicarbonate, without L-glutamine and sodium pyruvate, were obtained from 
Sigma-Aldrich (St. Louis, MO). Phosphate buffered saline (PBS) without calcium and 
magnesium and 200 mM L-glutamine solution were purchased from MediaTech 
(Manassas, VA). CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay 
(MTS) was purchased from Promega (Madison, WI).  Cell scrapers for RAW264.7 cells 
were purchased from BD Falcon (Franklin Lakes, NJ).  Propidium Iodide (PI), 1 mg mL
-1
 
solution in water and  RNAse Free water were purchased from Life Technologies (Grand 
Island, NY). 
Unless otherwise specified, the water used in these experiments was purified by a 
Millipore Milli-Q Plus to a volume resistivity of 18.2 MΩ•cm. 
8.2.2. MAPA synthesis and purification 
The synthesis scheme was adapted from previous reports [9, 10] and the reaction 
was conducted as follows:  The reactive free base of L-phenylalanine methyl ester 
hydrochloride was extracted by dissolving the solid L-phenylalanine methyl ester 
hydrochloride in 1 N NaOH and extracting with methylene chloride.  The resulting 
solution was chilled to 0°C and 2 molar equivalents anhydrous triethylamine were added.  
Methacryloyl chloride was added dropwise to the mixing solution under nitrogen.  The 
purge continued with stirring for 4 hours, after which the reaction mixture was sealed and 
allowed to react overnight at room temperature.  The reaction mixture was purified by 
successive equivolume washes of 1 N HCl, saturated NaHCO3, and saturated NaCl.  The 




Automated Flash Chromatography Instrument (Teledyne-Isco, Lincoln, NE) equipped 
with a 100 g silica column.  Column was equilibrated with 500 ml hexanes, purification 
run length was set to 50 min with a solvent flow rate of 35 ml min-1.  The solvent 
gradient was established as follows:  Solvent A – hexanes, Solvent B - ethyl acetate.  The 
gradient was adjusted from 0 – 40% B over 25 minutes and held for 10 minutes, then 
40% - 100% B over 10 minutes.  Fractions of interest were determined by monitoring 
absorbance at 258 nm.  The fractions were pooled and concentrated by rotary evaporation 
to yield a viscous, clear liquid.  Subsequent drying in a vacuum oven produced a 
crystalline, white powder of N-methacryloyl L-phenylalanine methyl ester (MAPA).  The 
chemical structure and molecular weight were verified using 
1
H-NMR and Mass 
Spectrometry, respectively. 
8.2.3. Polymer synthesis 
Hydrogel particles of nanoscale dimensions were synthesized via UV-initiated 
free radical photoemulsion polymerization/crosslinking according to previous reports 
from our laboratory [11-13].  Briefly, DEAEMA and TEGDMA were passed through a 
column of basic alumina powder to remove inhibitor prior to use.  MAPA was 
synthesized as described.  Poly(ethylene glycol) methyl ether methacrylate (PEGMA), 
Mn ~ 2080 was used as received.  DEAMA, TEGDMA, and MAPA were added to an 
aqueous solution containing 5 wt% PEGMA, Irgacure 2959 at 0.5 wt% of total monomer, 
4 mg mL
-1
 Brij-30 and ionic surfactant MyTAB.  The mixture was emulsified using a 
Misonix Ultrasonicator (Misonix, Inc., Newtown, CT).  The emulsion was purged with 




8.2.4. Polymer purification 
During the initial stages of purification, we attempted the previously described 
polyelectrolyte-ionomer purification method [11, 13].  However, the initial polymer-
ionomer collapse and centrifugation of the reaction mixture resulted in a highly turbid, 
acetone-rich supernatant.  After decanting the supernatant, the amount of remaining 
flocculated ionomer was uncharacteristically low and did not resuspend well in 0.5 N 
HCl.  Thus, further purification efforts focused on the turbid supernatants from 
purification cycles 1 and 2.  These fractions were pooled and cooled to -80°C in 50 ml 
centrifuge tubes.  Following 24 h at -80°C, the supernatant stratified into a clear acetone-
rich phase and semi-solid, turbid aqueous phase.  The organic phase was carefully 
decanted and the remaining aqueous layer was again frozen at -80°C for 24 h.   Following 
additional decanting of the organic phase, the aqueous layer was transferred to 12 – 14 
kDa MWCO Regenerated Cellulose Dialysis tubing (Spectrum Labs, Rancho 
Dominguez, CA).  Polymer particles were dialyzed against ultrapure water for 7 days 
with the water changed twice daily.  Following dialysis, polymers were flash frozen in 
liquid N2 and lyophilized for 5 days.   
8.2.5. 1H-NMR spectroscopy 
The composition of crosslinked PDETM30 was investigated using a Varian (Palo 
Alto, CA) DirectDrive 400 MHz nuclear magnetic resonance spectrometer equipped with 
automatic sampler.  Deuterium oxide (D2O, 99.9%) was obtained from Cambridge 
Isotope Laboratories (Andover, MA).  Deuterium chloride (DCl, 100.0%) was obtained 




Glass, Vineland, NJ), 2 mL sample vials, and Pasteur pipettes were dried overnight in a 
vacuum oven.  Polymer samples of approximately 40 mg were weighed directly in 
sample vials and D2O was added to bring the final polymer concentration to 20 mg mL
-1
.  
Samples were briefly sonicated in a sonic bath and transferred to NMR tubes for 
subsequent analysis.  All NMR Spectra were analyzed using SpinWorks 3
TM
 software. 
8.2.6. Dynamic light scattering analysis 
Measurements of the z-average particle size were collected at 25°C using a 
Malvern Zetasizer NanoZS (Malvern Instruments Corp., Malvern, UK) operating with a 
633 nm laser source equipped with MPT-2 Autotitrator.  DLS measurements of particle 
size and pH-responsive behavior were conducted by resuspending lyophilized particles in 
PBS at 0.5 mg mL
-1
.  The suspension pH was adjusted to 10.5 using 1 N NaOH and 
gradually lowered to pH 3.5 using 1 N HCl.  Measurements of the z-average particle size 
were collected at 25°C and pH intervals of 0.5.  
8.2.7. Transmission electron microscopy 
Transmission electron micrographs were collected using a FEI Tecnai (Hillsboro, 
OR) Transmission Electron Microscope (80 kV) at magnifications from 16,500× to 
160,000×.  Lyophilized particles were diluted in ddH2O and stained with 2% uranyl 
acetate immediately prior to imaging.  Typically, 5 µL of 0.02 w/v% of particle 
suspension was dropped onto a 400-mesh Formvar-coated copper TEM grid (Electron 
Microscopy Sciences, Hatfield, PA) and excess liquid wicked off using filter paper.  An 




stain for 60 seconds before excess liquid was wicked away with filter paper.  Particle 
volume in the dry state was taken as the cube of mean diameter from TEM images.  
Particle diameters were calculated from the particle area as determined by an ImageJ 
particle sizing algorithm.  Reported values represent the mean ± standard deviation (n > 
50).  
8.2.8. Electrophoretic light scattering 
Measurements of the effective surface charge were collected 25°C using a 
Malvern Zetasizer NanoZS (Malvern Instruments Corp., Malvern, UK) operating with a 
633 nm laser source equipped with MPT-2 Autotitrator.  Measurements of ζ-potential as 
a function of pH were conducted by resuspending lyophilized particles in 5 mM 
phosphate buffer at 0.5 mg mL
-1
.  The suspension pH was adjusted to 10.5 using 1 N 
NaOH and gradually lowered to pH 3.5 using 1 N HCl. Electrophoretic light scattering 
measurements of the surface ζ-potential were collected at 25°C with nanogels suspended 
in 5 mM sodium phosphate.  
8.2.9. Hemolysis assays 
Sheep blood in sodium citrate was obtained from Hemostat Laboratories (Dixon , 
CA) and used for up to two weeks after receipt.  Phosphate buffers (0.15 M) from pH 5.0 
– 8.0 were prepared by dissolving predetermined amounts of monosodium phosphate and 
disodium phosphate in ultrapure DI water.  The buffer pH was adjusted as needed using 1 
N HCl or 1 N NaOH.  Dry nanoscale hydrogels were suspended in 150 mM phosphate 
buffer at the desired pH at a concentration of 2.5 mg ml
-1




overnight.  Erythrocytes were isolated from whole sheep blood by 3 successive washes 
with freshly prepared 150 mM NaCl.  Red blood cells (RBCs) were separated by 
centrifugation from 10 minutes at 2,000×g.  The supernatant and remaining buffy coat 
were carefully aspirated and discarded.  After removing the supernatant following the 
final wash, RBCs were suspended in a volume of 150 mM phosphate buffer identical to 
that of the original blood aliquot at the pH matching that of the suspended polymers.  
This solution was diluted 10-fold in 150 mM phosphate buffer to yield an RBC 
suspension of approximately 5×10
8
 cells/mL.  In a typical experiment, 1×10
8
 RBCs were 
exposed to polymer concentrations from 1 µg mL
-1
 – 2 mg mL
-1
 while shaking in a bead 
bath (LabArmor, Cornelius, OR) pre-equilibrated at 37°C.   Following a 60 min 
incubation period, samples were centrifuged at 14,500 RPM for 5 min to separate cells 
and membrane fragments.  An aliquot of each sample was transferred to a clear 96-well 
plate and hemoglobin absorbance was measured at 541 nm.  Negative controls (0% lysis) 
consisted of 150 mM phosphate buffer at experimental pH and positive controls (100% 
lysis) consisted of RBCs incubated in ultrapure DI water. 
8.2.10. Cell Culture 
Human colorectal adenocarcinoma cells (Caco-2) and murine macrophages 
(RAW 264.7) were maintained in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 100 U mL
-1
 penicillin, 100 μg mL
-1
 streptomycin,  and 10% fetal 
bovine serum (FBS) (Complete DMEM).  Caco-2 cells were used between passage 34 
and 62.  RAW 264.7 cells were used between passage 9 and 17.  Caco-2 cells were 




subsequent incubation with 0.25% Trypsin-EDTA at 37°C.  Trypsin was neutralized by 
addition of fresh, prewarmed DMEM and cells were separated by centrifugation.  The 
resulting pellet was suspended in 10 mL DMEM and cell count was determined using a 
Scepter Automated Cell Counter (Millipore, Billerica, MA) with 60 µm tips.  The cell 
suspension was diluted as necessary and added to tissue-culture treated flasks or multi-
well plates.  Caco-2 cells were typically passaged at 1:5 ratio with media replenished 
every 2-3 days.  RAW 264.7 cells were passaged by washing with prewarmed DPBS and 
replacing the original culture volume with fresh DMEM.  Cells were removed from the 
flask surface by gentle scraping with a 25 cm cell scraper.  The number of suspended 
cells was counted using a Scepter Automated Cell Counter and diluted as necessary for 
addition to tissue culture flasks or multi-well plates.  RAW 264.7 cells were typically 
passaged every 2 days.    
8.2.11. Cytocompatibility Studies 
In vitro cytocompatibility was determined for polycationic nanoscale hydrogel 
networks using commercially available cytotoxicity assays.  MTS assays were performed 
using the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit in which the 
soluble tetrazolium salt [3-[4,5-dimethylthiazol-2-yl]-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] (MTS) is reduced to a purple formazan product.  The 
absorbance of the formazan product is proportional to the number of viable cells.  Stock 
solutions of polymer were suspended in PBS and allowed to equilibrate overnight.  Caco-
2 cells were seeded in 96-well plates at 10,000 cells/well and incubated for 36 hours prior 




and incubated for 36 hours prior to assay in 200 μL DMEM.  Media was aspirated and 
cells were washed 1× with DPBS and incubated in 160 µL serum-free DMEM for 30 
minutes.  Following this incubation period, polymer stock solutions at 5× were added to 
cells for designated exposure times.   
Following the exposure period (90 min or 360 min), media and polymer were 
aspirated and replaced with a DMEM/MTS solution.  Absorbance at 490 nm was 
recorded after 4 hours or 90 min incubation in the DMEM/MTS solution for Caco-2 and 
RAW, respectively.   
8.2.12. siRNA Complexation 
RNA complexation buffer was prepared by dissolving 3.15 g sodium phosphate 
dibasic heptahydrate, 0.02 g potassium phosphate monobasic monohydrate, 0.20 g 
potassium chloride , and 8.01 g sodium chloride  in Milli-Q purified water.  Following 
salt dissolution, the solution pH was adjusted to pH 5.50 using 1 N HCl and ultrapure 
water was added to bring the final solution volume to 100 mL.  To remove nucleases, 
diethylpyrocarbonate (DEPC) was added at 0.1% and incubated at room temperature 
overnight.  The buffer solution was then autoclaved to remove DEPC.  Polymer-siRNA 
complexes were formed by combining aqueous solutions of PDETM30, siRNA, 10x 
RNAse-free PBS, and RNAse-free water to obtain desired concentrations.  Typically, 
complexation was allowed to commence for 60 min and polymer-siRNA were complexed 




8.2.13. siRNA Internalization 
DyLight 647-labeled small interfering RNA (Sense: DY647-
UAAGGCUAUGAAGAGAUACUU) was purchased from Thermo Scientific (Lafayette, 
CO). (P(DEAEMA-co-MAPA-g-PEGMA) (PDETM30) was synthesized and purified as 
described in Section 8.2.4. Flow cytometry buffer was prepared by combining FBS, 
DPBS, and N3Na to form 1% FBS and 0.1% N3Na in DPBS. 
Concentrated suspensions (20×) of PDETM30, PDETM30/DY647-siRNA, or 
DY647-siRNAwere prepared to contain 0.5 mg mL
-1
 PDETM30, 26.5 µg mL
-1
 (~2000 
nM) DY647-siRNA, 1× complexation buffer, and RNAse free H2O.  Control samples 
(PDETM30 only, DY647-siRNA only) were prepared in a similar fashion, replacing the 
volume of the absent component(s) with RNAse free H2O. 
RAW 264.7 cells or Caco-2 cells were seeded at 1× 10
5
 cells/well and allowed to 
grow to 80% confluence before exposure.  Immediately prior to exposure to 
PDETM30/DY647-siRNA, cells were washed 1× with 2 mL DPBS and media was 
replaced with 1.9 mL serum-free DMEM.  Concentrated suspensions of PDETM30, 
PDETM30/DY647-siRNA, or DY647-siRNA were added to wells in 100 µL increments 
and allowed to incubate with cells for 60 min in a 37°C, 5% CO2 atmosphere.  Following 
this incubation period, cells were rinsed 3× DPBS (with calcium and magnesium) and the 
media was replaced with 2 mL serum-free DMEM.  Hoechst 33342 was added to each 
well for nuclear staining at a final concentration of 2.5 µg ml
-1
.  The nuclear staining 




37°C, 5% CO2.  Following Hoechst incubation, cells were rinsed 3× with DPBS (w/out 
calcium and magnesium).   
RAW 264.7 cells were isolated by replacing the final DPBS wash with 1 mL flow 
cytometry buffer and gently scraping the cells.  Cell suspensions from each well were 
transferred to microfuge tubes and centrifuged for 5 min at 500×g.  The supernatant was 
discarded and cell pellet re-suspended in 100 µL flow cytometry buffer. 
Caco-2 cells were isolated by replacing the final DPBS wash with 500 µL 0.25% 
trypsin-EDTA and incubating at 37°C, 5% CO2 for 8 min.  Trypsin was neutralized by 
adding 3 mL DMEM with 10% FBS and without phenol red.  Cell suspensions were 
centrifuged for 5 min at 500×g.  The supernatant was discarded and cell pellet re-
suspended in 100 µL flow cytometry buffer.  All cell suspensions were kept on ice until 
use. Propidium iodide (PI) was used as a live/dead discriminator and was added to cell 
suspensions immediately before analysis at a final concentration of 1 µg mL
-1
. 
Analysis of cellular internalization was conducted using an Amnis ImageStream 
(Seattle, WA) imaging flow cytometer equipped with lasers at 405 nm, 488 nm, 658 nm, 
and 785 nm.  Fluorescent data were collected using Channel 1 (430 – 505 nm, Hoechst), 
Channel 4 (595 – 660 nm, PI), Channel 5 (660 – 745 nm, DY647), and Channel 6 (745 – 
800 nm, side scatter).  Cells were imaged with a 60× objective.  Fluid velocity was set to 
a nominal value of 40 mm/sec.  Fluorescent compensation matrices were constructed 
using Amnis IDEAS® software and verified manually for proper fit.  At least 5,000 cells 
were collected for analysis.  Dead cells (PI positive) were excluded from analysis.  Out-
of-focus cells were also excluded from further analysis by gating the Gradient RMS 




changes in pixel values across the brightfield image.    Typically, cells with Gradient 
RMS value <40 were considered out of focus. 
8.3. RESULTS AND DISCUSSION 
8.3.1. MAPA synthesis and purification 
The acrylation of L-phenylalanine methyl ester (L-PhME) was performed 
according the to the reaction scheme in Figure 8.1.  The methyl ester analogue of L-
phenylalanine was chosen to avoid side reactions with unprotected carboxylate group of 
L-phenylalanine.  Initially, the hydrochloride salt of L-PhME was added to cold (4°C) 
dichloromethane (DCM).  However, after a short period of stirring, the entire mixture 
turned to a cloudy solid, likely due to chemical incompatibility between the DCM solvent 
and the salt form of L-PhME.  To isolate the free base of L-PhME, approximately 200 
mL of 1N NaOH was added to the solid organic mixture and agitated briefly.  The entire 
mixture was transferred to a separatory funnel and inverted several times.  After settling, 
the DCM phase was collected and saved (Extract fraction 1).  The remaining basic 
aqueous fraction was washed twice more with approximately 65 mL of DCM (Extract 
fractions 2 and 3).  A final organic wash with 65 mL DCM was accompanied by the 
addition of 9 g of NaCl to the basic aqueous phase (Extract fraction 4).  Subsequent 
1
H-
NMR and thin layer chromatography (TLC) analysis revealed the vast majority of L-
PhME partitioned into the organic phase during the first DCM wash (Extract fraction 1).  





H-NMR.  Therefore, Extract fraction 1 was concentrated via rotary evaporation and used 
as described in Section 8.2.2. and Figure 8.1. 
Following preliminary purification (described in Section 8.2.2 and concentration 
via partial rotary evaporation, the reaction product mixture consisted of a viscous liquid. 
Exhaustive rotary evaporation led to a crystallization of white solid on the flask walls.  
Thus, sufficient DCM was left in the flask to maintain the reaction product in solution.  
Column chromatography proceeded in 3 successive runs with approximately 1 mL of 
viscous reaction product added to the column per run.  A sample chromatogram from the 
flash chromatography is shown in Figure 8.2. 
The 
1
H-NMR spectrum of the purified MAPA product is shown in Figure 8.3 and 
peak assignments and relative areas in Table 8.1.  The peak areas match the expected 
proton ratios and the spectrum corresponds well with published reports [9, 10].  The high-
resolution mass spectrum (Figure 8.4) also confirms successful synthesis and isolation of 
the intended product.  The mass spectrum shows the presence of one peak at 248 Da, 
corresponding to the MZ+ fragment.  The expected molecular weight of MAPA is 247 
Da.  The MAPA monomer exhibits long-term stability when stored dry at 4°C.  
Additional mass spectroscopy studies revealed no loss of structural fidelity following 18 
months of storage under these conditions (data not shown). 
8.3.2. Polymer synthesis and purification 
The nanogel purification process employed in this study is distinctly different 
than our previous reports.  In contrast to all other previous formulations, the 




following the acetone-induced polyelectrolyte-polymer transition6 (described in Chapter 
4).  Rather, the supernatant from purification cycle 1 was a milky, slightly translucent 
solution.  The centrifuged pellet, normally a white mass, was much smaller and less 
densely packed than typically observed.  The supernatants from all tubes were then 
pooled and placed in a -80°C freezer to undergo fractional freezing purification.  After 24 
hours, the supernatants had phase-separated into a clear, acetone-rich organic phase, a 
hazy interface layer, and a white, quasi-solid, water-rich aqueous phase.  The organic 
layer, and any dissolved unreacted monomers or surfactant unimers, was carefully 
decanted and discarded.  The remaining quasi-solid thawed to a turbid, white liquid 
solution within minutes, suggesting a low freezing temperature and considerable acetone 
content.  This solution was subjected to another round of fractional freezing with similar 
phase separation observed after 24 h at -80°C.  Following removal of the clear, acetone-
rich phase, the turbid aqueous fraction dialyzed extensively to remove acetone, unreacted 
monomers, and surfactants.   
8.3.3. 1H-NMR spectroscopy 
The proton NMR spectrum (Figure 8.6) corresponds well with the 
1
H-NMR 
spectra of crosslinked P(DEAEMA-co-BMA-g-PEGMA) in D2O as seen in Chapter 4, 
Figure 4.7.  The oxyethylene protons (-O-CH2-CH2-) from grafted PEGMA are evident 
in a strong peak at δ = 3.6 ppm and the terminal methoxy protons (-O-CH3) from grafted 
PEGMA are visible at δ = 3.3 ppm.  The inset spectra also confirm the presence of 
MAPA and DEAEMA functional groups in the polymer.  The left inset shows the 
                                                 




aromatic protons from MAPA at δ = 7.2 – 7.4 ppm.   The right inset shows the 
ethylamino (-CH2-CH3)2 protons from DEAEMA at approximately δ = 1.25 ppm.   
Identification of residual surfactant is somewhat problematic in the spectra of this 
crosslinked polymer nanogel.  The primary surfactant used during synthesis, Brij-30, 
displays prominent peaks in chemical shift regions near or overlapping with the PEGMA 
(δ ~ 3.6 ppm) or DEAEMA (δ ~ 1.2 ppm) peaks.  Other minor peaks exist in the 
1
H-
NMR spectra of Brij-30, such as that of the etheric protons bridging the tetraethylene 
glycol portion and dodecane portion of Brij-30 (-O-CH2-CH2-C10H21).  These protons are 
visible at δ = 3.445 ppm and δ = 1.58 ppm in CDCl3.  No distinct peaks are observed near 
these chemical shifts in Figure 8.6.  Also, the terminal hydroxyl group of Brij-30 
demonstrates a chemical shift of δ ~ 2.8 ppm in organic solvents like CDCl3.  However, 
this peak is not expected to appear in D2O due to the rapid exchange rate with 
surrounding hydrogen or deuterium.  In practice, the 
1
H-NMR spectra of neat solutions of 
Brij-30 result in sharp, well-defined peaks at the expected chemical shift.  The spectrum 
in Figure 8.6 does not contain any such peaks and those present near δ = 3.6 ppm and δ = 
1.2 ppm are characteristically broad, in accordance with the previous work (Chapter 4, 
Section 4.3.3) of polymer NMR.  From these observations, it appears the fractional 
freezing and dialysis purification was sufficient to remove Brij-30 from PDETM30. 
A conclusive determination about the presence or absence of MyTAB was also 
problematic.  In part, the polyelectrolyte-ionomer flocculation and sedimentation was 
designed to expel the cationic surfactant MyTAB through electrostatic repulsion.  As this 
formulation did not undergo the polyelectrolyte-ionomer purification, the presence of 




correspond to the methyl protons on the quarternized amino group of MyTAB.  
1
H-NMR 
analysis of neat MyTAB in DMSO-d6 reveals strong peaks near δ = 3.08 ppm (9 protons) 
and δ = 1.28 ppm (24 protons).   
Compared to the area of the PEGMA methoxy protons (Peak c, Figure 8.6), the 










    (8.1) 
where AMyTAB,3.1 is the integrated area of the putative methyl protons adjacent to 
the quarternized amine of MyTAB, 9 is the number of equivalent protons associated with 
this peak, APEGMA3.3 is the integrated area of the terminal methoxy group of PEGMA, and 
3 is the number of equivalent protons.  Thus, the estimated molar ratio of MyTAB to 
PEGMA is 0.061.  Considering the nanogels are approximately 0.5 mol% PEGMA 
(according to Table 4.4), the approximate molar ratio of MyTAB to PDETM30 is ~3 × 
10
-4
.  This suggests that MyTAB, if present, is present only in a very small proportion. 
8.3.4. Dynamic light scattering analysis 
Dynamic light scattering was used to study the physicochemical properties of the 
PDETM30 nanogels, including size, swelling ratio, and critical swelling pH.  The 
hydrodynamic diameter and polydispersity index reported represent those determined by 
Cumulants analysis as outlined in ISO 13321 [14].  Figure 8.7 depicts representative 




(pH 6) state.  The existence of a single population suggests that the Cumulants method is 
appropriate for this analysis. 
The z-average diameter and polydispersity are plotted as a function of pH in 
Figure 8.8.  The PDETM30 nanogels are significantly larger in aqueous suspension than 
analogous preparations with t-butyl methacrylate (TBMA)7.  PDETM30 exhibits a 
collapsed diameter of approximately 150 nm.  In contrast, PDETB30 exhibits a collapsed 
diameter of approximately 92 nm [13].  Upon exposure to increasingly acidic conditions, 
PDTEM30 undergoes a phase conformation from collapsed hydrophobe to swollen 
hydrophile.  This phase conformation results in a distinct change in volumetric swelling, 
the magnitude of which is driven by a balance between the free energy of polymer-
solvent interactions, osmotic pressure generated by mobile counterions inside the gel, and 
elastic contractile response to gel deformation [15].   
The critical swelling pH was calculated according to Equations 4.2 and 4.3 and 
determined to be pHc = 7.00.  By comparison, the pHc of PDET and PDETB30 were 
measured at 7.37 and 6.65, respectively.  Prior studies have demonstrated that increased 
network hydrophobicity leads to a decrease in the pHc [13, 16].  Therefore, the network 
hydrophobicity imparted by the MAPA comonomer is intermediate relative the PDET 
(no comonomer) and PDETB30 (TBMA comonomer).  The breadth of the phase 
transition, simply the pH difference between swollen and collapsed states, is 
approximately 0.9 pH units.  The breadth of the phase transitions for PDET and 
PDETB30  are approximately 0.65 and 1.56, respectively.   
                                                 





The polydispersity index (PdI), is given by a ratio of the second (µ2) and first 
moment (Γ) of the Cumulants analysis (µ2/Γ
2
)8 and describes the apparent width of the 
size distribution [14].  Typically, with PdI in this manner, a PdI of <0.05 is considered 
monodisperse and a PdI of >0.7 is considered polydisperse.  The PDETM30 nanogels 
have a narrow size distribution in aqueous suspension; the PdI was estimated at 0.10 – 
0.12 throughout the measurement.  In contrast, nearly all other syntheses resulted in 
nanogels with PdI ~ 0.18 – 0.22. 
8.3.5. Transmission electron microscopy 
The dry diameter of PDETM30 nanogels was determined to be 47.9 ± 19.6 nm by 
transmission electron microscopy (TEM).  The diameter was calculated by determining 
the particle area in ImageJ® and calculating the corresponding circular diameter.  Images 
acquired at 26,500× and 43,000× were used to construct a number-average particle size 
distribution.  Representative TEM micrographs are shown in Figure 8.9 and the 
calculated number-average particle size distribution in Figure 8.10.  The TEM 
micrographs reveal circular particles, which corresponds to a roughly spherical 
morphology.  Moreover, the dry particle mean size and size distribution correspond well 
with those determined for TBMA and TBAEMA nanogels in Chapter 49. 
                                                 
8 See Appendix B: Practical Considerations in Light Scattering for a more detailed treatment of the 
Cumulants analysis. 




8.3.6. Electrophoretic light scattering 
Measurements of the ζ-potential were performed to evaluate the colloidal stability 
and effective surface charge in response to dynamic pH.  The ζ-potential  of PDETM30 is 
compared to the TMBA analogue, PDETB30, in Figure 8.11.  Similar to the other 
copolymer nanogels described in Chapter 4, Figure 4.13, PDETM30 possess a reversible 
surface charge and isoelectric point (IEP) ~ 7.67.  The surface charge is slightly positive 
at physiological pH, ζ-potential ~ 1.22 mV.  The maximum ζ-potential at pH 3.5 is 
approximately 16 mV.  In contrast, the maximum ζ-potential for PDETB30 at pH 3.5 is 
approximately 28 mV.  A potential reason for this disparity may be an increase in the 
PEG graft density on PDETM30 and therefore an increase in charge shielding by the 
PEG corona.  Evidence from the 
1
H-NMR spectra of crosslinked nanogels in DCl in 
Figure 4.7 and Figure 8.6 support this assertion.  Comparing the relative areas between 
PEGMA protons and DEAEMA protons in a given copolymer gives a semi-quantitative 
estimate of the relative prevalence of PEGMA on the surface of the nanogel.  This 
estimate, for the ratio of PDETM30 to PDETB30, yields a value of 4.45, suggesting that 
PDETM30 has a higher proportion of PEGMA to DEAEMA than does PDETB30.  This 
method of estimation is only semi-quantitative, however, in that significant signal 
attenuation occurs in the 
1
H-NMR analysis of crosslinked polymer networks.  The 
nanogel interior, even in the swollen state, is a likely a highly viscous network of 
polymer chains.  Therefore, this comparative method likely underestimates the DEAEMA 
content and overestimates the PEGMA content.   There is also a possibility that 




proportion of DEAEMA.  This result is not likely, given the nature and extent of the pH-
responsive transition observed by DLS in Figure 8.8.  Further investigations to quantify 
the ionizable amine content via acid titration are currently underway to more conclusively 
address this question. 
8.3.7. Hemolysis assays 
The membrane-disruptive properties of PDETM30 were investigated using the 
hemolysis assay described in Chapter 5.  These studies serve to provide insight on the 
combinations of pH values and concentrations at which the nanogels are most able to 
destabilize lipid bilayers.  These studies are shown to be a rapid screen to approximate 
endosomolytic ability of synthetic polymer for intracellular drug delivery [17, 18].   
The pH values tested in this analysis range from pH 5.0 – pH 8.0; experiments 
performed at pH 5.00, 5.50, 6.00, 6.50, 7.00, 7.20, 7.40, 7.60, 7.80, and 8.00.  The 
concentrations tested range from 1 – 100 µg ml
-1
; with experiments performed with 100, 
50, 25, 10, 5, 2.5, and 1 µg ml
-1
 PDET, PDETM30 or PDETB30 suspended in 150 mM 
phosphate buffer at the specified pH.   
The pH- and concentration-dependent hemolysis was determined according to 
Equation 8.2: 
% 𝑯𝒆𝒎𝒐𝒍𝒚𝒊𝒔 =  
𝑨𝒔𝒂𝒎𝒑𝒍𝒆 −𝑨𝒃𝒍𝒂𝒏𝒌
𝑨𝒎𝒂𝒙−𝑨𝒃𝒍𝒂𝒏𝒌
    (8.2)  
Where Asample represents RBCs exposed to polymer at a given pH and 
concentration, Ablank is the absorbance of the supernatant after RBC exposure to 
phosphate buffer at a given pH, and Amax represents maximum lysis following RBC 




The hemolytic ranges of PDET, PDETM30, and PDETB30 are shown on the 
contour plots in Figure 8.12 and arranged in order of membrane-disruptive ability.  There 
is a clear dependence of polymer composition on the ability to destabilize erythrocyte 
membranes.  The trends for membrane destabilization mirror those observed in DLS 
analysis.  In Section 8.3.4., the pHc values for these three copolymer formulations are 
7.37 for PDET, 7.00 for PDETM30., and 6.65 for PDETB30.  Moreover, the values for 
transition breadth (pHswollen – pHcollapsed) are 0.65 for PDET, 0.9 for PDETM30, and 1.45 
for PDETB30.   
Notably, the pH range for maximum hemolysis follows a similar trend.  PDET 
displays maximum hemolysis around pH 7.4 – 7.6; conditions that correspond to its 
determined pHc.  Similarly, PDETM displays maximum hemolysis around pH 6.5 – 7.2 
and PDETB30 displays maximum hemolysis around pH 6.0 – pH 7.0.  These data 
suggest that the phase transition is critically important to modulate membrane-disruptive 
behavior.  At pH values above the phase-transition, the collapsed nanogel may be well 
protected by PEG grafts and may not have sufficient exposed surface area to interact 
with, and destabilize, lipid bilayers.  At pH values well below the phase transition, the 
swollen nanogel may be sufficiently ionized to mitigate any hydrophobic interactions 
between the exposed nanogel surface and the lipid bilayer of erythrocyte membranes.  In 
the transition region, the partially-swollen nanogel may contain a heterogeneous mixture 
of ionized and hydrophobic segments.  The partial ionization will permit osmotic 





collapsed.  This leads to a concomitant decrease in the surface PEG graft density 




bilayers.  The analysis of pyrene emission in Chapter 5 provides additional support for 
relationship between nanogel hydrophobicity and membrane-disruptive activity.   
A comparative hemolysis profile for PDETB30 and PDETM30 is shown in Figure 
8.13.  These data show the pH-dependent hemolysis at a single nanogel concentration (50 
µg ml
-1
).  In practice, nanogels concentrations of 5 – 50 µg ml
-1
 were used in transfection 
experiments.  As seen in this comparison, PDETM30 is substantially less effective at 
erythrocyte disruption in the pH range (pH 5.50 – 6.50) expected in early endosomes.  
While PDETB30 demonstrates nearly 100% hemolysis at pH 6.50 and pH 6.00, 
PDETM30 demonstrates 32% and 20%, respectively.  However, PDETM30 is relatively 
non-disruptive (~8% hemolysis) at physiological pH where PDETB30 demonstrates 
~60% hemolysis at pH 7.4.  This suggests that while PDETM30 is not as potent as the 
TMBA analogue PDETB30, it may have some utility in intracellular delivery 
applications, particularly as a mild membrane-destabilizing agent. 
8.3.8. Cytocompatibility 
The influence of polymer composition on cytotoxicity was examined in Chapter 
5.  In this work, the polymer toxicity was inversely related to the ionizable amine content 
(i.e. nanogels containing less DEAEMA were less cytotoxic under tested conditions).  
The LD50, or polymer dose that results 50% reduction in cellular metabolic activity, was 
estimated by fitting cytotoxicity data with a four parameter Hill model of the form:  
 
𝒚 =  𝒚𝟎 +
𝒂∙𝒙𝒃
𝒄𝒃+𝒙𝒃




Where y is the measured cellular proliferation (relative to untreated cells), y0 is 
the background signal or lower asymptote, a – y0 is the range for the fit, b is the slope of 
the response curve, and x is the polymer concentration (mg mL
-1
) to which the cells were 
exposed for designated time points.  This model is a typical dose-response curve 
commonly employed to model ligand-receptor binding and drug concentration-effects 
[19].   
Based on the data presented in Chapter 5 and the aqueous solution properties of 
PDETM30 discussed heretofore in this Chapter, it is expected that PDETM30 will exhibit 
cytotoxicity at intermediate levels relative to P(DEAEMA-g-PEGMA) (PDET) and 
P(DEAEMA-co-TMBA-g-PEGMA) (PDETB30).   
8.3.8.1. Caco-2 Cells 
PDETM30 demonstrates both time- and concentration-dependent toxicity, as 
shown in Figure 8.14.  Exposure times of 90 minutes and 360 minutes were chosen to as 
liberal and conservative approximations for the mean intestinal transport time, estimated 
to be approximately 3 – 4 h in humans [20].  According to the MTS assay, PDETM30 
caused no decrease in cellular proliferation (relative to untreated control) in Caco-2 cells 
at concentrations up to 0.25 µg mL
-1
 for 90 min exposure or 0.10 mg mL
-1
 for 360 min 
exposure.  The calculated LD50 values for PDETM30 and Caco-2 cells are 1.18 mg mL
-1
 
for 90 min exposure and 0.43 mg mL
-1
 for 360 min exposure. 
PDETM30 displays comparable toxicity to PDETB30 and improved toxicity 
relative to PDET (Figure 8.15).  The similarity in toxicity profile of PDETM30 and 




exposure.  This result is expected based on the previous relationships between polymer 
composition, aqueous solution properties, and cytotoxicity developed in Chapter 5.  
Below concentrations of 0.25 mg mL
-1
, both PDETM30 and PDETB30 display negligible 
toxicity.  In fact, these nanogels appear to exert a stimulatory effect on the metabolic 
activity of Caco-2 cells under the test conditions.  As expected from the ionizable amine 
density, PDET is considerably more toxic than the hydrophobically-modified nanogels 
PDETB30 and PDETM30.   
8.3.8.2. RAW 264.7 Cells 
Similar the observations in Chapter 5, RAW 264.7 cells were categorically more 
sensitive to the presence of nanogels than were Caco-2 cells.  The LD50 for PDETM30 
was estimated to be 0.27 mg mL
-1
 for 90 min exposure and 0.14 mg mL
-1
 for 360 min 
exposure (Figure 8.17).  The nature of this increase in toxicity can be ascribed to the 
phagocytic activity of the RAW macrophages.  Whereas nanogels will be internalized 
through nonspecific uptake pathways in Caco-2 cells, there will be additional uptake 
from phagocytosis in RAW 264.7 cells.  In all further studies examining cellular 
internalization of DY647-siRNA/PDETM30 complexes, PDETM30 was used at a 
concentration (0.025 mg mL
-1
) well below the toxic thresholds for Caco-2 and RAW 
264.7 cells.   
8.3.9. siRNA Internalization 
Imaging flow cytometry was used to assess the ability of PDETM30 to facilitate 




of qualitative visual evidence and quantitative statistical counting.  In this analysis of 
siRNA internalization, imaging flow cytometry was used to investigate the proportion of 
siRNA positive cells and the relative quantity of siRNA uptake by comparing fluorescent 
intensity between DY647-siRNA/PDETM30-treated and untreated samples. Moreover, 
detailed image analysis comparing thousands of combined fluorescent and brightfield 
images permitted the assessment of cellular internalization (vs. surface adsorption) and 
intracellular texture. 
As seen in the micrographs in Figure 8.18, PDETM30 enables the cytoplasmic 
delivery of DY647-siRNA to RAW 264.7 cells.  Cell nuclei are shown in blue (Hoechst) 
and siRNA in red (DY647).  Panels A - C show representative images of cells exposed 25 
µg mL
-1
 PDETM30 and 100 nM DY647-siRNA for 60 minutes.  Panels D - F show 
representative images of cells exposed only to 100 nM DY647-siRNA for 60 min.  As 
expected due to its high MW (~13 kDa) and negative charge, little to no internalization 
was observed by the naked siRNA.  Following complexation with PDEM30, the siRNA 
internalization increased substantially.  Similar observations were made for Caco-2 cells 
exposed to PDETM30/DY647-siRNA or DY647-siRNA under identical conditions 
(Figure 8.19). 
Figure 8.20 shows the total number (and proportion) of siRNA positive cells 
relative to untreated control.  Cells were deemed siRNA positive by gating the entire 
Channel 5 (Em: 660 – 745 nm, DY647) fluorescent intensity histogram of an untreated 
control sample.  Cells in this range of fluorescent intensity were considered siRNA 
negative.  Cells with fluorescent intensity greater than this gated region were considered 




nearly 100% of RAW 264.7 cells (Panel A) and approximately 93% of Caco-2 cells 
(Panel B).  As previously mentioned in Section 8.2.13., only live cells with suitable 
brightfield focus were analyzed.  This rapid and ubiquitous internalization is 
encouraging, particularly in the absence of any dedicated targeting ligands to promote 
internalization.   
The fluorescent intensity histograms in Figure 8.21 reveal that PDETM30 
drastically increases the fluorescent signal of DY647-siRNA.  These histograms compare 
populations exposed to DY647-siRNA alone (blue) or PDETM30/DY647-siRNA (red).  
In accordance with Figure 8.20, these observations are consistent in both RAW 264.7 
cells (Figure 8.21, Panel A) and Caco-2 cells (Figure 8.21, Panel B).  The similarity in 
median fluorescence intensity between RAW 264.7 cells (~33,000) and Caco-2 cells 
(~30,000) suggests that phagocytosis, a mechanism of internalization in the RAW 
macrophages, does not account for a significant fraction of the internalized siRNA.    
A major advantage of imaging flow cytometry is the ability to distinguish 
between intracellular and surface localization of fluorescent probes.  Extensive rinsing of 
cells with PBS is typically employed prior to conventional flow cytometry; generally this 
is sufficient for the putative removal of surface-adsorbed ligands.  In this analysis, the 
brightfield cell image and fluorescent siRNA image were compared to determine the 
extent of internalization, or internalization coefficient.  This parameter is defined by the 
ratio of intensity inside the cell to the intensity of the entire cell, where inside the cell and 
entire cell are defined by masks created in the brightfield channel.  Positive values for the 
internalization coefficient signify intracellular localization, while negative values signify 




As seen in Figure 8.22, the median internalization coefficient is positive for both 
RAW 264.7 cells (Panel A) and Caco-2 cells (Panel B), indicating that PDETM30 
facilitates intracellular delivery of DY647-siRNA to these two cell types.  A similar 
analysis examined the colocalization of DY647-siRNA and cell nuclei stained with 
Hoechst 33342.  As expected, there was no evidence for nuclear localization of DY647-
siRNA. 
Figure 8.23 illustrates the distribution in intracellular spots of siRNA in RAW 
264.7 cells and Caco-2 cells.  Punctate staining patterns are typically associated with 
vesicular entrapment of fluorescently labeled molecules.  A spot counting algorithm in 
IDEAS® software was used to determine the number of punctate spots in each live, 
focused cell.  The spot mask was established to identify bright spots 3 – 2000 pixels in 
area.  With a 60× objective, each pixel corresponds to 0.3 µm × 0.3 µm.  Therefore, the 
mask was able to identify punctate spots of approximately 0.58 µm – 4.78 µm in 
diameter.  Mature late endosomes have a diameter of 0.25 – 1 µm [21] and lysosomal 
compartments can range from 0.5 nm – 1.5 µnm [22].  Thus, this method will not 
accurately account for all endolysosomal entrapment but can theoretically detect 
vesicular entrapment in some late endosomes and most lysosomes. 
The spot count distributions in Figure 8.23 suggest a diffuse staining pattern (few 
spots) of DY647-siRNA fluorescence rather than a punctate staining pattern (many 
spots).  These distributions are in good agreement with the micrographs from Figure 8.18 
and Figure 8.19, which show few distinct spots in the intracellular siRNA fluorescence.  
Given that over 90% of RAW 264.7 cells and Caco-2 cells contain detectable DY647-




internalization.  These data suggest that PDETM30 is an efficient vehicle for enabling 
internalization and endosomal escape of siRNA. 
8.4. CONCLUSIONS 
A reactive phenylalanine derivative, N-methacryloyl L-phenylalanine methyl 
ester (MAPA) was successfully synthesized in order to modulate hydrophobicity and 
physicochemical properties of pH-responsive nanogels.  The structure and molecular 
weight of the intended MAPA product were verified via 
1
H-NMR and mass 
spectroscopy, respectively.  The MAPA monomer was used in a photoemulsion 
polymerization to create P(DEAEMA-co-MAPA-g-PEGMA) nanogels.  These 
responsive polymer networks have a roughly spherical morphology and dry diameter of 
approximately 47 nm, as determined by TEM.  These nanogels exhibit a volume phase 
transition from collapsed hydrophobe to swollen hydrophile around pH 7.0, as 
determined by DLS.  DLS measurements also indicate a relatively narrow distribution of 
particle sizes with a z-average diameter of approximately 150 nm.   
In many of the in vitro assays, PDETM30 displayed intermediate performance 
relative to unmodified nanogel PDET and the best performing TBMA-modified nanogel 
PDETB30.  For comparison, relevant physical and in vitro properties of PDETM30 and 
PDETB30 are summarized in Table 8.2 and Table 8.3.  In studies of membrane 
destabilization using sheep erythrocytes, PDETM30 was most disruptive at pH values 
proximal to its critical pH for phase transition.  Relative to the PDET nanogels, 
PDETM30 was a more potent agent for membrane destabilization but was less effective 




to PDET and comparable cytocompatibility to PDETB30.  Moreover, PDETM30 displays 
no overt toxicity to Caco-2 cells or RAW 264.7 cells at conventional transfection 
concentrations (< 50 µg ml
-1
) for up to 6 h exposure.   
Analysis of cellular internalization demonstrated rapid and ubiquitous uptake of 
the DY647-siRNA; over 90% of live cells contained siRNA after only 60 min of 
exposure.  Image analysis of the RAW 264.7 cells and Caco-2 cells indicates a 
predominately diffuse staining pattern in the cells, suggesting endosomal escape by the 
siRNA cargo.   
From these data, it is clear that inclusion of the MAPA comonomer improves in 
vitro performance characteristics (lower pHc, greater hemolysis, improved 
cytocompatibility) relative to the unmodified PDET.  Despite decreased performance 
characteristics relative to PDETB30 (higher pHc, lower hemolysis, comparable 
cytocompatibility), PDETM30 facilitates efficient intracellular delivery of siRNA.  
Ongoing studies are evaluating the knockdown efficiency of siRNA delivered via 
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Figure 8.2- Purification of MAPA reaction products using flash chromatography.  Eluent 
absorbance at 258 nm is shown in red (left axis) and solvent (Solvent A – 






Figure 8.3 - 
1
H-NMR Spectrum of purified N-methacryloyl L-phenylalanine methyl ester 








Table 8.1 – Peak assignments and relative integration values of the 
1
H-NMR spectrum of 
purified N-methacryloyl L-phenylalanine methyl ester (MAPA) monomer 
Peak Assignment δ (ppm) Protons Integration Value 
A 7.05 – 7.30 5, R-C6H5 5.416 
B 6.10 – 6.28 1, R-NH-R 1.082 
C 5.60 – 5.70 1, R-C=CH2 1.046 
D 5.30 – 5.40 1, R-C=CH2 1.049 
E 4.85 – 5.00 1, R2-CH-NH-R 1.105 
F 3.65 – 3.85 3, -O-CH3 3.000 
G 3.12 – 3.28 2, Ph-CH2-R 2.101 






Figure 8.4 - Mass spectrum of purified N-methacryloyl L-phenylalanine methyl ester.  Anticipated molecular weight of the 















Figure 8.6 - 
1
H-NMR spectra of crosslinked  P(DEAEMA-co-MAPA-g-PEGMA)  








Figure 8.7 - Representative intensity-weighted particle size distribution for PDETM30 in 
the collapsed (solid) and swollen (dashed) state.  Distribution in the 
collapsed state is from a measurement at pH 9.0 and distribution in the 
swollen state is from a measurement at pH 6.0.   
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Figure 8.8 – Z-average diameter (●, left axis) and polydispersity (○, right axis) of 
P(DEAEMA-co-MAPA-g-PEGMA) networks crosslinked with 2.5 mol% 
TEGDMA in response to dynamic pH.   Data points represent the mean of 3 
sequential runs of 12 measurements each and error bars represent the 
standard deviation.  The line represents a hyperbolic tangent best fit. 
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Figure 8.9 - Representative transmission electron microscopy image of TEGDMA-
crosslinked P(DEAEMA-co-MAPA-g-PEGMA).  Particles stained with 
uranyl acetate and images collected at 26,500× (A) and 43,000× (B).  Scale 







Figure 8.10 - Number-average particle size distribution of P(DEAEMA-co-MAPA-g-
PEGMA) (PDETM30) generated by quantitative particle sizing from TEM 
micrographs.  Distribution mean = 47.9, std. dev. = 19.6, n = 197.  Bars 
represent calculated data and line represents best fit Gaussian distribution 
(R
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Figure 8.11 - Effective zeta-potential of P(DEAEMA-co-MAPA-g-PEG)  PDETM30 (●) 
compared to P(DEAEMA-co-BMA-g-PEG) PDETB30 (○).  Data points 
























Figure 8.12 – Membrane-disruptive activity of pH-responsive nanogels PDET (A), 
PDETM30 (B), and PDETB30 (C).  Sheep erythrocytes used as model 







Figure 8.13 – Comparative hemolysis profile for PDETM30 (●) and PDETB30 (○) at 
0.05 mg mL
-1
.  Data points represent the mean of a single experiment 


























Figure 8.14 - Relative proliferation of Caco-2 cells upon exposure to 
P(DEAEMA-co-MAPA-g-PEG) (PDETM30) for 90 minutes (●) 
or 6 hours (■).  The relative proliferation of Caco-2 cells was 
determined by MTS assay and is expressed as a fraction of the 

















































Figure 8.15 – Relative proliferation of Caco-2 cells upon exposure to PDETM30 (■), 
PDETB30 (◊), or PDET (■) for 90 min. The relative proliferation of RAW 
cells was determined by MTS assay and is expressed as a fraction of the 
control (untreated) cells.  Data are expressed as mean ± SEM, n = 4.  
Polym er C oncentration  (m g m l 
-1
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Figure 8.16 - Relative proliferation of Caco-2 cells upon exposure to PDETM30 (■) or 
PDETB30 (Δ) for 360 min. The relative proliferation of Caco-2 cells was 
determined by MTS assay and is expressed as a fraction of the control 

















































Figure 8.17 - Relative proliferation of RAW 264.7 cells upon exposure to P(DEAEMA-
co-MAPA-g-PEG) (PDETM30) for 90 minutes (●) or 6 hours (■).  The 
relative proliferation of RAW cells was determined by MTS assay and is 
expressed as a fraction of the control (untreated) cells.  Data are expressed 















































Figure 8.18 – DY647-siRNA delivery to RAW 264.7 cells.  Nuclear stain (Hoechst 
33342) shown in blue and DY647-siRNA (DyLight 647) shown in red.  Two 
representative examples of RAW 264.7 cells exposed to PDETM30/DY647-
siRNA (A-C) or DY647-siRNA alone (D-F) are shown.  Scale bar 







Figure 8.19 - DY647-siRNA delivery to Caco-2 cells.  Nuclear stain (Hoechst 33342) 
shown in blue and DY647-siRNA (DyLight 647) shown in red.  Three 
representative examples of Caco-2 cells exposed to PDETM30/DY647-
siRNA (A-C) or DY647-siRNA alone (D-F) are shown.  Scale bar 






Figure 8.20 – Number (left axis) and proportion (right axis) of live cells with internalized 
DY647-siRNA.  Untreated cells (gray), cells exposed to 100 nM DY647-
siRNA alone (blue) or 100 nM DY647-siRNA + 25 µg ml
-1
 PDETM30 (red) 
in RAW 264.7 cells (A) and Caco-2 cells (B).  Data represent pooled 






Figure 8.21 - Fluorescence intensity of DY647-siRNA in RAW 264.7 cells (A) and Caco-
2 cells (B).  Fluorescence histograms generated from cells exposed to 
DY647-siRNA alone (blue) or PDETM30/ DY647-siRNA (red).  Data 






Figure 8.22 - Internalization coefficient of DY647-siRNA in RAW 264.7 cells (A) and 
Caco-2 cells (B).  Histograms generated from image analysis of cells 
exposed to DY647-siRNA alone (blue) or PDETM30/ DY647-siRNA (red).  






Figure 8.23 – Intracellular texture, or spot counting, of DY647-siRNA in RAW 264.7 
cells (A) and Caco-2 cells (B).  Histograms generated from image analysis 
of cells exposed to DY647-siRNA alone (blue) or PDETM30/ DY647-
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93.4 121 2.6 ± 1.6 21.6 ± 0.7 50 ± 17 
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61.1 ± 2.5 
103.9 ± 
3.8 





8.0 ± 0.2 32.4 ± 3.7 0.27 1.18 3. 3 × 10
4
 
1  Hemolysis using a polymer concentration of 0.05 mg ml-1 
2  Toxicity determined using MTS assay following 90 min polymer exposure  
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Chapter 9: Conclusions and Future Recommendations 
The work described in this thesis outlines the development and evaluation of 
nanoscale delivery systems for small interfering RNA.  These delivery systems were 
examined with a hierarchical screening process for physical and biological 
characterization and evaluated according to several design criteria.  These design criteria 
were dictated by the physiological demands of an effective endosomolytic nanocarrier 
and include requirements for size, surface charge, pH response, cytotoxicity, siRNA 
binding, and siRNA delivery.   
As a first order screen, nanogel size and critical swelling pH were the most 
important design parameters.  For effective intracellular drug delivery, a cationic nanogel 
carrier should avoid a conformational transition at or near physiological pH.  A preferred 
transition pH is that of the endosomes (pH 5.5 – pH 6.5) to ensure that encapsulated 
siRNA cargo may remain protected at physiological pH.  Many amine-based monomers, 
including the principal monomer used in this work (2-diethylaminoethyl methacrylate) 
have a pKa near pH 7 – 8.  Therefore, the polymer composition was modulated to shift 
the pH for onset of critical phenomena toward the endosomal pH region and away from 
the physiological pH region. Initial studies examined the competing influence of two tert-
butyl containing methacrylate monomers, tert-butyl methacrylate (TMBA) and tert-
butylamino methacrylate (TBAEMA), on the aqueous solution properties of pH-
responsive nanogels.   
In P(DEAEMA-co-TBMA-g-PEGMA) copolymers, increasing TBMA serves to 
decrease the onset of pH-dependent swelling, reaching ~ pH 7.2 with maximum volume 





collapsed hydrophobe and swollen hydrophile in light scattering and pyrene fluorescence 
spectroscopy studies.  In P(DEAEMA-co-TBAEMA-g-PEGMA) copolymers, the 
compositional dependence is less obvious. Pyrene fluorescence spectroscopy reveals an 
increase in the critical pH for hydrophobic-hydrophilic phase transition but dynamic light 
scattering reveals no compositional trend in the volume swelling transition. 
Second order screens evaluated the membrane-disruptive activity.  As siRNA is 
unable to cross cell membranes, a suitable delivery system should facilitate its passage 
through cell membrane barriers to permit cytoplasmic localization.  Three model 
membrane systems were used to assess the membrane-disruptive ability of responsive 
nanogels as a function of environmental pH and concentration.  
Red blood cells were used as model lipid membranes to investigate the influence 
of pH on membrane destabilization.  These studies served to approximate the 
endosomolytic ability of nanogels as a function of pH, particularly that of endosomal pH 
(5.5 – 6.5), by quantifying the release of hemoglobin from damaged erythrocyte 
membranes.  In all nanogel formulations, the pH range of maximum hemolysis was in 
excellent agreement with the pH range for the phase transition as determined by pyrene 
fluorescence spectroscopy.   
Lactate dehydrogenase (LDH) leakage assays in Caco-2 cells were used to 
evaluate the untoward membrane disruption at physiological pH.  These studies served to 
investigate the influence of polymer composition and exposure time on membrane 
damage to live cells.  These studies corroborate the importance of the pH-dependent 





lower pH values (e.g. PDETB30) were less disruptive to Caco-2 cell membranes than 
were nanogels with higher pH values (e.g. PDET, PDETBA30).   
Confocal micrscopy analysis of synthetic lipid vesicles in pH 6.50 buffer revealed 
the putative mechanism of membrane destabilization to be transient pore formation.  In 
these investigations, PDETB30 permitted the rapid efflux of an encapsulated fluorescent 
dye while leaving the lipid membrane intact.  PDET, which demonstrates a phase 
transition at approximately pH 7.3 and minimal hemolysis at pH 6.50, was not disruptive 
to the lipid vesicles under the experimental conditions.  The conclusion of these studies 
yielded one nanogel formulation (PDETB30) with a critical transition near endosomal pH 
and an excellent combination of pH-dependent membrane disruption and 
biocompatibility.   
Third order screens evaluated the siRNA loading capacity and siRNA delivery to 
target cell types.  These investigations revealed that PDETB30 enables the internalization 
(primarily through macropinocytosis), vesicular escape, and functional gene silencing 
activity of siRNA cargoes.  Internalization of nanoparticles is a highly complex and 
regulated cellular process which has tremendous bearing on the intracellular fate of 
internalized nanoparticles.  Understanding the mechanism of uptake is critical to enabling 
(or increasing) productive intracellular delivery of any biotherapeutic.   
 In this thesis, the use of TBMA to modulate physicochemical properties and 
create responsive nanogels with desirable drug delivery characteristics was quite 
effective.  However, the lack of a nanogel degradation mechanism will undoubtedly limit 
the in vivo utility of these nanogel carriers.  To impart a mechanism for nanogel 





to permit nanogel degradation in the reductive intracellular environment.  Additional 
modifications to enhance biocompatibility, such as the replacement of TBMA with a 
reactive phenylalanine derivative (MAPA) were also investigated.  Though replacement 
of TBMA did not increase biocompatibility, the resulting nanogels are efficient delivery 
vehicles for siRNA and merit further investigation. 
There are many facets of this work that are ripe for further investigation.  More 
detailed information regarding the degradation kinetics of disulfide-crosslinked nanogels 
and chemical nature of corresponding degradation products will be important in future in 
vivo or perhaps clinical applications.  Comprehensive evaluation of gene silencing in is 
also an area for future study.  GAPDH was suitable in this initial work for comparison 
across several cell lines, further development should investigate more therapeutically 
relevant disease targets and cell lines.  Macrophage cells have traditionally been difficult 
to transfect with siRNA delivery systems.  However, mounting evidence suggests the 
culture conditions (2D vs. 3D, substrate stiffness, etc.) play an important role their 
susceptibility to transfection.  Further efforts in this direction should seek to more 
accurately recapitulate the native target cell environment.  Moreover, in vitro models for 
predicting in vivo and clinical efficacy are notoriously poor.  For a true assessment of the 
utility and performance of these nanogels in siRNA delivery applications, progression to 








APPENDIX A: POLYMER NOMENCLATURE 
The naming convention of the copolymer nanoscale hydrogels described in this 
thesis was established to reflect the copolymer composition.   










PDET P(DEAEMA-g-PEGMA) DEAEMA  0 TEGDMA 4,5 
PDETB10 P(DEAEMA-co-TMBA-g-PEGMA) DEAEMA TBMA 10 TEGDMA 4,5 
PDETB20 P(DEAEMA-co-TBMA-g-PEGMA) DEAEMA TBMA 20 TEGDMA 4,5 
PDETB20 P(DEAEMA-co-TBMA-g-PEGMA) DEAEMA TBMA 20 TEGDMA 4,5 
PDETB30 P(DEAEMA-co-TBMA-g-PEGMA) DEAEMA TBMA 30 TEGDMA 4 – 8 
PDETBA10 P(DEAEMA-co-TBAEMA-g-PEGMA) DEAEMA TBAEMA 10 TEGDMA 4,5 
PDETBA20 P(DEAEMA-co-TBAEMA-g-PEGMA) DEAEMA TBAEMA 20 TEGDMA 4,5 
PDETBA30 P(DEAEMA-co-TBAEMA-g-PEGMA) DEAEMA TBAEMA 30 TEGDMA 4,5 
PDESSB30 P(DEAEMA-co-TBMA-g-PEGMA) DEAEMA TBAEMA 30 SSXL 7 
PDETM30 P(DEAEMA-co-MAPA-g-PEGMA) DEAEMA TBAEMA 30 TEGDMA 8 
1
Per 100 mol of primary monomer 
 
Abbreviations: DEAEMA: 2-(diethylaminoethyl methacrylate), TBMA: tert-
butyl methacrylate, TBAEMA: tert-butylaminoethyl methacrylate, MAPA: N-
methacryloyl L-phenylalanine methyl ester, TEGDMA: tetra(ethylene glycol) 
dimethacrylate,  SSXL: bis(2-methacryloyloxyethyl) disulfide, PEGMA: poly(ethylene 





APPENDIX B: PRACTICAL CONSIDERATIONS IN DYNAMIC LIGHT SCATTERING 
Dynamic light scattering (DLS), also termed photon correlation spectroscopy and 
quasi-elastic light scattering, is a powerful technique to calculate the hydrodynamic 
diameter of particles undergoing Brownian motion in solution.  In general, a typical light 
scattering experiment is conducted by passing a monochromatic incident beam through a 
solution of volume, V, and detector at a fixed angle, Θ.   The scattering volume V is 
formed by the intersection of incident beam and detector.  The time-dependent 
fluctuations in scattered light intensity due to random diffusion can be resolved into a 
time-correlation function via an autocorrelator, where the intensity correlation approaches 
1 at small times (τ  0) and approaches 0 at long times (τ  ∞).  A graphical illustration 
of this behavior is shown in Figure B.1.  
 
Figure B.1 - Time-dependent intensity fluctuations in dynamic light scattering 
These fluctuations can be averaged over time to form a correlation function, 





function of time.  One should note that in light scattering of macromolecular samples, 
relatively small macromolecules will give rise to a correlation function that is valid for 
very short times, as a small macromolecule diffuses more quickly and its spatial position 
at time t + Δt is less likely to be related to its spatial position at time t.  Conversely, 
relatively large marcomolecules will give rise to a correlation function that persists for 
much longer times, because the macromolecule is diffusing more slowly.  Common 
methods of interpreting the autocorrelation function include fitting a single exponential to 
the correlation function, as done in the cumulant analysis (defined in ISO13321 Part 8), 
or to fit a multiple exponential to the correlation function, as done in CONTIN or NNLS 
algorithms.  Of these, the Cumulants analysis is the most common and valid for a single 
population of spherical particles.  In this analysis, the correlation function is fit to the 
exponential described by: 
    deGC
 )(     (B.1) 
Where Γ is the characteristic decay rate, τ is time, and G(Γ) is proportional to the 
relative scattering from each species within the given population.  Thus, the correlation 
function can be considered the sum of all exponential decay functions from all species.  
For convenience, this exponential function is expanded in a Taylor series, where the 
coefficients of τ are termed Cumulants.  Typically, the first and second moments of this 
Taylor series expansion are considered the most important.  The first moment, 𝛤, can be 
given by:  
2qD       (B.2) 





















     (B.3) 
Where n is the index of refraction (1.5174 for PDEAEMA (Brandup and 
Immergut 1989), λ0 is the incident light source wavelength (633 nm), and Θ is the 
scattering angle (173°).  The second moment, µ2, is given by: 
 
  4222 qDD       (B.4) 
Where D* is the population-average translational diffusion coefficient.  Once the 
translational diffusion coefficient is known, it can be used to calculate the particle 







    (B.5) 
Where k is the Boltzmann constant, T is the absolute temperature, and ƞ is the 
dynamic viscosity at zero shear.  It is worth noting that the calculated hydrodynamic 
diameter is inversely proportional to viscosity.  Therefore, errors in viscosity estimation 
are manifested directly by proportional errors in the calculated hydrodynamic diameter.   
Furthermore, this equation assumes that particles undergoing Brownian motion 
are non-interacting spheres, so careful attention must be paid to determine a 
concentration regime to ameliorate the influence of particle interactions and multiple 
scattering events.  Measuring the z-average particle size as a function of concentration 
(Figure ) revealed that the calculated diameter remained relatively constant (±5 nm) from 
0.01 – 1.0 mg mL
-1





identified in Figure B.3, where the instrument count rate (kcps) is directly related to the 
concentration.  Following this analysis, 0.5 mg mL
-1
 polymer solutions were used for 
subsequent light scattering studies.   
 
 


































Figure B.3 - Count rate (kcps) as a function of particle concentration.  In the 
concentration range where z-average size is independent of concentration, 
count rate exhibits a linear dependence.   
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APPENDIX C:  GATING STRATEGY FOR IMAGING FLOW CYTOMETRY 
This appendix describes the sequential gating strategy employed to analyze 
images in the mechanistic study of cellular internalization (Chapter 6) and later in the 
RNA internalization studies (Chapters 6 – 8).  In the subsequent sections, named 
populations selected by gating are denoted in quotations (e.g. “Cells”, “Single Cells”, 
etc.) 
Cell and Debris Discrimination 
“Cells” were separated from debris by gating according to side scatter (a measure 
of cell complexity or granularity) vs. brightfield area, as shown in Figure C.1. 
 
 
Figure C.1. – Side scatter vs. Brightfield area of Caco-2 cells in Imaging flow cytometry.   
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Single Cell and Multi-Cell Discrimination 
From the “Cells” population, “Single Cells” were selected by examining the 
brightfield aspect ratio vs. brightfield area.  Typically, single cells have a high aspect 
ratio (0.8 – 1.0) and moderate area (300 – 700 µm
2













Focused Cell Discrimination 
To discriminate between focused and unfocused “Single Cells”,  the Gradient 
RMS feature in IDEAS® software was used.  This feature measures image sharpness by 
examining large changes in pixel values of a given image.  Sharp, or in-focus, images 
will have characteristically higher Gradient RMS values.  Typically, the lower limit for 
Gradient RMS was set to 40.  Images with Gradient RMS of 40 and greater form the 
population “Focused Cells”.  At camera magnification used for these studies (60×), the 
depth of field is 2.5 µm.  Thus, if the outer circumfrence of a given cell is in focus, the 
focal plane represents a 2.5 µm slice through the center section of the cell.  
 
Figure C.3. – Discrimination between focused and unfocused cells according to their 






To separate live cells from dead or dying cells, propidium iodide was added to the 
cell suspensions as a live/dead discriminator.  Propidium iodide is impermeable to live 
cell membranes and thus will present only in dead or dying cells with compromised 
membrane integrity.   In a typical flow cytometry run, “Live Cells” formed 
approximately 90% of the single, focused cell population. 
 
 









APPENDIX D: CONTROLLED DRUG DELIVERY FROM ALGINATE SPHERES IN A DESIGN-
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